<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">64041</article-id><article-id pub-id-type="doi">10.7554/eLife.64041</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Attenuated dopamine signaling after aversive learning is restored by ketamine to rescue escape actions</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-211594"><name><surname>Wu</surname><given-names>Mingzheng</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4415-6296</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-211595"><name><surname>Minkowicz</surname><given-names>Samuel</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1555-1158</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-209092"><name><surname>Dumrongprechachan</surname><given-names>Vasin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5890-6778</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-211596"><name><surname>Hamilton</surname><given-names>Pauline</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-211597"><name><surname>Xiao</surname><given-names>Lei</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1640-9690</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-45086"><name><surname>Kozorovitskiy</surname><given-names>Yevgenia</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3710-1484</contrib-id><email>Yevgenia.Kozorovitskiy@northwestern.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Neurobiology, Northwestern University</institution><addr-line><named-content content-type="city">Evanston</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Penzo</surname><given-names>Mario</given-names></name><role>Reviewing Editor</role><aff><institution>National Institute of Mental Health</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Wassum</surname><given-names>Kate M</given-names></name><role>Senior Editor</role><aff><institution>University of California, Los Angeles</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>27</day><month>04</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e64041</elocation-id><history><date date-type="received" iso-8601-date="2020-10-15"><day>15</day><month>10</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-04-26"><day>26</day><month>04</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Wu et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Wu et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-64041-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-64041-figures-v2.pdf"/><related-article ext-link-type="doi" id="ra1" related-article-type="commentary" xlink:href="10.7554/eLife.70148"/><abstract><p>Escaping aversive stimuli is essential for complex organisms, but prolonged exposure to stress leads to maladaptive learning. Stress alters neuronal activity and neuromodulatory signaling in distributed networks, modifying behavior. Here, we describe changes in dopaminergic neuron activity and signaling following aversive learning in a learned helplessness paradigm in mice. A single dose of ketamine suffices to restore escape behavior after aversive learning. Dopaminergic neuron activity in the ventral tegmental area (VTA) systematically varies across learning, correlating with future sensitivity to ketamine treatment. Ketamine’s effects are blocked by chemogenetic inhibition of dopamine signaling. Rather than directly altering the activity of dopaminergic neurons, ketamine appears to rescue dopamine dynamics through actions in the medial prefrontal cortex (mPFC). Chemogenetic activation of Drd1 receptor positive mPFC neurons mimics ketamine’s effects on behavior. Together, our data link neuromodulatory dynamics in mPFC-VTA circuits, aversive learning, and the effects of ketamine.</p></abstract><abstract abstract-type="executive-summary"><title>eLife digest</title><p>Over 264 million people around the world suffer from depression, according to the World Health Organization (WHO). Depression can be debilitating, and while anti-depressant drugs are available, they do not always work. A small molecule drug mainly used for anesthesia called ketamine has recently been shown to ameliorate depressive symptoms within hours, much faster than most anti-depressants. However, the molecular mechanisms behind this effect are still largely unknown.</p><p>Most anti-depressant drugs work by restoring the normal balance of dopamine and other chemical messengers in the brain. Dopamine is released by a specialized group of cells called dopaminergic neurons, and helps us make decisions by influencing a wide range of other cells in the brain. In a healthy brain, dopamine directs us to rewarding choices, while avoiding actions with negative outcomes. During depression, these dopamine signals are perturbed, resulting in reduced motivation and pleasure. But it remained unclear whether ketamine’s anti-depressant activity also relied on dopamine.</p><p>To investigate this, Wu et al. used a behavioral study called “learned helplessness” which simulates depression by putting mice in unavoidable stressful situations. Over time the mice learn that their actions do not change the outcome and eventually stop trying to escape from unpleasant situations, even if they are avoidable. The experiment showed that dopaminergic neurons in an area of the brain that is an important part of the “reward and aversion” system became less sensitive to unpleasant stimuli following learned helplessness. When the mice received ketamine, these neurons recovered after a few hours.</p><p>Individual mice also responded differently to ketamine. The most ‘resilient’, stress-resistant mice, which had distinct patterns of dopamine signaling, also responded most strongly to the drug. Genetic and chemical manipulation of dopaminergic neurons confirmed that ketamine needed intact dopamine signals to work, and revealed that it acted indirectly on dopamine dynamics via another brain region called the medial prefrontal cortex.</p><p>These results shed new light on how a promising new anti-depressant works. In the future, they may also explain why drugs like ketamine work better for some people than others, ultimately helping clinicians select the most effective treatment for individual patients.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>dopamine</kwd><kwd>aversive learning</kwd><kwd>ketamine</kwd><kwd>mPFC</kwd><kwd>VTA</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001447</institution-id><institution>Rita Allen Foundation</institution></institution-wrap></funding-source><award-id>Rita Allen Foundation Scholar Award</award-id><principal-award-recipient><name><surname>Kozorovitskiy</surname><given-names>Yevgenia</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01NS107539</award-id><principal-award-recipient><name><surname>Kozorovitskiy</surname><given-names>Yevgenia</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005665</institution-id><institution>Kinship Foundation</institution></institution-wrap></funding-source><award-id>Searle Scholar Award</award-id><principal-award-recipient><name><surname>Kozorovitskiy</surname><given-names>Yevgenia</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000997</institution-id><institution>Arnold and Mabel Beckman Foundation</institution></institution-wrap></funding-source><award-id>Beckman Young Investigator Award</award-id><principal-award-recipient><name><surname>Kozorovitskiy</surname><given-names>Yevgenia</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000874</institution-id><institution>Brain and Behavior Research Foundation</institution></institution-wrap></funding-source><award-id>NARSAD and P&amp;S Fund Award</award-id><principal-award-recipient><name><surname>Kozorovitskiy</surname><given-names>Yevgenia</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>T32 AG20506 affiliate fellow</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Mingzheng</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100008982</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source><award-id>GRFP DGE-1842165</award-id><principal-award-recipient><name><surname>Minkowicz</surname><given-names>Samuel</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>19PRE34380056 predoctoral fellowship</award-id><principal-award-recipient><name><surname>Dumrongprechachan</surname><given-names>Vasin</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01MH117111</award-id><principal-award-recipient><name><surname>Kozorovitskiy</surname><given-names>Yevgenia</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Interconnected ventral tegmental area and medial prefrontal cortex circuits causally link dopamine dynamics, aversive learning, and the effects of a promising rapidly acting antidepressant ketamine.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Major depressive disorder (MDD) is a prevalent mental illness linked to diminished quality of life and increased mortality. Persistent changes in mood and emotional reactivity represent fundamental features of MDD, extensively investigated in human subjects (<xref ref-type="bibr" rid="bib106">Rottenberg, 2017</xref>; <xref ref-type="bibr" rid="bib104">Rottenberg et al., 2005</xref>). Reduced reactivity to both positive and negative stimuli has been consistently observed in clinically depressed patients (<xref ref-type="bibr" rid="bib19">Bylsma et al., 2008</xref>; <xref ref-type="bibr" rid="bib105">Rottenberg and Hindash, 2015</xref>), suggesting that MDD may involve systematic changes in the processing of reward and aversion. These changes in reward-based and aversive responses can be modeled in animals (<xref ref-type="bibr" rid="bib1">Abler et al., 2007</xref>; <xref ref-type="bibr" rid="bib52">Heldt et al., 2007</xref>; <xref ref-type="bibr" rid="bib85">Nestler and Carlezon, 2006</xref>; <xref ref-type="bibr" rid="bib101">Proulx et al., 2014</xref>). In animal models involving prolonged stress, the reactivity to positive valence (e.g. social stimuli) and negative valence (e.g. tail suspension) experiences is usually diminished (<xref ref-type="bibr" rid="bib17">Beyer and Freund, 2017</xref>), suggesting that prolonged aversive experience induces maladaptive learning. One established model of aversive learning is learned helplessness (LH) (<xref ref-type="bibr" rid="bib2">Abramson et al., 1978</xref>; <xref ref-type="bibr" rid="bib77">Maier and Seligman, 1976</xref>; <xref ref-type="bibr" rid="bib112">Seligman and Maier, 1967</xref>). Following prolonged inescapable stress exposure, animals learn that outcomes are independent of their behavioral actions; this learning eventually diminishes attempts to escape from avoidable stressful stimuli (<xref ref-type="bibr" rid="bib79">Maier and Seligman, 2016</xref>). This form of aversive learning has been reproduced in humans and other animals, including rodents (<xref ref-type="bibr" rid="bib2">Abramson et al., 1978</xref>; <xref ref-type="bibr" rid="bib24">Chourbaji et al., 2005</xref>; <xref ref-type="bibr" rid="bib78">Maier, 1984</xref>; <xref ref-type="bibr" rid="bib79">Maier and Seligman, 2016</xref>). Reduced reactivity to aversive stimuli after LH is reversed by antidepressant treatments in animal models (<xref ref-type="bibr" rid="bib12">Belujon and Grace, 2014</xref>; <xref ref-type="bibr" rid="bib24">Chourbaji et al., 2005</xref>; <xref ref-type="bibr" rid="bib63">Krishnan and Nestler, 2011</xref>). Several studies have implicated the involvement of neuromodulatory systems, including dopamine, norepinephrine, and serotonin in the acquisition of LH and its expression over time (<xref ref-type="bibr" rid="bib13">Belujon and Grace, 2017</xref>; <xref ref-type="bibr" rid="bib35">Eley et al., 2004</xref>; <xref ref-type="bibr" rid="bib85">Nestler and Carlezon, 2006</xref>; <xref ref-type="bibr" rid="bib87">Nutt et al., 2006</xref>).</p><p>Dopaminergic (DA) neurons in the ventral tegmental area (VTA) primarily encode reward and aversion, responding to both types of stimuli (<xref ref-type="bibr" rid="bib67">Lammel et al., 2014</xref>; <xref ref-type="bibr" rid="bib84">Morales and Margolis, 2017</xref>; <xref ref-type="bibr" rid="bib116">Tan et al., 2012</xref>; <xref ref-type="bibr" rid="bib118">Tsai et al., 2009</xref>; <xref ref-type="bibr" rid="bib124">Watabe-Uchida et al., 2017</xref>). The activation of DA neurons is important in the development of aversive conditioning (<xref ref-type="bibr" rid="bib30">de Jong et al., 2019</xref>), and the activity of DA neurons is differentially modulated by acute and chronic stress (<xref ref-type="bibr" rid="bib46">Grace, 2016</xref>; <xref ref-type="bibr" rid="bib53">Hollon et al., 2015</xref>; <xref ref-type="bibr" rid="bib107">Russo and Nestler, 2013</xref>). Establishing a causal connection between DA neuron activity and depressive-like behavior, optogenetic activation of VTA DA neurons increases behavioral resilience to social defeat stress (<xref ref-type="bibr" rid="bib22">Chaudhury et al., 2013</xref>) and promotes active coping actions (<xref ref-type="bibr" rid="bib119">Tye et al., 2012</xref>). How VTA DA neurons adjust their activity during aversive learning and how these activity changes relate to reduced reactivity to aversive stimuli after learning remains unclear.</p><p>Widely used antidepressants, mostly targeting monoamine reuptake systems, are limited by delayed onset of efficacy, incomplete remission, and low remission rates (<xref ref-type="bibr" rid="bib122">Walker et al., 2015</xref>). Ketamine acts primarily as an antagonist at the glutamatergic N-methyl-D-aspartate (NMDA) receptors, showing rapid onset anti-depressant effects in depressed patients (<xref ref-type="bibr" rid="bib14">Berman et al., 2000</xref>; <xref ref-type="bibr" rid="bib28">Daly et al., 2018</xref>). In addition, mechanisms beyond direct NMDAR antagonism likely participate in the rapid behavioral effects of ketamine, implicating other classes of glutamate receptors, neuromodulators, and emergent circuit-level dynamics (<xref ref-type="bibr" rid="bib3">Ali et al., 2020</xref>; <xref ref-type="bibr" rid="bib21">Chatterjee et al., 2012</xref>; <xref ref-type="bibr" rid="bib34">Duman, 2018</xref>; <xref ref-type="bibr" rid="bib49">Hare et al., 2020</xref>; <xref ref-type="bibr" rid="bib74">Lorrain et al., 2003</xref>; <xref ref-type="bibr" rid="bib134">Zanos et al., 2016</xref>). Ketamine ameliorates depressive-like behaviors in animal models of acute and prolonged stress (<xref ref-type="bibr" rid="bib33">Duman et al., 2016</xref>; <xref ref-type="bibr" rid="bib31">Duman and Aghajanian, 2012</xref>; <xref ref-type="bibr" rid="bib40">Fuchikami et al., 2015</xref>; <xref ref-type="bibr" rid="bib50">Harmer et al., 2017</xref>; <xref ref-type="bibr" rid="bib63">Krishnan and Nestler, 2011</xref>), and rescues escape actions in response to aversive stimuli after LH induction (<xref ref-type="bibr" rid="bib12">Belujon and Grace, 2014</xref>). A recently published meta-analysis suggests that acute sub-anesthetic doses of ketamine may increase DA levels in the cortex, dorsal striatum, and nucleus accumbens (<xref ref-type="bibr" rid="bib59">Kokkinou et al., 2018</xref>). In vivo recordings from electrophysiologically identified VTA DA neurons in rats highlight ketamine’s modulation of neuronal firing (<xref ref-type="bibr" rid="bib12">Belujon and Grace, 2014</xref>). The medial prefrontal cortex (mPFC), essential for higher order cognitive functions including the control of emotional processing, is one key site for ketamine effects in the brain. Ketamine has been shown to modulate mPFC activity and plasticity to rescue depressive-like behaviors (<xref ref-type="bibr" rid="bib70">Li et al., 2010</xref>; <xref ref-type="bibr" rid="bib74">Lorrain et al., 2003</xref>; <xref ref-type="bibr" rid="bib83">Moda-Sava et al., 2019</xref>; <xref ref-type="bibr" rid="bib86">Ng et al., 2018</xref>; <xref ref-type="bibr" rid="bib113">Shirayama and Hashimoto, 2017</xref>; <xref ref-type="bibr" rid="bib127">Wu et al., 2021a</xref>). Given the bidirectional connectivity between VTA and mPFC (<xref ref-type="bibr" rid="bib11">Beier et al., 2015</xref>), ketamine may regulate VTA DA activity through actions in mPFC, proposed to potentiate the activity of pyramidal neurons rapidly through disinhibition by suppressing inhibitory interneurons (<xref ref-type="bibr" rid="bib3">Ali et al., 2020</xref>; <xref ref-type="bibr" rid="bib49">Hare et al., 2020</xref>; <xref ref-type="bibr" rid="bib54">Homayoun and Moghaddam, 2007</xref>). Despite some reported and suggested links between ketamine and DA systems, the causal relationship between the DA system and ketamine’s effects on behavior remains to be elucidated.</p><p>Here, we use fiber photometry to record the responses of VTA DA neurons to aversive stimuli across different phases of learning in LH. By leveraging the tunability of LH induction parameters, we also design a modified, weaker LH paradigm to reveal the activity patterns of VTA DA neurons for distinct behavioral outcomes, correlating the activity signatures with future sensitivity to ketamine treatment. By using chemogenetic inhibition, we demonstrate that VTA DA activity and downstream signaling is necessary for the behavioral effects of ketamine. Finally, combining fiber photometry, anatomical tracing, and chemogenetics, we find that mPFC serves as an action site of ketamine to restore DA dynamics and escape actions.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>VTA DA neuron activity during aversive learning</title><p>To define the function of midbrain DA neurons during aversive learning, we used a variant of learned helplessness (LH) (<xref ref-type="bibr" rid="bib24">Chourbaji et al., 2005</xref>). A shuttle box with two compartments connected by a door allows animals to escape from one side to the other when an electric foot shock is delivered to either compartment. Prior to LH induction, mice were exposed to 30 escapable shocks to test baseline escape behaviors. Initially, mice escape from electric foot shocks. However, following repeated exposure to <italic>inescapable</italic> foot shocks, mice reduce escapes from avoidable 10 s-long foot shocks (<xref ref-type="fig" rid="fig1">Figure 1a and b</xref>). Our data and prior publications (<xref ref-type="bibr" rid="bib12">Belujon and Grace, 2014</xref>; <xref ref-type="bibr" rid="bib16">Beurel et al., 2011</xref>; <xref ref-type="bibr" rid="bib76">Maeng et al., 2008</xref>) show that a single low dose of racemic ketamine 4 hr prior to the test (10 mg/kg, b.w., i.p.) is sufficient to rescue escape behavior in this LH paradigm (<xref ref-type="fig" rid="fig1">Figure 1b</xref>). A separate group of mice that received saline instead of ketamine following the same experimental design did not decrease escape failures after LH (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1a</xref>). Thus, reduced failures to escape after ketamine treatment are not simply a function of time elapsed since LH induction (i.e. spontaneous fear extinction). Reduced escape behavior after LH induction, as well as its reversal by ketamine, are not strictly context-dependent, since the proportion of failures to escape was similar regardless of whether behavioral evaluation was carried out in the induction context or in a novel environment (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1b</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Ketamine rescues escape behavior and dampened DA neuronal activity after aversive learning.</title><p>(<bold>a</bold>). Schematic illustrating the timeline of behavioral and pharmacological manipulations in the LH paradigm. (<bold>b</bold>). Left, summary data showing the percentage of failures to escape an escapable aversive shock across phases of learning (Baseline, LH, and LH+ KET). Middle, same as left, but for latency to escape. Right, for all conditions, the correlation between percentage of failure to escape and escape latency (failure to escape trials scored as 10 sec latency). n = 24 trials from eight mice. % Failures: repeated measures one-way ANOVA, F (1.89, 13.23) = 27.9, p = 0.0001, Sidak’s multiple comparison test, Baseline vs LH, p = 0.0001, LH vs LH+ KET, p = 0.0037. Latency to escape: repeated measure one-way ANOVA, F (1.96, 13.72) = 29.63, p &lt; 0.0001, Sidak’s multiple comparison test, Baseline vs LH, p = 0.0003, LH vs LH+ KET, p = 0.0141. Pearson correlation: <italic>R</italic> = 0.9346, p &lt; 0.0001. (<bold>c</bold>). Left, schematic for viral transduction in the VTA and subsequent fiber implant. Right, fiber placement verification. Green, GCaMP6f; blue, Hoechst nuclear stain. Scale bar: 500 μm. (<bold>d</bold>). Left, baseline adjusted raw traces of VTA DA neuron Ca<sup>2+</sup> responses to inescapable foot shocks (3 s, pink) in one animal, at the start of induction, at the end of induction, and 4 hr following a single dose of ketamine (LH+ KET, 10 mg/kg i.p.). Right, average traces in the same subject aligned to shock start time (20 trials/condition, mean ± SEM). (<bold>e</bold>). Left, quantification of peak Ca<sup>2+</sup> transient amplitude during and after foot-shock stimuli across conditions. Right, same but for area under the curve (AUC). Both positive and negative values are quantified. n = 8 animals, repeated measures one-way ANOVA, Holm-Sidak’s multiple comparison test, Peak: During shock, F (1.823, 12.76) = 5.387, p = 0.0222, Induction start vs Induction end, p = 0.0458, Induction end vs LH + KET, p = 0.0788. After shock, F (1.693, 11.85) = 6.805, p = 0.0132, Induction start vs Induction end, p = 0.0230, Induction end vs LH + KET, p = 0.0068. AUC: During shock, F (1.705, 11.94) = 8.942, p = 0.0054, Induction start vs Induction end, p = 0.0058, Induction end vs LH + KET, p = 0.0258. After shock, F (1.437, 10.06) = 5.499, p = 0.0318, Induction start vs Induction end, p = 0.0257, Induction end vs LH + KET, p = 0.0069. *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001. Error bars reflect SEM.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Numerical data for the graphs in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64041-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64041-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Characterization of behavior after learned helplessness.</title><p>(<bold>a</bold>). Left, summary data showing the percentage of failures to escape an escapable aversive shock across phases of learning (Baseline, LH, and LH+ Saline). Right, same as left, but for latency to escape. n = 5 animals. One-way ANOVA, Sidak’s multiple comparison test, LH vs LH+ KET, % Failures, = 0.5299, latency to escape, p = 0.7027. (<bold>b</bold>). Left, summary data showing the percentage of failures to escape an escapable aversive shock in learning and novel contexts (LH, and LH+ KET). Right, same as left, but for latency to escape. n = 5 animals. Two-way ANOVA, Sidak’s multiple comparison test, learning vs novel contexts, % Failures, LH, p = 0.5669, LH+ KET, p = 0.3924. Latency to escape, LH, p = 0.6409, LH+ KET, p = 0.5089. LH vs LH+ KET, % Failures, learning context, p** = 0.0013, novel context, p** = 0.0023. Latency to escape, learning context, p* = 0.0219, novel context, p* = 0.0336.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Numerical data for the graphs in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64041-fig2-data2-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64041-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>VTA DA neuron responses to anesthesia, foot shock, and motion transitions.</title><p>(<bold>a</bold>). Photometry-guided fiber implantation into the VTA. Recording began when the fiber traversed the pia. A gradual increase of fluorescence intensity was observed as the fiber tip approached GCaMP6f-expressing neurons, 3.8–4.5 mm from the pia, followed by a sharp signal increase and stabilization close to the VTA. (<bold>b</bold>). Oscillation of VTA DA Ca<sup>2+</sup> transients under anesthesia. Approximately 1–2 Hz oscillations were observed in every animal. Summary data show the dominant oscillation frequencies. (<bold>c</bold>). Average neural activity-independent fluorescence transients illustrated for one EGFP-expressing animal in response to inescapable foot-shocks across learning phases. Traces are aligned to shock start time (20 trials/animal, n = 3 animals). (<bold>d</bold>). Average Ca<sup>2+</sup> transients (mean ± SEM) in response to foot shocks for all animals across learning phases. Traces are aligned to shock start time (20 trials/animal, 8 animals). (<bold>e</bold>). Atlas locations showing fiber placements for data in <xref ref-type="fig" rid="fig1">Figure 1e</xref>. (<bold>f</bold>). Heatmap of single trial Ca<sup>2+</sup> traces across learning in one mouse. Pink rectangle and green dashed lines mark the timing of shock stimuli. Colormap of dF/F, blue –0.3, red 0.3, saturated for values outside this range for illustration purposes. (<bold>g</bold>). Left, latencies from shock onset to dF/F peak (averages of sequential bins of 10 traces) for subjects across learning days. Right, cumulative frequency distribution of latencies to peak. n = 8 animals, one-way ANOVA, F (2, 258) = 9.387, p = 0.0001. Sidak’s multiple comparison test, Day 1 vs Day 2, p = 0.0001, Day 2 vs LH+ KET, p = 0.0342. (<bold>h</bold>). Open field locomotion (m/min) for n = 5 mice across learning phases. Repeated measures one-way ANOVA, F (1.038, 4.153) = 1.479, p = 0.2910. (<bold>i</bold>). Average Ca<sup>2+</sup> transients around motion onset and offset for mice in the Baseline, LH, and LH+ KET conditions. Dashed black line marks motion onset/offset. The number of onsets/offsets, as noted. n = 5 animals. *p &lt; 0.05, **** p &lt; 0.0001. Error bars reflect SEM.</p><p><supplementary-material id="fig1s2sdata1"><label>Figure 1—figure supplement 2—source data 1.</label><caption><title>Numerical data for the graphs in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64041-fig3-data3-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64041-fig1-figsupp2-v2.tif"/></fig></fig-group><p>To understand the relationship between VTA DA neuron activity and ketamine’s rescue of escape behavior, we used fiber photometry to monitor the activity of the genetically encoded calcium indicator GCaMP6f in VTA DA neurons. DAT<sup>icre</sup> neonates were virally transduced with Cre-dependent AAV1.CAG.FLEX.GCaMP6f. Four to six weeks after transduction, optical fibers were implanted in the VTA (<xref ref-type="fig" rid="fig1">Figure 1c</xref>), guided by real-time photometry (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2a</xref>). During fiber implant procedure, we observed that surgical anesthesia was associated with ~1 Hz oscillations in VTA calcium transients (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2b</xref>). After mice recovered from surgery, we evaluated the activity of VTA DA neurons during aversive learning in young adult mice (P40-60) of both sexes. We first recorded Ca<sup>2+</sup> transients of VTA DA neurons in response to brief, inescapable foot shocks (3 s, 0.3 mA) during the learning period and after ketamine treatment. At the start of learning (Induction start), the activity of VTA DA neurons first decreased during the aversive foot shocks and then rose after the termination of the shock (<xref ref-type="fig" rid="fig1">Figure 1d and e</xref>). This biphasic response is consistent with recently published observations of VTA DA activity during other forms of aversive conditioning (<xref ref-type="bibr" rid="bib30">de Jong et al., 2019</xref>). Notably, the responses of VTA DA neurons to inescapable foot shocks were blunted at the end of the second-day induction (Induction end). A single low dose of racemic ketamine (10 mg/kg, b.w., i.p., LH + KET) largely restored the characteristic Ca<sup>2+</sup> transient features, in parallel to the behavioral rescue (<xref ref-type="fig" rid="fig1">Figure 1d and e</xref>; <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2d</xref>, e). Visualizing sequential Ca<sup>2+</sup> traces from individual trials illustrates (1) the prevalence of after-shock peaks at the start of learning, (2) their decreased latency relative to shock onset during the second day of training, and (3) the recovery of Ca<sup>2+</sup> transient latency to peak following ketamine administration (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2f</xref>). To quantify this temporal structure, we computed the latency to peak on sequential averaged trials (n = 10 trials/avg) and plotted the data as a scatter plot and cumulative distribution (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2g</xref>). No significant transients were observed in GFP-expressing controls in this behavioral assay (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2c</xref>).</p><p>Since the activity of DA neurons has been linked to movement (<xref ref-type="bibr" rid="bib27">da Silva et al., 2018</xref>; <xref ref-type="bibr" rid="bib57">Howe and Dombeck, 2016</xref>), one potential explanation for how aversive learning could modulate Ca<sup>2+</sup> activity of VTA DA neurons involves altered locomotor behavior. While ketamine acutely changes locomotion, this effect normally occurs within tens of minutes following administration (<xref ref-type="bibr" rid="bib3">Ali et al., 2020</xref>), and resolves by the time clinically relevant changes in affective behavior are observed (<xref ref-type="bibr" rid="bib14">Berman et al., 2000</xref>; <xref ref-type="bibr" rid="bib95">Peltoniemi et al., 2016</xref>). We found no differences in open-field locomotion across phases of learning (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2h</xref>). Additionally, changes in VTA DA neuron activity were not associated with motion transitions, including onset and offset of locomotion (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2i</xref>). This result is not surprising, since movement transitions are typically associated with the activity of DA neurons in the Substantia Nigra pars Compacta rather than the VTA (<xref ref-type="bibr" rid="bib27">da Silva et al., 2018</xref>; <xref ref-type="bibr" rid="bib57">Howe and Dombeck, 2016</xref>). Together, our data demonstrate that VTA DA neuron activity is restructured by LH, which is rescued following ketamine treatment.</p></sec><sec id="s2-2"><title>Outcome-specific VTA DA dynamics during weaker aversive learning and after ketamine treatment</title><p>To better understand the relationship between VTA DA neuron activity and specific behavioral responses across phases of learning, we designed a weaker learning paradigm (wLH), which allowed us to compare Ca<sup>2+</sup> transients across distinct behavioral outcomes, escapes versus failures. wLH includes a larger number of brief escapable foot shocks as the test stimuli (3 s long, 100 trials), with only a single day of LH induction with inescapable shocks (<xref ref-type="fig" rid="fig2">Figure 2a</xref>). As anticipated, a weaker form of LH, characterized by a lower average failure rate, was observed in this paradigm compared to stronger LH (sLH, as in <xref ref-type="fig" rid="fig1">Figure 1</xref>) (two-way ANOVA for sLH and wLH across behavioral states, Sidak’s multiple comparison, sLH 78 % vs wLH 48%, p = 0.0022). Again, escape behavior recovered after ketamine treatment, compared to saline-treated animals (<xref ref-type="fig" rid="fig2">Figure 2b</xref>, right panel). Another group of control animals underwent test sessions but no induction; they showed no changes in escape behavior over the time of the experiment (one-way ANOVA, p = 0.9882).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Weak learning analysis links DA activity, behavioral outcomes, and response to ketamine.</title><p>(<bold>a</bold>). Top, schematic of experimental timeline for weak LH (wLH). Bottom, schematic of viral transduction, test trial description, and timing of photometry recording. (<bold>b</bold>). Left, summary data showing the percentage of failures to escape an escapable aversive shock across 6 days for two groups (Gray bar, controls; Cyan, wLH). Right, summary of behavioral data for wLH mice with KET or Saline treatment. Left, responses across days, two-way ANOVA, Sidak’s multiple comparison test, Control vs wLH, Day 1, p = 0.9934, Day 2, p = 0.1147, Days 3 and 4, p &lt; 0.0001, Day 5, p = 0.0007, and D6, p = 0.0691. Control, n = 12; wLH, n = 9 animals. Right, two-way ANOVA, Sidak’s multiple comparison test, wLH+ KET vs wLH+ Saline, Days 1 and 2, p = 0.6403, Days 3 and 4, p = 0.8715, Days 5 and 6, p &lt; 0.0001. n = 9 animals/group. (<bold>c</bold>). Fiber photometry recordings of VTA DA Ca<sup>2+</sup> transients, separated by behavioral response and aligned to shock start time (purple, escape; orange, failure; average dF/F across animals). Gray rectangles mark shock length in time, which is constant for failures to escape but variable for successful escapes and is shaded proportionally. Donut plots depict proportion of behavioral responses. n = 8 animals, baseline: 1405 trials, 25% failure 75% escape; wLH: 1459 trials, 60% failure 40% escape; wLH+ KET: 1403 trials, 36% failure, 64% escape. (<bold>d</bold>). Left, schematic illustration for measured variables. Middle, summary data for AUC of the positive Ca<sup>2+</sup> transient peaks in escapes across learning phases. Right, same but AUC for both positive and negative peaks in failures, as shown in the schematic. n = 12 animals, AUC (Escapes), positive peak, repeated measures one-way ANOVA, F (1.897, 20.87) = 1.881, p = 0.1787. AUC (Failures), negative peak, repeated measures one-way ANOVA, F (1.852, 20.38) = 9.260, p = 0.0017, Holm-Sidak’s multiple comparison test, Baseline vs wLH, p = 0.0069, wLH vs wLH+ KET, p = 0.0069. Positive peak, repeated measures one-way ANOVA, F (1.540, 16.94) = 2.541, p = 0.1181. (<bold>e</bold>). Learning curves for individual animals. n = 7 animals, 600 trials/animal. (<bold>f</bold>). Left, schematic illustration for the measured variable, Euclidean norm of the difference between mean escape and failure-associated Ca<sup>2+</sup> transients for each subject. Right, trace distances for each subject across learning phases with subject specific colors as in e. (<bold>g</bold>). Correlation between trace distance and the percentage of failures in wLH+ KET. n = 11 animals. (<bold>h</bold>). Correlation between trace distance in the baseline condition and the percentage of failures in wLH. n = 11 animals. (<bold>i</bold>). Correlation between trace distance in the baseline condition and the percentage of failures in wLH+ KET. n = 11 animals. ** p &lt; 0.01, *** p &lt; 0.001, **** p &lt; 0.0001. Error bars reflect SEM.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Numerical data for the graphs in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64041-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64041-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Characterization of behavioral sequences and dampened VTA DA activity in weak learned helplessness (wLH) paradigm.</title><p>(<bold>a</bold>). Graphs depicting transition probabilities between behavioral responses during baseline (top), wLH (middle), and wLH+ KET (bottom). Arrow sizes are proportional to transition probability, noted numerically. Table, Frobenius norms of differences between graphs for each graph pair. n = 7 animals, 1400 trials/condition. (<bold>b</bold>). Summary data showing the probability of successive responses of different lengths (1-11) for escape (left) and failure (right) across learning states. Two-way ANOVA, Sidak’s multiple comparison test. Escape main effect, Baseline vs wLH and Baseline vs wLH+ KET, p &lt; 0.0001, wLH vs wLH+ KET, p = 0.0031. Failure main effect, Baseline vs wLH and wLH vs wLH+ KET, p &lt; 0.0001, Baseline vs wLH+ KET, p = 0.3291. For comparison within specific length of responses, * p &lt; 0.05 ** p &lt; 0.01 vs Baseline, # p &lt; 0.05 vs wLH, n = 7 animals. (<bold>c</bold>). Left, average Ca<sup>2+</sup> transients in response to foot shocks during wLH induction (mean ± SEM). Traces are aligned to shock start time (20 trials/animal, 8 animals). Right, quantification of peak Ca<sup>2+</sup> transient amplitude of first and last 20 trials during induction. Two-tailed paired t-test, p = 0.009. *p &lt; 0.05, ** p &lt; 0.01, **** p &lt; 0.0001. <sup>#</sup>p &lt; 0.05, <sup>##</sup>p &lt; 0.01, <sup>####</sup>p &lt; 0.0001. Error bars reflect SEM.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Numerical data for the graphs in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64041-fig5-data5-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64041-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Outcome-specific VTA DA responses in wLH paradigm.</title><p>(<bold>a</bold>). Schematic illustration for the measured variables. (<bold>b</bold>). Left, summary data for latency to peak of the positive Ca<sup>2+</sup> transient peaks in escapes across learning phases. Right, same but for both positive and negative peaks in failures, as shown in the schematic. n = 12 animals, Escapes, positive peak, repeated measures one-way ANOVA, F (1.902, 20.92) = 0.622, p = 0.5388. Failures, negative peak, repeated measures one-way ANOVA, F (1.784, 19.62) = 36.23, p &lt; 0.0001, Holm-Sidak’s multiple comparison test, Baseline vs wLH, p &lt; 0.0001, wLH vs wLH+ KET, p = 0.0025. Positive peak, repeated measures one-way ANOVA, F (1.301, 14.31) = 5.369, p = 0.0286, Holm-Sidak’s multiple comparison test, Baseline vs wLH, p = 0.0003, wLH vs wLH+ KET, p = 0.0446. *p &lt; 0.05, ** p &lt; 0.01, *** p &lt; 0.001. Error bars reflect SEM.</p><p><supplementary-material id="fig2s2sdata1"><label>Figure 2—figure supplement 2—source data 1.</label><caption><title>Numerical data for the graphs in <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64041-fig6-data6-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64041-fig2-figsupp2-v2.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Outcome-specific VTA DA responses in control mice without wLH induction.</title><p>(<bold>a</bold>). Fiber photometry recordings of VTA DA Ca<sup>2+</sup> transients, separated by behavioral response and aligned to shock start time (purple, escape; orange, failure; average dF/F across animals). Donut plots depict proportion of behavioral responses. n = 6 animals, Days 1 and 2: 11 % failure, 89% escape; Days 3 and 4: 12% failure, 88% escape; Days 5 and 6: 12% failure, 88% escape. (<bold>b</bold>). Left, schematic illustration for measured variables. Middle, summary data for AUC of the positive Ca<sup>2+</sup> transient peaks in escapes across learning phases. Right, same but AUC for both positive and negative peaks in failures, as shown in the schematic. n = 6 animals, AUC (Escapes), positive peak, repeated measures one-way ANOVA, F (1.617, 8.084) = 2.103, p = 0.1858. AUC (Failures), negative peak, repeated measures one-way ANOVA, F (1.422, 7.112) = 0.2283, p = 0.7291, Positive peak, repeated measures one-way ANOVA, F (1.584, 8.918) = 1.191, p = 0.3391.</p><p><supplementary-material id="fig2s3sdata1"><label>Figure 2—figure supplement 3—source data 1.</label><caption><title>Numerical data for the graphs in <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64041-fig7-data7-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64041-fig2-figsupp3-v2.tif"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 4.</label><caption><title>Outcome-specific VTA DA responses in wLH mice with saline treatment.</title><p>(<bold>a</bold>). Fiber photometry recordings of VTA DA Ca<sup>2+</sup> transients, separated by behavioral response and aligned to shock start time (purple, escape; orange, failure; average dF/F across animals). Donut plots depict proportion of behavioral responses. n = 9 animals, wLH: 44% failure, 56% escape; wLH+ Saline: 59% failure, 41% escape. (<bold>b</bold>). Left, schematic illustration for measured variables. Middle, summary data for AUC of the positive Ca<sup>2+</sup> transient peaks in escapes across learning phases. Right, same but AUC for both positive and negative peaks in failures, as shown in the schematic. n = 9 animals, AUC (Escapes), positive peak, two-tailed paired t-test, p = 0.9420. AUC (Failures), negative peak, two-tailed paired t-test, p = 0.3578, Positive peak, two-tailed paired t-test, p = 0.3988.</p><p><supplementary-material id="fig2s4sdata1"><label>Figure 2—figure supplement 4—source data 1.</label><caption><title>Numerical data for the graphs in <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64041-fig8-data8-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64041-fig2-figsupp4-v2.tif"/></fig><fig id="fig2s5" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 5.</label><caption><title>Trace distance of GCaMP transients between escape and failure trials.</title><p>(<bold>a–b</bold>). Example trace distance calculation for two animals. Top row, individual animals marked on the trace distance graph from <xref ref-type="fig" rid="fig2">Figure 2f</xref>. Second row, average traces of escapes and failures across learning states. Third row, difference between the average escape and failure traces. Bottom row, Euclidean norm of subtraction traces.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64041-fig2-figsupp5-v2.tif"/></fig></fig-group><p>A three-state transition model depicts the probability of transitioning between behavioral responses, allowing us to compare patterns of response sequences across learning (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1a</xref>). In addition to escapes and failures, responses were labeled ‘spontaneous’ when the animal spontaneously ran to the other side of the chamber during the random length pretrial time. Baseline and post-ketamine sequences of behavioral responses were more similar to each other than either was to wLH. In addition to changing the average probabilities of pairs of responses, wLH also altered longer sequences of outcomes within animals, reflected in decreased probability and length of successive escapes, as well as increased successive failures. Ketamine treatment partially recovered the probability and length of successive escapes, while a more prominent effect was observed on decreasing successive failures back to baseline levels (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1b</xref>). Altogether, these analyses suggest that ketamine specifically restructures behavioral sequences that are altered by wLH learning.</p><p>The weaker LH paradigm, along with a large number of escapable foot shocks as the test stimuli, enabled broad sampling of Ca<sup>2+</sup> transients during both escape and failure trials across conditions. Similar reductions in VTA DA responses to inescapable foot shocks were observed during wLH induction, as for strong LH (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1c</xref>). For escapable shocks, separately plotting VTA DA neuron activity for trials where the animal escaped or failed to escape revealed that each behavioral response is associated with distinct Ca<sup>2+</sup> transient shapes (<xref ref-type="fig" rid="fig2">Figure 2c</xref>). Failure trial transients were biphasic, where fluorescence decreased during the shock and increased afterwards. In contrast, monophasic transients accompanied escape trials, with an increase in fluorescence following successful transitions to the other side of the box. After learning, an increase in the similarity of the activity patterns between escape and failure trials was observed (<xref ref-type="fig" rid="fig2">Figure 2c and d</xref>). For successful escape responses, VTA DA Ca<sup>2+</sup> transients did not change in wLH and wLH+ ketamine. The increased similarity of Ca<sup>2+</sup> transients between outcomes after learning was explained by the reduction in negative transients associated with failures. These failure-linked negative transients recovered following ketamine treatment (<xref ref-type="fig" rid="fig2">Figure 2d</xref>). The timing of peaks in failure outcomes varied across conditions (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2a</xref>, b). Outcome-specific GCaMP6f transients, for either successful escapes or failures, did not vary across days in control mice without wLH induction, suggesting that the exposure to inescapable shocks is necessary to shape the responses of VTA DA neurons (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3a</xref>, b). In a separate control group, saline treatment did not change DA transients in either escape or failure trials after wLH (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4a</xref>, b).</p><p>In humans and other animals, individual variability in stress susceptibility and in responsiveness to neuroactive compounds is broadly acknowledged (<xref ref-type="bibr" rid="bib55">Honey et al., 2008</xref>). To visualize behavioral trajectories, learning curves were constructed by starting at 0 and incrementing by one for every escape trial, decrementing by one for every failure, and keeping constant for spontaneous transitions (<xref ref-type="fig" rid="fig2">Figure 2e</xref>). These learning curves highlight individual variability in learning and ketamine responsiveness. To depict the relationship between an animal’s ketamine responsiveness and VTA DA activity, we plotted the Euclidean norm of the difference between their Ca<sup>2+</sup> transients during escape and failure trials (<inline-formula><mml:math id="inf1"><mml:msub><mml:mrow><mml:mo>|</mml:mo><mml:mo>|</mml:mo><mml:mi>e</mml:mi><mml:mi>s</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>p</mml:mi><mml:mi>e</mml:mi><mml:mo>-</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>l</mml:mi><mml:mi>u</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mo>|</mml:mo><mml:mo>|</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>) across learning (<xref ref-type="fig" rid="fig2">Figure 2f</xref>, <xref ref-type="fig" rid="fig2s5">Figure 2—figure supplement 5a</xref>, b). We selected this trace distance metric because it is agnostic to amplitude and kinetics of the response, specifically assaying the degree to which the activity of VTA DA neurons differentiates specific trial outcomes. <xref ref-type="fig" rid="fig2">Figure 2g</xref> shows a correlation between behavioral response (% failures) and trace distance following ketamine. Stronger ketamine behavioral effects were linked to more distinct Ca<sup>2+</sup> transients when comparing escape and failure trials (R<sup>2</sup> = 0.399). Animals characterized by a larger trace distance in the baseline were more resilient to inescapable stress during LH illustrated by fewer failures to escape after wLH (<xref ref-type="fig" rid="fig2">Figure 2h</xref>, R<sup>2</sup> = 0.629). Intriguingly, individuals with larger differences between DA GCaMP signals on escape and failure trials in the baseline showed stronger responses to future ketamine treatment (<xref ref-type="fig" rid="fig2">Figure 2i</xref>, R<sup>2</sup> = 0.715).</p></sec><sec id="s2-3"><title>DA neuron activity is necessary for behavioral effects of ketamine after LH</title><p>The association between DA transients, behavioral states, and trial outcomes raises the possibility that particular signatures of DA signals in response to aversive stimuli are required for escape actions. To test whether VTA DA activity is required for escape actions in general, or alternatively, whether it becomes important for restoring escapes after LH, we conditionally expressed an inhibitory DREADD (designer receptor exclusively activated by designer drug) hM4Di in VTA DA neurons. This engineered muscarinic receptor is activated by clozapine-N-oxide (CNO) to drive Gα<sub>i</sub>-coupled pathways (<xref ref-type="bibr" rid="bib5">Armbruster et al., 2007</xref>; <xref ref-type="bibr" rid="bib61">Kozorovitskiy et al., 2015</xref>; <xref ref-type="bibr" rid="bib60">Kozorovitskiy et al., 2012</xref>; <xref ref-type="bibr" rid="bib103">Roth, 2016</xref>). We used a CBA promoter-driven Cre-conditional hM4Di AAV, with expression in VTA DA neurons confirmed by immunofluorescence (<xref ref-type="fig" rid="fig3">Figure 3a</xref>). Efficacy was evaluated using cell-attached recordings of hM4Di-mCherry<sup>+</sup> VTA DA neurons, with a flow in and a washout of 1 µM CNO (<xref ref-type="fig" rid="fig3">Figure 3b</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Ketamine behavioral effects in aversive learning require VTA DA activity.</title><p>(<bold>a</bold>). Schematic for viral transduction in the VTA and hM4Di expression in VTA DA neurons (red, hM4Di.mCherry; blue, tyrosine hydroxylase (TH) immunofluorescence). Scale bars, 500 μm and 20 μm. (<bold>b</bold>). Cell-attached recording of spontaneous activity in mCherry<sup>+</sup> VTA neuron before, during, and after bath application of 1 µM clozapine-N-oxide (CNO). Example traces (left) and summary data (right). n = 4 cells from three mice, repeated measures one-way ANOVA, F (2, 6) = 9.634, p = 0.0134, Sidak’s multiple comparison test, Baseline vs CNO, p = 0.0104, CNO vs Washout, p = 0.0488. (<bold>c</bold>). Schematic of experimental timeline and pharmacological interventions in strong LH paradigm. (<bold>d</bold>). Left, summary data showing the percentage of failures to escape an escapable aversive shock across learning and treatment conditions for hM4Di AAV expressing DAT<sup>iCre</sup>-positive and negative littermates. Middle, within subject summary data for behavioral responses after ketamine treatment only, compared with ketamine+ CNO, 4 hr after treatment. Right, same but for 24 hr after treatment. Two-way ANOVA, Sidak’s multiple comparison test, KET + CNO 4 hrs, p &lt; 0.0001, KET + CNO 24 hr, p = 0.0107, KET only, following 4, 24, and 72 hr, p &gt; 0.9, n = 7–8 animals. (<bold>e</bold>). Total distance traveled per minute in an open field locomotion assay for hM4Di<sup>+</sup> animals before and after CNO treatment. Two-tailed paired t-test, p = 0.1473, n = 5 animals. (<bold>f</bold>). Summary data showing the percentage of failures to escape an escapable aversive shock in the baseline condition, for hM4Di-expressing mice before and after CNO treatment. n = 5–6 animals, Two-way ANOVA, Sidak’s multiple comparison test, Baseline, p = 0.9538, LH, p = 0.9947. (<bold>g</bold>). Left, schematic of experimental timeline and pharmacological interventions in weak LH paradigm. Right, summary data showing the percentage of failures to escape an escapable aversive shock across 6 days for two groups (white bar, hM4Di- controls; purple, hM4Di+). Two-way ANOVA, Sidak’s multiple comparison test, hM4Di + vs hM4Di-, D1-D4, p &gt; 0.5, D5, p &lt; 0.0001, D6, p = 0.0001, n = 8 animals. *p &lt; 0.05, *** p &lt; 0.001, **** p &lt; 0.0001. Error bars reflect SEM.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Numerical data for the graphs in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64041-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64041-fig3-v2.tif"/></fig><p>Mice conditionally expressing hM4Di in VTA DA neurons were compared to their Cre<sup>-</sup> littermate controls in the strong LH paradigm. Here, two ketamine treatments were administered on sequential days—the first one along with CNO, and the second one without (<xref ref-type="fig" rid="fig3">Figure 3c</xref>). The expression of hM4Di in DA neurons did not change baseline behavior or learned helplessness induction (<xref ref-type="fig" rid="fig3">Figure 3d</xref>). However, inhibiting DA neurons by CNO application (3 mg/kg, b.w., i.p.) co-administered with ketamine (10 mg/kg, b.w., i.p.) blocked ketamine’s rescue of escape behaviors. This effect was evident 4 hr after CNO/Ketamine treatment and persisted at 24 hr. Yet, when ketamine was administered alone on the following day, the behavioral rescue in hM4Di<sup>+</sup> mice was successful. Persistent LH was evident in multiple animals of both groups 72 hr following the ketamine only treatment (last two bars, <xref ref-type="fig" rid="fig3">Figure 3d</xref>). Comparing behavioral responses following ketamine alone versus ketamine plus CNO, within animals at two separate time-points, showed that the responses of hM4Di<sup>-</sup> animals lie around the unity line (<xref ref-type="fig" rid="fig3">Figure 3d</xref>). In contrast, hM4Di<sup>+</sup> responses were above the unity line, reflecting selective efficacy of ketamine treatment in the absence of CNO. Locomotor behavior in hM4Di-expressing animals was not grossly altered by a single CNO administration, suggesting that the observed changes in escape actions are not due to reduced movement (<xref ref-type="fig" rid="fig3">Figure 3e</xref>).</p><p>Although chemogenetic inhibition of DA activity blocked the behavioral effect of ketamine after aversive learning, the administration of CNO in the absence of ketamine in separate groups of hM4Di<sup>+</sup> mice did not alter the proportion of failures to escape in the baseline condition or after sLH (<xref ref-type="fig" rid="fig3">Figure 3f</xref>). These data support the alternative hypothesis that the effect of ketamine after LH specifically requires the associated restoration of DA signals. Although VTA DA activity varies with behavioral outcomes before LH, innate escape actions may not fundamentally require DA activity. In addition, CNO co-administration blocked the behavioral effects of ketamine in the relatively weaker learning paradigm, as expected (wLH, <xref ref-type="fig" rid="fig3">Figure 3g</xref>). These data support the necessity of VTA DA signaling for the behavioral reversal of aversive learning by ketamine, rather than for native escape responses in naïve animals.</p></sec><sec id="s2-4"><title>Ex vivo local effects of ketamine on VTA DA neurons</title><p>In the next series of experiments, we sought to address the mechanisms underlying ketamine modulation of VTA DA activity and escape actions. In vivo ketamine treatment may modulate DA neuronal activity in a cell-autonomous manner locally in the VTA, or alternatively, indirectly, through effects on brain regions interconnected with the VTA. To determine whether ketamine application changes VTA DA GCaMP activity locally, we performed two-photon calcium imaging of VTA DA neurons with and without ex vivo ketamine application. DAT<sup>icre</sup> neonates were transduced with AAV1.CAG.FLEX.GCaMP6f, and acute brain slices of VTA were prepared and imaged 4–6 weeks after viral transduction (<xref ref-type="fig" rid="fig4">Figure 4a and b</xref>). We observed spontaneous Ca<sup>2+</sup> oscillations of DA neurons ex vivo (<xref ref-type="fig" rid="fig4">Figure 4c</xref>), which have been shown to match action potentials in previous reports (<xref ref-type="bibr" rid="bib36">Engelhard et al., 2019</xref>). Further, bath application of ketamine (50 μM) in acute VTA brain slices did not alter the power or frequency tuning of spontaneous Ca<sup>2+</sup> dynamics in DA neurons (<xref ref-type="fig" rid="fig4">Figure 4C</xref> ), suggesting that the effect of in vivo ketamine treatment on VTA DA Ca<sup>2+</sup> dynamics is not likely to be caused by direct cell-autonomous regulation. To reveal whether ex vivo ketamine application regulates VTA DA firing or spontaneous synaptic inputs, we also carried out cell-attached and whole-cell voltage clamp recordings from genetically targeted VTA DA neurons. DAT<sup>icre</sup> neonates were transduced with AAV1.FLEX.EGFP, and EGFP-expressing cells were recorded in acute brain slices from the VTA (<xref ref-type="fig" rid="fig4">Figure 4g</xref>). Consistent with imaging results, ex vivo application of ketamine did not change spontaneous firing rate of VTA DA cells (<xref ref-type="fig" rid="fig4">Figure 4h and i</xref>), or the amplitudes and inter-event intervals of spontaneous EPSCs and IPSCs (<xref ref-type="fig" rid="fig4">Figure 4J-o</xref> ). Altogether, our data suggest the in vivo effects of ketamine on DA activity and behavior are not likely caused by local regulation in the VTA.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Ex vivo ketamine application does not alter GCaMP6f transients, neuronal firing, and synaptic inputs of VTA DA neurons.</title><p>(<bold>a</bold>). Schematic illustrating viral transduction strategy and two-photon Ca<sup>2+</sup> imaging of VTA DA neurons in acute brain slices. (<bold>b</bold>). Example 2PLSM image of VTA DA neurons expressing GCaMP6f. Scale bar, 20 µm. (<bold>c</bold>). Spontaneous Ca<sup>2+</sup> oscillations in one neuron with and without ketamine bath application (50 µM). Black, ACSF; blue, with ketamine. (<bold>d</bold>). Power spectral density of Ca<sup>2+</sup> transients for the neuron in (<bold>c</bold>). (<bold>e</bold>). Left, quantification of max power with and without ketamine treatment (n = 410 neurons). Right, quantification of frequency at max power. Paired two-tailed t test, ACSF vs KET, Max power, p = 0.8865, Frequency at max power, p = 0.3779. (<bold>f</bold>). Left, histogram showing the distribution of changes in max power with ketamine application. Right, same but for frequency at max power. n = 410 neurons. (<bold>g</bold>). Schematic illustrating viral transduction strategy and electrophysiological recording of VTA DA neurons in acute brain slices. (<bold>h</bold>). Spontaneous action potentials recorded in one neuron with and without ketamine bath application (50 µM). Black, ACSF; blue, with ketamine. (<bold>i</bold>). Quantification of neuronal firing rate with and without ketamine treatment (n = 9 neurons from three animals). Paired two-tailed t test, ACSF vs KET, p = 0.2561. (<bold>j</bold>). Spontaneous EPSCs recorded in one neuron with and without ketamine bath application (50 µM). Black, ACSF; blue, with ketamine. Holding membrane potential at –70 mV, 10 µM Gabazine in ASCF for both conditions. (<bold>k</bold>). Left, cumulative frequency distribution of sEPSCs amplitudes. Right, quantification of sEPSC amplitude in recorded neurons. Paired two-tailed t test, ACSF vs KET, p = 0.1958. n = 17 neurons from three animals. (<bold>l</bold>). Same as (<bold>k</bold>), but for sEPSCs inter-event intervals (IEI). Paired two-tailed t test, ACSF vs KET, p = 0.8413. (<bold>m</bold>). Spontaneous IPSCs recorded in one neuron with and without ketamine bath application (50 µM). Black, ACSF; blue, with ketamine. Holding membrane potential at –70 mV with high chloride internal solution, 10 µM CNQX in ASCF for both conditions. (<bold>n</bold>). Left, cumulative frequency distribution of sIPSCs amplitudes. Right, quantification of sIPSC amplitude in recorded neurons. Paired two-tailed t test, ACSF vs KET, p = 0.9164. n = 12 neurons from two animals. (<bold>o</bold>). Same as (<bold>n</bold>), but for sIPSCs inter-event intervals (IEI). Paired two-tailed t test, ACSF vs KET, p = 0.5675.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Numerical data for the graphs in <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64041-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64041-fig4-v2.tif"/></fig></sec><sec id="s2-5"><title>Local mPFC ketamine infusion rescues VTA Ca<sup>2+</sup> transients and escape actions after LH</title><p>The absence of local modulation of DA neuron activity by ketamine supports the possibility of circuit-level mechanisms. In addition to spontaneous tonic activity, VTA DA neurons are driven by multiple sources of glutamatergic excitation, including inputs from mPFC, PPTg, and PAG, among others (<xref ref-type="bibr" rid="bib84">Morales and Margolis, 2017</xref>). To explore whether ketamine acts through one or more among core glutamatergic VTA inputs to rescue escape actions, we locally infused ketamine into three different brain regions (mPFC, PAG, and PPTg), along with the VTA itself, in separate experiments (<xref ref-type="fig" rid="fig5">Figure 5a</xref>). Local infusion of ketamine into mPFC alone sufficed to rescue escape behavior after LH (<xref ref-type="fig" rid="fig5">Figure 5b</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1a</xref>). In contrast, ketamine infusion into the periaqueductal gray (PAG) and the pedunculopontine tegmental nucleus (PPTg) did not rescue escape actions. Local VTA infusion of ketamine also failed to rescue escape behavior after LH, further supporting the idea that the in vivo effects of ketamine on behavior are not implemented through local regulatory mechanisms in the VTA (<xref ref-type="fig" rid="fig5">Figure 5b</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Local ketamine infusion in mPFC rescues escape behavior and VTA DA activity after LH.</title><p>(<bold>a</bold>). Top, schematic for selected glutamatergic input regions to VTA. Bottom, experimental timeline. (<bold>b</bold>). Summary data showing the percentage of failures after local infusion of ketamine or ACSF in mPFC, and ketamine in PAG, PPTg, and VTA. Two-way ANOVA, Sidak’s multiple comparison test, LH vs LH+ KET, mPFC, p&lt; 0.0001, PAG, p = 0.4965, PPTg, p = 0.9998, VTA, p = 0.9986. LH vs LH+ ACSF (mPFC), p = 0.9993. (<bold>c</bold>). Schematic for viral transduction and VTA photometry recording of Ca<sup>2+</sup> transients with local ketamine delivery in mPFC. (<bold>d</bold>). Left, average Ca<sup>2+</sup> transients (mean ± SEM) in response to foot shocks at the start of induction, at the end of induction, and following local ketamine infusion. Traces are aligned to shock start time (20 trials/animal, 6 animals). Right, quantification of peak Ca<sup>2+</sup> transient amplitude during and after foot shock stimuli across conditions. Both positive and negative values are quantified. n = 6 animals, repeated measures one-way ANOVA, Holm-Sidak’s multiple comparison test, Peak: During shock, F (1.948, 9.739) = 5.547, p = 0.0252, Induction start vs Induction end p = 0.0433, Induction end vs LH + KET, p = 0.0823. After shock, F (1.468, 7.341) = 10.05, p = 0.0105, Induction start vs Induction end, p = 0.0462, Induction end vs LH + KET, p = 0.0147. *p &lt; 0.05, *** p &lt; 0.001, **** p &lt; 0.0001. Error bars reflect SEM.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Numerical data for the graphs in <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64041-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64041-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>VTA DA activity after local ASCF infusion in mPFC.</title><p>(<bold>a</bold>). Atlas location and dye infusion in mPFC. Blue: Chicago Sky Blue 6B. Scale bar: 500 µm. (<bold>b</bold>). Top, schematic for VTA photometry recording of Ca<sup>2+</sup> transients with local ACSF delivery in mPFC. Bottom, average Ca<sup>2+</sup> transients (mean ± SEM) in response to foot shocks in LH mice before and after local ACSF infusion. Traces are aligned to shock start time (20 trials/animal, 6 animals). (<bold>c</bold>). Quantification of peak Ca<sup>2+</sup> transient amplitude during and after foot shock stimuli across conditions. Both positive and negative values are quantified. n = 6 animals, two-tailed paired t-test, Peak: During shock, p = 0.3615; After shock, p = 0.9509.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Numerical data for the graphs in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64041-fig12-data12-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64041-fig5-figsupp1-v2.tif"/></fig></fig-group><p>To test whether local ketamine effects in mPFC rescue VTA DA dynamics after aversive learning in parallel to the behavioral changes, we infused ketamine locally into mPFC (12.5 µg, 500 nl), with fiber photometry as a readout of VTA activity (<xref ref-type="fig" rid="fig5">Figure 5c</xref>). In vivo local infusion of ketamine into mPFC sufficed to recover Ca<sup>2+</sup> activity signatures in VTA DA neurons after aversive learning, along with behavioral rescue (<xref ref-type="fig" rid="fig5">Figure 5d</xref>), while infusion of ACSF did not recover VTA DA activity (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1b</xref>, c). These data support the idea that ketamine rescues VTA DA dynamics through circuit-level effects involving mPFC.</p></sec><sec id="s2-6"><title>mPFC Drd1+ neurons mediate behavioral effects of ketamine</title><p>Next, in order to define the mPFC cell populations that project to the VTA, we combined retrograde tracing with fluorescence in situ hybridization (FISH). We injected red retrograde tracer fluorescent beads (retrobeads, RTB) into the VTA (<xref ref-type="fig" rid="fig6">Figure 6a</xref>) and observed red RTB fluorescence in mPFC 7–9 days after injection (<xref ref-type="fig" rid="fig6">Figure 6b</xref>). Results from FISH experiments demonstrate that the majority of RTB<sup>+</sup> neurons in deep layers (layers 5/6) of mPFC express <italic>Drd1a</italic> mRNA. In contrast, only a small fraction of the retrobead<sup>+</sup> neurons in layers 2/3 of mPFC have <italic>Drd1a</italic> mRNA (<xref ref-type="fig" rid="fig6">Figure 6b and c</xref>). To determine whether the deep layer Drd1<sup>+</sup> population in mPFC projects to the VTA, we expressed AAV8.FLEX.EGFP in Drd1<sup>Cre</sup>(FK150) animals and found that VTA neurons reside within fields of dense projections from mPFC Drd1<sup>+</sup> neurons (<xref ref-type="fig" rid="fig6">Figure 6d</xref>). These anatomical tracing results are consistent with previous reports showing that VTA-targeting mPFC neurons may also receive VTA DA inputs (<xref ref-type="bibr" rid="bib11">Beier et al., 2015</xref>; <xref ref-type="bibr" rid="bib84">Morales and Margolis, 2017</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Activation of mPFC Drd1<sup>+</sup> neurons rescues escape actions.</title><p>(<bold>a</bold>). Left, schematic illustrating retrograde labeling strategy. Right, coronal image of retrobead (RTB) injection site. Red, retrobeads; green, <italic>Dat</italic> mRNA; blue, DAPI. Scale bar, 500 μm. (<bold>b</bold>). Left, retrobead fluorescence in mPFC (atlas overlay, dashed line). Middle and right, colocalization of RTB and <italic>Drd1</italic> mRNA in superficial and deep layers of mPFC. Scale bars, 500 μm (left), 20 μm (middle and right). (<bold>c</bold>). Left, the proportional distribution of RTB<sup>+</sup> neurons across superficial and deep cortical layers. Right, quantification of the percentage of <italic>Drd1a <sup>+</sup></italic> cells among RTB<italic><sup>+</sup></italic> cells across layers. n = 2 animals, 31.3% RTB<sup>+</sup> neurons in layer 2/3, 68.7% RTB<sup>+</sup> in layer 5/6. Among those RTB<sup>+</sup> neurons, 13.2% ± 6.2% are <italic>Drd1<sup>+</sup></italic> in layer 2/3, + ± 2.5 are <italic>Drd1<sup>+</sup></italic> in layer 5/6. (<bold>d</bold>). Left, schematic illustrating viral transduction strategy. Right, a coronal image showing the expression of EGFP (green) in the mPFC Drd1<sup>+</sup> neurons. Scale bar, 500 μm. (<bold>e</bold>). Left, schematic illustrating viral transduction strategy. Right, epifluorescent image of hM3Dq-mCherry expression in mPFC. Scale bar, 500 μm. (<bold>f</bold>). Whole-cell recording of action potentials evoked by different amplitude current injections in one mCherry<sup>+</sup> mPFC neuron before, during, and after bath application of 1 µM CNO. Left, example traces. Right, summary data for minimal injected current sufficient to evoke action potential firing before and after CNO application. n = 6 cells from two animals, two-tailed paired t-test, p = 0.0028. (<bold>g</bold>). Summary data showing the percentage of failures to escape an escapable aversive shock in Drd1-Cre<sup>+</sup> and Drd1-Cre<sup>-</sup> mice expressing hM3Dq across phases of learning and after CNO treatment (Baseline, LH, LH+ CNO 2 hrs, and LH+ CNO 4 hrs). n = 8 animals for Cre<sup>-</sup>, n = 10 mice for Cre<sup>+</sup>, two-way ANOVA, Sidak’s multiple comparison test, LH+ CNO 2 hr, p = 0.0157, LH+ CNO 4 hr, p &lt; 0.0001, Baseline/LH, p &gt; 0.9. (<bold>h</bold>). Left, colocalization of c-fos immunolabeling in hM3Dq.mCherry<sup>+</sup> mPFC neurons in saline and CNO-treated Drd1 Cre<sup>+</sup>, hM3Dq-expresing mice. Right, the quantification of percentage of c-fos<italic><sup>+</sup></italic> cells among mCherry<italic><sup>+</sup></italic> cells. Scale bar, 20 μm. n = 3 mice/condition, two-tailed unpaired t-test, p = 0.0031. (<bold>i</bold>). Total distance traveled per minute in an open-field locomotion assay for hM3Dq<sup>+</sup> animals before and after CNO treatment. Two-tailed paired t-test, p = 0.6289, n = 5 animals. *p &lt; 0.05, ** p &lt; 0.01, **** p &lt; 0.0001. Error bars reflect SEM.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Numerical data for the graphs in <xref ref-type="fig" rid="fig6">Figure 6</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64041-fig6-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64041-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Activity of Drd1<sup>+</sup> neurons in mPFC after in vivo ketamine treatment.</title><p>(<bold>a</bold>). Left, schematic for viral transduction of GCaMP6f in the mPFC with subsequent fiber implant in Drd1<sup>Cre</sup>(FK150) mice. Right, timeline of photometry recording with saline and ketamine treatment (10 mg/kg, i.p.). (<bold>b</bold>). Left, fiber placement illustration on a coronal section through mPFC, with a close-up image of Drd1<sup>+</sup> (white dashed lines, Paxinos atlas overlay; yellow dashed lines, fiber track). Green, GCaMP6f; blue, Hoechst nucleic stain. Scale bars: 500 μm and 50 μm. Right, atlas location of fiber placement for each subject. (<bold>c</bold>). Example traces showing Ca<sup>2+</sup> transients of Drd1<sup>+</sup> neurons in the mPFC from one mouse in baseline, following saline treatment, and after ketamine treatment (5–10, 15–20, 25–30 min, and 24 hr). Black, baseline; gray, saline; red, after ketamine. (<bold>d</bold>). Summary data showing area under the curve (AUC) of Ca<sup>2+</sup> transients in 5 min bins across conditions (Baseline, Saline, 5–10, 15–20, 25–30 min, and 24 hr after ketamine). n = 6 animals, repeated measures one-way ANOVA, F (2.498, 12.49) = 16.94, p = 0.0002. Sidak’s multiple comparison test vs Baseline, Saline, p &gt; 0.9, KET 5–10 min, p = 0.3605, KET 15–20 min, p = 0.0131, KET 25–30 min , p = 0.0063, KET 24 hr, p = 0.0031. *p &lt; 0.05, ** p &lt; 0.01.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Numerical data for the graphs in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64041-fig14-data14-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64041-fig6-figsupp1-v2.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Inhibition of Drd1<sup>+</sup> neurons in mPFC blocks the behavioral effects of ketamine.</title><p>(<bold>a</bold>). Left, schematic illustrating viral transduction strategy. Right, epifluorescent image of hM3Dq-mCherry expression in mPFC. Scale bar, 500 μm. (<bold>b</bold>). Summary data showing the percentage of failures to escape an escapable aversive shock in Drd1-Cre<sup>+</sup> and Drd1-Cre<sup>-</sup> mice expressing hM4Di across phases of learning and after CNO treatment (Baseline, LH, LH+ CNO 4 hr, and LH+ CNO 24 hr). n = 6 animals, two-way ANOVA, Sidak’s multiple comparison test, LH+ CNO 4 hr, p = 0.0056, LH+ CNO 24 hr, p = 0.0002, Baseline/LH, p &gt; 0.9.</p><p><supplementary-material id="fig6s2sdata1"><label>Figure 6—figure supplement 2—source data 1.</label><caption><title>Numerical data for the graphs in <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64041-fig15-data15-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64041-fig6-figsupp2-v2.tif"/></fig><fig id="fig6s3" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 3.</label><caption><title>Behavioral outcomes and viral expression distributions.</title><p>(<bold>a</bold>). Left, violin plot showing the percentage of failures to escape an escapable aversive shock before and after LH induction. The width of the box indicates relative number of data points and the crossbars indicate three quartiles (<bold>Q1, Q2, Q3</bold>). Middle and right, density histograms fitted with the Gaussian distribution. Parameter estimated (Mean, SD± error): Baseline (2.19 ± 0.38, 3.844 ± 0.27), LH (74.02 ± 2.15, 22.23 ± 1.52). n = 105, 107 mice for baseline and LH. (<bold>b</bold>). Same as (<bold>a</bold>) but for wLH. Days 1 and 2 (11.88 ± 1.22, 7.10 ± 0.86), Days 3 and 4 (48.91 ± 2.60, 15.14 ± 1.84). n = 34 mice/condition. (<bold>c</bold>). Heatmap showing viral expression in the VTA of DAT<sup>iCre</sup> mice. n = 10 mice. Scale bar = 1 mm. (<bold>d</bold>). Same but for the mPFC of Drd1<sup>Cre</sup>(FK150) mice. n = 10 mice.</p><p><supplementary-material id="fig6s3sdata1"><label>Figure 6—figure supplement 3—source data 1.</label><caption><title>Numerical data for the graphs in <xref ref-type="fig" rid="fig6s3">Figure 6—figure supplement 3</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64041-fig16-data16-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64041-fig6-figsupp3-v2.tif"/></fig></fig-group><p>To determine whether ketamine modulates the activity of DA-sensing mPFC Drd1<sup>+</sup> neurons in vivo, we used fiber photometry to monitor the activity of Drd1<sup>+</sup> neurons in mPFC before and after ketamine treatment. To restrict the expression of GCaMP6f, we transduced AAV1.CAG.FLEX.GCaMP6f in Drd1<sup>Cre</sup>(FK150) mice (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1a, b</xref>). We observed a rapid enhancement in population activity of cortical Drd1<sup>+</sup> neurons after i.p. ketamine treatment (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1c, d</xref>). This ketamine-induced enhancement of population activity is likely mediated by suppressing the activity of local inhibitory interneurons (<xref ref-type="bibr" rid="bib3">Ali et al., 2020</xref>; <xref ref-type="bibr" rid="bib49">Hare et al., 2020</xref>; <xref ref-type="bibr" rid="bib54">Homayoun and Moghaddam, 2007</xref>). If ketamine effect on mPFC Drd1<sup>+</sup> neurons is crucial for behavioral changes, then the activation of mPFC Drd1<sup>+</sup> neurons should rescue escape actions. We used the Gα<sub>q</sub>-coupled hM3D to directly enhance the excitability of Drd1 expressing neurons in mPFC following aversive learning (<xref ref-type="fig" rid="fig6">Figure 6e</xref>). The expression and functional activation of hM3Dq were validated by immunohistochemistry and electrophysiology (<xref ref-type="fig" rid="fig6">Figure 6f</xref>). The expression of hM3Dq also did not change baseline escape/failure rates, or the magnitude of aversive learning. After LH induction, a single i.p. dose of CNO was sufficient to rescue escape behavior rapidly within 2 hr, with a larger effect observed 4 hr after CNO treatment (<xref ref-type="fig" rid="fig6">Figure 6g</xref>). At the end of the experiment, the successful enhancement of neuronal activity was further validated by evaluating immediate early gene product c-fos expression in mCherry<sup>+</sup> neurons (<xref ref-type="fig" rid="fig6">Figure 6h</xref>). The activation of hM3Dq in Drd1-positive mPFC neurons did not alter locomotion, suggesting the rescue of escape action is not due to hyperlocomotor activity (<xref ref-type="fig" rid="fig6">Figure 6i</xref>). In addition to our results, a recently published study showed that optogenetic activation of Drd1<sup>+</sup> mPFC neurons decreases immobility time in the forced swim test, suggesting the possibility that these Drd1-expressing neurons may broadly regulate aversive or active coping responses (<xref ref-type="bibr" rid="bib48">Hare et al., 2019</xref>). Furthermore, consistent with prior findings (<xref ref-type="bibr" rid="bib48">Hare et al., 2019</xref>), chemogenetic inhibition of mPFC Drd1<sup>+</sup> neuronal excitability through Gα<sub>i</sub>-coupled hM4D blocked the behavioral effects of ketamine after LH (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2a,b</xref>). Altogether, our data demonstrate that mPFC serves as an action site of ketamine to rescue VTA DA dynamics, which is necessary to drive escape actions after LH.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Animals must learn to avoid dangerous stimuli in order to survive, underscoring the ethological significance of aversive learning. However, overlearned responses can be maladaptive. Prolonged exposure to stressful events can lead to learned helplessness (<xref ref-type="bibr" rid="bib24">Chourbaji et al., 2005</xref>; <xref ref-type="bibr" rid="bib78">Maier, 1984</xref>; <xref ref-type="bibr" rid="bib79">Maier and Seligman, 2016</xref>), where an individual fails to avoid unpleasant stimuli. Here, we demonstrate that aversive learning restructures neuronal activity in the VTA DA system, associated with a shift in behavioral outcome distribution. A single low-dose ketamine treatment suffices to temporarily normalize both DA signaling and behavior, with the efficacy of treatment correlating with VTA DA activity features prior to learning. Inhibition of somatic DA activity or consequences of DA release abolishes the behavioral effects of ketamine. We identify mPFC as a key action site that mediates ketamine’s effects on VTA DA dynamics, where the activation of mPFC Drd1<sup>+</sup> neurons is sufficient to rescue escape actions.</p><sec id="s3-1"><title>Individual variability in VTA DA activity and behavioral susceptibility</title><p>Multivalenced encoding of information by VTA DA neurons and their projections is now well established (<xref ref-type="bibr" rid="bib15">Berridge and Kringelbach, 2015</xref>; <xref ref-type="bibr" rid="bib67">Lammel et al., 2014</xref>; <xref ref-type="bibr" rid="bib84">Morales and Margolis, 2017</xref>; <xref ref-type="bibr" rid="bib85">Nestler and Carlezon, 2006</xref>; <xref ref-type="bibr" rid="bib111">Schultz, 2016</xref>). Prior reports demonstrate that stress and aversive learning change DA neuron activity in both acute and chronic paradigms (<xref ref-type="bibr" rid="bib22">Chaudhury et al., 2013</xref>; <xref ref-type="bibr" rid="bib30">de Jong et al., 2019</xref>; <xref ref-type="bibr" rid="bib67">Lammel et al., 2014</xref>; <xref ref-type="bibr" rid="bib66">Lammel et al., 2012</xref>; <xref ref-type="bibr" rid="bib65">Lammel et al., 2011</xref>). Our findings here show that VTA GCaMP transients are shaped both by trial outcomes—escape or failure to escape from an avoidable stimulus—as well as by the general behavioral state induced by LH learning and ketamine treatment. This malleability and multifaceted activity of DA signaling opens the possibility that particular patterns and levels of VTA DA activity map to specific behavioral outcome distributions. In this framework, differences in VTA DA activity between success and failure outcomes map to the tendency to escape aversive stimuli. Accordingly, decreases in the differences between VTA DA activity on escape and failure trials after aversive learning are associated with increased failures to escape avoidable stressful stimuli. Future behavioral responses to ketamine are correlated with trace distances between escape and failure-associated GCaMP transients before learning occurs. Building on these correlative observations, chemogenetic inhibition of VTA DA neuron activity supports a causal relationship between learning, DA activity, and ketamine effects. These data demonstrate that DA activity changes in LH paradigms and perturbations of DA dynamics shape behavioral outcomes in escape behavior.</p><p>The question of what key biological parameters distinguish resilient and susceptible animals remains enigmatic. In this study, we observe substantial individual variability of behavioral expression after LH. Other studies have mapped this type of variability to a binary structure of resilience and susceptibility (<xref ref-type="bibr" rid="bib8">Bagot et al., 2017</xref>; <xref ref-type="bibr" rid="bib22">Chaudhury et al., 2013</xref>; <xref ref-type="bibr" rid="bib38">Friedman et al., 2014</xref>; <xref ref-type="bibr" rid="bib97">Peña et al., 2019</xref>; <xref ref-type="bibr" rid="bib123">Wang et al., 2017</xref>). While there is some utility in forcing a binary behavioral outcome, in this relatively large dataset (n &gt; 130 mice), we noted a broad (and not bimodal) variance in LH outcomes for both strong and weaker LH, reflecting the diversity of individual learning experiences (<xref ref-type="fig" rid="fig6s3">Figure 6—figure supplement 3a</xref>, b). Notably, we also observe biologically significant variability in VTA DA responses, correlated with future behavioral outcomes after learning and ketamine treatment. The biological nature of this variability may relate to resilience or susceptibility to stress. One interesting possibility is that projections and activity profiles of DA neuron subgroups could be related to early-life and adolescent experience (<xref ref-type="bibr" rid="bib91">O’Donnell, 2010</xref>; <xref ref-type="bibr" rid="bib97">Peña et al., 2019</xref>; <xref ref-type="bibr" rid="bib96">Peña et al., 2017</xref>; <xref ref-type="bibr" rid="bib121">Wahlstrom et al., 2010</xref>), resulting in variability of the overall low-dimensional activity pattern of the VTA DA population recorded using photometry. Based on this observation, it is expected that task-specific VTA DA activity may serve as a potential biomarker for the degree of susceptibility to stressful events. In the context of human populations, PET studies have been used to measure aspects of DA system function (<xref ref-type="bibr" rid="bib58">Jönsson et al., 1999</xref>; <xref ref-type="bibr" rid="bib75">MacDonald et al., 2012</xref>; <xref ref-type="bibr" rid="bib88">Okubo et al., 1997</xref>; <xref ref-type="bibr" rid="bib120">Volkow et al., 1996</xref>). Importantly, genetic variability which can drive differences in DA signaling (<xref ref-type="bibr" rid="bib58">Jönsson et al., 1999</xref>), could provide additional biomarkers to predict clinical ketamine efficacy.</p><p>Animals used in this study derive from a genetically homogenous background, and one can expect larger variances in DA-associated genes in the human population. DA signaling has been associated with positive and negative emotionality and related to variability in psychopathology (<xref ref-type="bibr" rid="bib37">Felten et al., 2011</xref>). Polymorphisms in DA genes regulate DA transmission throughout the brain, influencing depression-related phenotypes (<xref ref-type="bibr" rid="bib39">Frisch et al., 1999</xref>; <xref ref-type="bibr" rid="bib47">Haeffel et al., 2008</xref>; <xref ref-type="bibr" rid="bib93">Pearson-Fuhrhop et al., 2014</xref>). Variance in DA genes and their interactors, along with early life experience, may shape activity patterns of DA neurons and DA release in response to stressful events, defining depression susceptibility in humans.</p></sec><sec id="s3-2"><title>Circuit-level mechanisms underlying the effects of ketamine on behavior</title><p>Multiple studies demonstrate that mPFC is broadly involved in the rapid and lasting behavioral effects of ketamine. NMDA receptor antagonists, including ketamine, have been shown to rapidly enhance neuronal and dendritic activity of cortical pyramidal neurons through disinhibition (<xref ref-type="bibr" rid="bib3">Ali et al., 2020</xref>; <xref ref-type="bibr" rid="bib49">Hare et al., 2020</xref>; <xref ref-type="bibr" rid="bib54">Homayoun and Moghaddam, 2007</xref>; <xref ref-type="bibr" rid="bib98">Picard et al., 2019</xref>; <xref ref-type="bibr" rid="bib135">Zanos and Gould, 2018</xref>). Further, on a relative longer timescale, increases in cortical dendritic spine density, induced by ketamine, maintain behavioral effects after ketamine clearance in vivo (<xref ref-type="bibr" rid="bib70">Li et al., 2010</xref>; <xref ref-type="bibr" rid="bib83">Moda-Sava et al., 2019</xref>). The enhancement in cortical spinogenesis requires mTORC1, BDNF, subtypes of glutamate receptors, as well as dopaminergic signaling (<xref ref-type="bibr" rid="bib3">Ali et al., 2020</xref>; <xref ref-type="bibr" rid="bib32">Duman et al., 2012</xref>; <xref ref-type="bibr" rid="bib70">Li et al., 2010</xref>; <xref ref-type="bibr" rid="bib72">Liu et al., 2013</xref>; <xref ref-type="bibr" rid="bib108">Sarkar and Kabbaj, 2016</xref>; <xref ref-type="bibr" rid="bib127">Wu et al., 2021a</xref>). Optogenetic stimulation of mPFC neurons reverses depressive-like behaviors (<xref ref-type="bibr" rid="bib26">Covington et al., 2010</xref>; <xref ref-type="bibr" rid="bib40">Fuchikami et al., 2015</xref>; <xref ref-type="bibr" rid="bib64">Kumar et al., 2013</xref>). Evidence from this study and others has consistently demonstrated that the activation of mPFC Drd1 neurons is important for ketamine’s behavioral effects. Consistent with diverse outputs of mPFC, local ketamine actions there may subsequently change the activity of multiple downstream brain regions, including the VTA, but also basolateral amygdala, nucleus accumbens (NAc), and lateral habenula, among others. These brain regions likely contribute to specific behavioral effects of ketamine observed in different behavioral paradigms (<xref ref-type="bibr" rid="bib12">Belujon and Grace, 2014</xref>; <xref ref-type="bibr" rid="bib48">Hare et al., 2019</xref>; <xref ref-type="bibr" rid="bib64">Kumar et al., 2013</xref>; <xref ref-type="bibr" rid="bib131">Yang et al., 2018a</xref>).</p><p>Besides modulating mPFC Drd1<sup>+</sup> neurons, DA signaling in many brain regions regulates escape actions and avoidance behaviors. For example, the release and postsynaptic function of DA in the NAc and amygdala have been extensively studied in conditioned avoidance learning (<xref ref-type="bibr" rid="bib4">Antunes et al., 2020</xref>; <xref ref-type="bibr" rid="bib29">Darvas et al., 2011</xref>; <xref ref-type="bibr" rid="bib82">McCullough et al., 1993</xref>; <xref ref-type="bibr" rid="bib89">Oleson et al., 2012</xref>; <xref ref-type="bibr" rid="bib90">Oleson and Cheer, 2013</xref>; <xref ref-type="bibr" rid="bib115">Stelly et al., 2019</xref>; <xref ref-type="bibr" rid="bib126">Wenzel et al., 2018</xref>). In this study, we found that VTA DA activity is not necessarily critical for innate escape actions, since chemogenetic suppression of VTA DA activity does not increase failures to escape from shock stimuli in the absence of prior learning. Importantly, after LH, the responses of VTA DA neurons to both inescapable and escapable shocks are significantly changed. Since DA release has been shown to be highly correlated with somatic DA neuronal activity (<xref ref-type="bibr" rid="bib30">de Jong et al., 2019</xref>; <xref ref-type="bibr" rid="bib68">Lee et al., 2021</xref>; <xref ref-type="bibr" rid="bib92">Patriarchi et al., 2018</xref>), we predict that downstream DA release in the NAc and amygdala is also modulated after LH and ketamine treatment.</p><p>Which specific projections carry information about different aversive stimuli (e.g., conditioned cues or unpredicted aversive events) and whether they derive from the same or different sub-populations of VTA DA neurons, remains an active area of research (<xref ref-type="bibr" rid="bib11">Beier et al., 2015</xref>; <xref ref-type="bibr" rid="bib30">de Jong et al., 2019</xref>; <xref ref-type="bibr" rid="bib65">Lammel et al., 2011</xref>; <xref ref-type="bibr" rid="bib66">Lammel et al., 2012</xref>; <xref ref-type="bibr" rid="bib132">Yang et al., 2018b</xref>). VTA DA neurons are highly heterogenous based on their input/output anatomy and transcriptional profiles (<xref ref-type="bibr" rid="bib11">Beier et al., 2015</xref>; <xref ref-type="bibr" rid="bib84">Morales and Margolis, 2017</xref>). Prior studies have demonstrated that VTA DA neurons respond to foot shocks differently, based on the brain regions they project to (<xref ref-type="bibr" rid="bib30">de Jong et al., 2019</xref>). In this study, we do not distinguish responses of DA neurons based on their projections or transcriptional profiles. Thus, the observed effects are sufficiently powerful to be seen on the background of a mixed DA population that maintains projection target diversity.</p></sec><sec id="s3-3"><title>Ketamine effects on DA activity and mPFC-VTA recurrent circuit hypothesis</title><p>Given the absence of local ketamine effects on VTA DA neurons, as shown in ex vivo calcium imaging and electrophysiological recordings, along with in vivo infusion experiments, the modulation of VTA DA activity by ketamine in vivo must depend on changes in the activity of projections from other brain regions. Based on evidence from electron microscopy reconstructions and anatomical tracing, VTA DA neurons that project to mPFC receive inputs from mPFC pyramidal neurons, forming excitatory connections (<xref ref-type="bibr" rid="bib11">Beier et al., 2015</xref>; <xref ref-type="bibr" rid="bib20">Carr and Sesack, 2000</xref>). Trans-synaptic tracing analyses and optogenetic assays provide evidence that mPFC pyramidal neurons send excitatory glutamatergic projections to VTA (<xref ref-type="bibr" rid="bib11">Beier et al., 2015</xref>; <xref ref-type="bibr" rid="bib73">Lodge, 2011</xref>; <xref ref-type="bibr" rid="bib130">Xiao et al., 2018</xref>; <xref ref-type="bibr" rid="bib132">Yang et al., 2018b</xref>). Prior data from our lab (<xref ref-type="bibr" rid="bib130">Xiao et al., 2018</xref>) and others (<xref ref-type="bibr" rid="bib11">Beier et al., 2015</xref>; <xref ref-type="bibr" rid="bib20">Carr and Sesack, 2000</xref>; <xref ref-type="bibr" rid="bib43">Geisler et al., 2007</xref>) confirm that VTA DA neurons receive excitatory mPFC inputs. Glutamate release from mPFC terminals elicits excitatory responses in VTA DA neurons (<xref ref-type="bibr" rid="bib42">Gariano and Groves, 1988</xref>; <xref ref-type="bibr" rid="bib64">Kumar et al., 2013</xref>; <xref ref-type="bibr" rid="bib117">Tong et al., 1996</xref>; <xref ref-type="bibr" rid="bib133">You et al., 2007</xref>), driving synchronized activity across VTA and mPFC, as well as other limbic structures (<xref ref-type="bibr" rid="bib64">Kumar et al., 2013</xref>). Although the mPFC and VTA are the not only brain regions that control escape behaviors, the enhanced activity within these two brain regions is likely one important mechanism underlying behavioral effects of ketamine. Our data show that local mPFC ketamine infusion rescues both VTA DA activity and behavior (<xref ref-type="fig" rid="fig5">Figure 5</xref>). In vivo ketamine treatment rapidly enhances Drd1 neuronal activity in mPFC (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>) and chemogenetic activation of mPFC Drd1+ neurons rescues escape behaviors (<xref ref-type="fig" rid="fig6">Figure 6g</xref>). Moreover, in recently published work, we show that DA signaling through Drd1 activation is necessary for ketamine’s action on restoring glutamate-evoked dendritic spinogenesis in mPFC (<xref ref-type="bibr" rid="bib127">Wu et al., 2021a</xref>), which has been shown to maintain the lasting behavioral effects of ketamine after corticosterone treatment (<xref ref-type="bibr" rid="bib83">Moda-Sava et al., 2019</xref>). Chemogenetic activation of Gα<sub>s</sub>-coupled signaling cascades downstream of Drd1 activation in mPFC also rescues escape behavior after LH (<xref ref-type="bibr" rid="bib127">Wu et al., 2021a</xref>). Based on the sum of these data across multiple laboratories and experimental modalities, we hypothesize that the initial enhancement of activity induced by ketamine in mPFC may be amplified within recurrent mPFC-VTA circuit, which may help extend ketamine behavioral effects beyond its in vivo bioavailability. Future studies are necessary to explicitly test this model.</p><p>Other potential circuit mechanisms for ketamine’s enhancement of VTA DA activity may involve ventral hippocampal inputs to nucleus accumbens and lateral habenula projections to the VTA, both of which are modulated by stressful experience and ketamine (<xref ref-type="bibr" rid="bib7">Bagot et al., 2015</xref>; <xref ref-type="bibr" rid="bib12">Belujon and Grace, 2014</xref>; <xref ref-type="bibr" rid="bib71">Li et al., 2011</xref>; <xref ref-type="bibr" rid="bib99">Pignatelli et al., 2020</xref>; <xref ref-type="bibr" rid="bib131">Yang et al., 2018a</xref>). One such potential mechanism could involve actions in the lateral habenula, which sends glutamatergic inputs to GABAergic neurons that suppress VTA DA activity (<xref ref-type="bibr" rid="bib44">Gonçalves et al., 2012</xref>). Excitatory synapses onto VTA-projecting lateral habenula neurons are potentiated in rats in behavioral and genetic models of LH (<xref ref-type="bibr" rid="bib71">Li et al., 2011</xref>). Ketamine could disinhibit VTA DA neurons by suppressing the activity of lateral habenula glutamatergic neurons (<xref ref-type="bibr" rid="bib131">Yang et al., 2018a</xref>). Rapid and lasting behavioral effects of ketamine likely result from synergistic actions across many brain regions, involving multiple molecular pathways.</p></sec><sec id="s3-4"><title>Clinical implications in co-morbidity</title><p>Drugs that modulate the dopaminergic system represent first line therapies for a large number of diverse neurological and mental health conditions that are comorbid with major depressive disorder, including Parkinson’s disease, schizophrenia, OCD, ADHD, and eating disorders (<xref ref-type="bibr" rid="bib18">Biederman et al., 1998</xref>; <xref ref-type="bibr" rid="bib25">Corcos et al., 2000</xref>; <xref ref-type="bibr" rid="bib80">Masellis et al., 2003</xref>; <xref ref-type="bibr" rid="bib81">Mayeux et al., 1981</xref>; <xref ref-type="bibr" rid="bib114">Siris, 2000</xref>). The recent FDA approval of esketamine for the treatment of major depressive disorder is a major expansion of its clinical use. Our results on dopaminergic mediation of ketamine’s effects on behavior and plasticity suggest the possibility of ketamine’s differential clinical effects in patients receiving exogenous DA precursors (e.g. L-DOPA), re-uptake inhibitors, and dopaminergic receptor agonists and antagonists.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">C57BL/6</td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">Cat#000664;RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:000664">IMSR_JAX:000664</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">B6.SJL-<italic>Slc6a3tm1.1(cre)Bkmn</italic>/J(DAT<sup>iCre</sup>)</td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">Cat#006660;RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:006660">IMSR_JAX:006660</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">B6.FVB(Cg)-<italic>Tg(Drd1a-cre)FK150Gsat</italic>/Mmucd(Drd1<sup>Cre</sup> (FK150))</td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:MMRRC_036916-UCD">MMRRC_036916-UCD</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">AAV1.CAG.Flex.GCaMP6f.WPRE.SV40</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib23">Chen et al., 2013</xref>, Dr. Douglas Kim</td><td align="left" valign="bottom">Addgene viral prep; # 100835-AAV1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">AAV8.CAG.Flex.EGFP</td><td align="left" valign="bottom">UNC Vector Core, (Dr. Boyden)</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">AAV1.CBA.DIO.hM4Di.mCherry</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib56">Hou et al., 2016</xref>, Packaged by Vigene, (Plasmid, Dr. Sabatini)</td><td align="left" valign="bottom">Addgene plasmid # 81,008</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">AAV2.hSyn.DIO.hM3Dq.mCherry</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib62">Krashes et al., 2011</xref>, Dr. Bryan Roth</td><td align="left" valign="bottom">Addgene viral prep; # 44361-AAV2</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rabbit polyclonal anti-Tyrosine Hydroxylase</td><td align="left" valign="bottom">Millipore</td><td align="left" valign="bottom">Cat#AB152; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_390204">AB_390204</ext-link></td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal anti-Tyrosine Hydroxylase</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat#AB129991; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_11156128">AB_11156128</ext-link></td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rabbit polyclonal anti-RFP</td><td align="left" valign="bottom">Rockland</td><td align="left" valign="bottom">Cat#600-401-379; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2209751">AB_2209751</ext-link></td><td align="char" char="." valign="bottom">(1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rabbit polyclonal anti-c-Fos</td><td align="left" valign="bottom">Synaptic systems</td><td align="left" valign="bottom">Cat# 226 003; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2231974">AB_2231974</ext-link></td><td align="char" char="." valign="bottom">(1:5000)</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Ketamine</td><td align="left" valign="bottom">Vedco</td><td align="left" valign="bottom">217-484-6; CAS: 1867-66-9</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Clozapine-N-oxide</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">C0823; CAS: 34233-69-7</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Red retrobeads (RRBs)</td><td align="left" valign="bottom">Lumafluor</td><td align="left" valign="bottom">Cat#R180</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">SR95531 hydrobromide</td><td align="left" valign="bottom">Tocris</td><td align="left" valign="bottom">Cat#1262; CAS 104104-50-9</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">CNQX disodium salt</td><td align="left" valign="bottom">Tocris</td><td align="left" valign="bottom">Cat#1045; CAS 479347-85-8</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Chicago Sky Blue 6B</td><td align="left" valign="bottom">Tocris</td><td align="left" valign="bottom">Cat#0846; CAS 2610-05-1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">RNAscope Fluorescence Multiplex Assay</td><td align="left" valign="bottom">ACDBio</td><td align="left" valign="bottom">Cat No. 320,850</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">RNAscope Probe-Mm-<italic>drd1a(Drd1</italic>)</td><td align="left" valign="bottom">ACDBio</td><td align="left" valign="bottom">Cat No. 406491-C2</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">RNAscope Probe-Mm-<italic>slc6a3(Dat</italic>)</td><td align="left" valign="bottom">ACDBio</td><td align="left" valign="bottom">Cat No. 315,441</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GraphPad Prism 7</td><td align="left" valign="bottom">GraphPad</td><td align="left" valign="bottom">RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002798">SCR_002798</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">FIJI</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib109">Schindelin et al., 2012</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://fiji.sc/">http://fiji.sc/</ext-link>; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002285">SCR_002285</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">MATLAB</td><td align="left" valign="bottom">MathWorks</td><td align="left" valign="bottom">RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_001622">SCR_001622</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Toxtrac</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib102">Rodriguez et al., 2018</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Python</td><td align="left" valign="bottom">Python Software Foundation</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_008394">SCR_008394</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Clampfit 11.2</td><td align="left" valign="bottom">Molecular Devices</td><td align="left" valign="bottom">SCR_011323</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Active/Passive Avoidance Shuttle Box</td><td align="left" valign="bottom">MazeEngineers</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://mazeengineers.com/portfolio/active-passive-avoidance-shuttle-box/#description">https://mazeengineers.com/portfolio/active-passive-avoidance-shuttle-box/#description</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Raspberry Pi</td><td align="left" valign="bottom">Raspberry Pi Foundation</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.raspberrypi.org/">https://www.raspberrypi.org/</ext-link></td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Mouse strains and genotyping</title><p>Animals were handled according to protocols approved by the Northwestern University Animal Care and Use Committee. Weanling and young adult male and female mice (postnatal days 40–80) were used in this study. Approximately equal numbers of males and females were used for every experiment. All mice were group-housed, with standard feeding, 12 h light and 12 hr dark cycle (6:00 or 7:00 lights on), and enrichment procedures. Littermates were randomly assigned to conditions. C57BL/6 mice used for breeding and backcrossing were acquired from Charles River (Wilmington, MA), and all other mouse lines were acquired from the Jackson Laboratory (Bell Harbor, ME) and bred in house.</p><p>B6.SJL-<italic>Slc6a3<sup>tm1.1(cre)Bkmn</sup></italic>/J mice, which express Cre recombinase under control of the dopamine transporter promoter, are referred to as DAT<sup>iCre</sup> (<xref ref-type="bibr" rid="bib6">Bäckman et al., 2006</xref>); B6.FVB(Cg)-<italic>Tg(Drd1-cre)FK150Gsat</italic>/Mmucd mice, which express Cre recombinase under control of the dopamine Drd1a receptor promoter, are referred to as Drd1<sup>Cre</sup>(FK150) (<xref ref-type="bibr" rid="bib45">Gong et al., 2007</xref>). All transgenic animals were backcrossed to C57BL/6 for several generations. Heterozygous Cre<sup>+</sup> mice were used in experiments. Standard genotyping primers are available on the Jackson Lab website.</p></sec><sec id="s4-2"><title>Stereotactic injections and optic fiber implants</title><p>Conditional expression of target genes in Cre-containing neurons was achieved using recombinant adeno-associated viruses (AAVs) using the FLEX cassette or encoding a double-floxed inverted open-reading frame (DIO) of target genes, as described previously (<xref ref-type="bibr" rid="bib61">Kozorovitskiy et al., 2015</xref>). For fiber photometry and ex vivo two-photon calcium imaging experiments in the VTA, DAT<sup>iCre</sup> mice were transduced with AAV1.CAG.FLEX.GCaMP6f.WPRE-SV40 (1.33 × 10<sup>13</sup> GC/ml) from the UPenn viral core (Philadelphia, PA, a gift from the Genetically Encoded Neuronal Indicator and Effector Project (GENIE) and Douglas Kim; Addgene viral prep #100835-AAV1) (<xref ref-type="bibr" rid="bib23">Chen et al., 2013</xref>) or AAV8.CAG.FLEX.EGFP (3.1 × 10<sup>12</sup> GC/ml, UNC vector core, Dr. Ed Boyden). For fiber photometry experiments in the mPFC, Drd1<sup>Cre</sup>(FK150) mice were transduced with AAV1.CAG.FLEX.GCaMP6f.WPRE.SV40 (1.33 × 10<sup>13</sup> GC/ml). For chemogenetic experiments in mPFC, Drd1<sup>Cre</sup>(FK150) mice were transduced with AAV2.hSyn.DIO.hM3Dq.mCherry (8.6 × 10<sup>12</sup> GC/ml, Addgene viral prep #44361-AAV2, Dr. Bryan Roth) (<xref ref-type="bibr" rid="bib62">Krashes et al., 2011</xref>). For chemogenetic experiments in VTA, DAT<sup>iCre</sup> mice were transduced with a custom built AAV1.CBA.DIO.hM4Di.mCherry (1.28 × 10<sup>13</sup> GC/ml, Vigene Biosciences, Rockville, MD, plasmid a gift from Dr. Bernardo Sabatini) (<xref ref-type="bibr" rid="bib56">Hou et al., 2016</xref>). For retrograde labeling, mice were intracranially injected with Red Retrobeads (Lumafluor Inc) in VTA.</p><p>Neonatal viral transduction was carried out to minimize invasiveness and increase surgical efficiency (<xref ref-type="bibr" rid="bib10">Bariselli et al., 2016</xref>; <xref ref-type="bibr" rid="bib51">He et al., 2018</xref>; <xref ref-type="bibr" rid="bib61">Kozorovitskiy et al., 2015</xref>; <xref ref-type="bibr" rid="bib60">Kozorovitskiy et al., 2012</xref>; <xref ref-type="bibr" rid="bib94">Peixoto et al., 2016</xref>). P3-6 mice were cryoanesthetized, received ketoprofen for analgesia and were placed on a cooling pad. Virus was delivered at a rate of 100 nl/min for up to 150–200 nl using an UltraMicroPump (World Precision Instruments, Sarasota, FL). Medial prefrontal cortex (mPFC) was targeted in the neonates by directing the needle immediately posterior to the eyes, 0.3 mm from midline, and 1.8 mm ventral to skin surface. Ventral tegmental area (VTA) was targeted in the neonates by directing the needle approximately ±0.2 mm lateral from Lambda and 3.8 mm ventral to skin surface. Coordinates were slightly adjusted based on pup age and size. Following the procedure, pups were warmed on a heating pad and returned to home cages.</p><p>For intracranial injections, mice were anesthetized with isoflurane (3 % for induction value, 1.5%–2% for maintenance) or ketamine:xylazine (100:12.5 mg/kg b.w.), received ketoprofen for analgesia, and were placed on a small animal stereotax frame (David Kopf Instruments, Tujunga, CA). AAVs or retrobeads were delivered through a pulled glass pipette at a rate of 100–150 nl/min using an UltraMicroPump (World Precision Instruments, Sarasota, FL). Ketamine, ACSF, or Chicago Sky Blue 6B were delivered intracranially at a rate of 150 nl/min using the UltraMicroPump. Injection coordinates for VTA, 2.8 mm posterior to bregma, 0.4 mm lateral, and 4.3–4.5 mm below the pia; for mPFC, 2.3 mm anterior to bregma, 0.4 mm lateral, and 1.3–1.6 mm below the pia; for PAG, 4.2 mm posterior to bregma, 0.1 mm lateral, and 2.2 below the pia; for PPTg, 4.5 mm posterior to bregma, 1.2 mm lateral, and 2.5 below the pia. Pipettes were held at the injection location for 15 min following AAV or retrobead release. Coordinates were slightly adjusted based on mouse age and size.</p><p>For photometry fiber placement in the VTA or mPFC, mice were implanted with a 400 µm diameter 0.48 NA single mode optical fiber (Doric lenses, Quebec City, QC, Canada) directly above the VTA at –2.8 mm (AP); + 0.4 mm (ML); 4.3–4.5 mm (DV), mPFC +2.0 mm (AP); + 0.4 mm (ML); 1.3–1.6 mm (DV), 4–6 weeks after viral transduction. Behavioral experiments were conducted 7–12 days after implantation. Real-time photometry recording was performed during optical fiber implant above the VTA, for optimal targeting. When the fiber tip approached the VTA region, a continuous increase of fluorescence intensity was observed. The final position of implantation was determined by the cessation of further increases in fluorescence intensity. Mice recovered for at least 7 days after implantation.</p></sec><sec id="s4-3"><title>Behavior assays</title><sec id="s4-3-1"><title>Aversive learning</title><p>P40-60 mice were used for behavioral assays with fiber photometry and chemogenetics experiments. The strong learned helplessness procedure consisted of two induction sessions (one session per day; 360 inescapable foot shocks per session; 0.3 mA, 3 s; random 1–15 s inter-shock intervals). Active/Passive Avoidance Shuttle Boxes from MazeEngineers (Boston, MA) were used for the experiment. To assess the degree of aversive learning, test sessions (30 escapable foot shocks per session; 0.3 mA, 10 s; random 5–30 s inter-shock intervals) were conducted before induction, 24 hr after the last induction session, and following pharmacological manipulations. The testing was performed in a shuttle box (18 × 18 × 20 cm) equipped with a grid floor and a gate separating the two compartments. No conditioned stimulus was delivered either before or after the shocks. Escapes were scored when the animal shuttled between compartments during the shock. Escape latency was measured as the time from the start of the shock to the escape. The shock automatically terminated when the animal shuttled to the other compartment. Failures were scored when the animal failed to escape before the shock end. All behavioral assays were conducted during the active phase of the circadian cycle. Schematics with mice were made using BioRender.</p><p>To evaluate learned helplessness behavior in a novel context, another shuttle box with different decorative designs was used. In addition to a differently designed gate, decorations with black and white patterns (bars and circles) were applied to the walls. To evaluate the effect of ketamine on learned helplessness behavior, a single dose of ketamine (10 mg/kg b.w., i.p.) was given 48 hr after the last induction session, with the test session performed 4 hr later. For chemogenetic activation in mPFC, 48 hr after the last induction session, Clozapine N-oxide (CNO) was administered i.p., followed by test sessions 2 hr and 4 hr later. For chemogenetic inhibition in VTA, the first CNO dose (3 mg/kg, i.p.) was co-administered with ketamine 48 hr after the last induction, followed by test sessions 4 and 24 hr later. Then, immediately following the last test session ketamine was administered alone, followed by test sessions 4, 24, and 72 hr later.</p><p>For the weak aversive learning procedure, a single induction session (360 inescapable foot shocks; 0.3 mA, 3 s; random 1–15 s intershock intervals) was performed at the end of the second day. Six test sessions were performed (one session per day; 100 escapable foot shocks per session; 0.3 mA, 3 s; random 5–15 s intershock intervals). A single dose of ketamine (10 mg/kg b.w., i.p.) was given 4 hr before the fifth test session. The final test session was performed 24 hr after ketamine treatment. Age-matched controls were given six test sessions, in the absence of induction sessions or ketamine treatment.</p></sec><sec id="s4-3-2"><title>Locomotion test</title><p>To assess the locomotor activity, mice were placed in the center of a plastic chamber (48 cm × 48 cm × 40 cm) or in the shuttle box in a dimly lit room. Mice explored the arena for 15 min, with video (30 fps) and photometry recording performed during the final 10 min.</p></sec></sec><sec id="s4-4"><title>Fiber photometry</title><p>Hardware was created based on open-source resources made available by Dr. Thomas Davidson (<ext-link ext-link-type="uri" xlink:href="https://drive.google.com/drive/folders/0B7FioEJAlB1aNmdPOEsxTjhxajg">https://drive.google.com/drive/folders/0B7FioEJAlB1aNmdPOEsxTjhxajg</ext-link>) (<xref ref-type="bibr" rid="bib69">Lerner et al., 2015</xref>). Briefly, a custom-built setup was created combining Doric fluorescence mini-cube (Doric, Westport, CT) and a 2151 Femtowatt photoreceiver with a lensed adapter (Newport, Irvine, CA). All downstream hardware including fiberoptic cannuale and patch cords, except for LEDs and drivers (Thorlabs, Newton, NJ), is readily available from Doric. A conventional single-cell electrophysiology recording system (DAQ+ software) was used to acquire signal and drive the LED, with a modified version of MATLAB based Scanimage (<xref ref-type="bibr" rid="bib100">Pologruto et al., 2003</xref>) adapted for electrophysiology recordings by Dr. Bernardo Sabatini (<ext-link ext-link-type="uri" xlink:href="https://github.com/bernardosabatinilab">https://github.com/bernardosabatinilab</ext-link>). Signals were sampled at 1 kHz and downsampled to 250 Hz for time-locked and to 10 Hz for non-time-locked analyses. Fluorescence signal was baseline adjusted in non-overlapping 100 sec windows as (signal-median(signal)) / median(signal), denoted as dF/F. Recordings were made during a subset of the sessions of LH and open-field locomotion, as noted in the text. Additional analyses details and link to analysis code are below.</p></sec><sec id="s4-5"><title>Acute slice preparation and electrophysiology</title><p>Coronal brain slice preparation was modified from previously published procedures (<xref ref-type="bibr" rid="bib61">Kozorovitskiy et al., 2015</xref>; <xref ref-type="bibr" rid="bib60">Kozorovitskiy et al., 2012</xref>; <xref ref-type="bibr" rid="bib129">Xiao et al., 2017</xref>). Animals were deeply anesthetized by inhalation of isoflurane, followed by a transcardial perfusion with ice-cold, oxygenated artificial cerebrospinal fluid (ACSF) containing (in mM) 127 NaCl, 2.5 KCl, 25 NaHCO<sub>3</sub>, 1.25 NaH<sub>2</sub>PO<sub>4</sub>, 2.0 CaCl<sub>2</sub>, 1.0 MgCl<sub>2</sub>, and 25 glucose (osmolarity 310 mOsm/L). After perfusion, the brain was rapidly removed, and immersed in ice-cold ACSF equilibrated with 95%O<sub>2</sub>/5%CO<sub>2</sub>. Tissue was blocked and transferred to a slicing chamber containing ice-cold ACSF, supported by a small block of 4 % agar (Sigma-Aldrich). Bilateral 250 or 300 µm-thick slices were cut on a Leica VT1000s (Leica Biosystems, Buffalo Grove, IL) in a rostro-caudal direction and transferred into a holding chamber with ACSF, equilibrated with 95%O<sub>2</sub>/5%CO<sub>2</sub>. Slices were incubated at 34°C for 30 min prior to electrophysiological recording and two-photon calcium imaging. Slices were transferred to a recording chamber perfused with oxygenated ACSF at a flow rate of 2–4 ml/min at room temperature.</p><p>To assess spontaneous firing rate of dopaminergic neurons in the VTA, cell-attached recordings were performed. Cell-attached recording electrode pipettes were filled with the internal solution for voltage clamp recordings to monitor spontaneous break in, with pipette resistance varying between 3 and 7 MΩ. To assess spontaneous synaptic inputs (sEPSC/sIPSC), voltage clamp recordings were performed. Dopaminergic neurons were identified by the expression of mCherry or GFP in DAT<sup>iCre</sup> mice. Recording electrodes contained the following (in mM): Cell-attached recordings and voltage clamp for sEPSCs: 120 CsMeSO<sub>4</sub>, 15 CsCl, 10 HEPES, 10 Na- phosphocreatine, 2 MgATP, 0.3 NaGTP, 10 QX314, and 1 EGTA (pH 7.2–7.3, ~ 295 mOsm/L); Voltage clamp for sIPSCs (high chloride internal solution): 100 CsCl, 35 CsF, 4 MgCl2, 10 HEPES, 10 Na-phosphocreatine, 4 MgATP, 0.4 Na2GTP, and 1 EGTA (pH 7.2, 295 mOsm/L). In voltage clamp recordings, cells were held at –70 mV. Recordings were made using 700B amplifiers (Axon Instruments, Union City, CA); data were sampled at 10 kHz and filtered at 4 kHz with a MATLAB-based acquisition script (MathWorks, Natick, MA). Offline analysis of electrophysiology data was performed using MATLAB (Mathworks, Natick, MA), and Clampfit 11.2 (Molecular Devices, San Jose, CA).</p></sec><sec id="s4-6"><title>Two-photon GCaMP6f imaging</title><p>Calcium sensor imaging was accomplished on a custom-built microscope combining two-photon laser-scanning microscopy (2PLSM), as previously described (<xref ref-type="bibr" rid="bib9">Banala et al., 2018</xref>; <xref ref-type="bibr" rid="bib61">Kozorovitskiy et al., 2015</xref>; <xref ref-type="bibr" rid="bib60">Kozorovitskiy et al., 2012</xref>; <xref ref-type="bibr" rid="bib130">Xiao et al., 2018</xref>; <xref ref-type="bibr" rid="bib129">Xiao et al., 2017</xref>). A mode-locked Ti:Sapphire laser (Mai Tai eHP DeepSee, Spectra-Physics, Santa Clara, CA) was tuned to 910 nm for GCamp6f. The intensity of the laser was controlled by Pockels cells (Conoptics, Danbury, CT). A modified version of Scanimage software was used for data acquisition (<xref ref-type="bibr" rid="bib100">Pologruto et al., 2003</xref>). Calcium imaging of GCaMP6f expressing DA neurons in acute brain slices of the VTA was done at 910 nm and sampled at 12 Hz. Spontaneous activity was imaged for 5 min in the baseline at 34°C, followed by a 5 min recording after ex vivo ketamine application (50 μM, with 15–40 min delay).</p></sec><sec id="s4-7"><title>Pharmacology</title><p>Pharmacological agents were acquired from Vedco (St. Joseph, MO) or Sigma-Aldrich (St. Louis, MO). In vivo injections included intraperitoneal and subcutaneous injections of ketamine (10 mg/kg, Vedco, St. Joseph, MO) and Clozapine N-oxide (3 mg/kg in vivo, 1 μM in vitro, Sigma-Aldrich); intracranial injections of ketamine (12.5 µg in 500 nl ACSF) and Chicago Sky Blue 6B (50 µg in 500 nl ACSF, Tocris, Bristol, United Kingdom). Ex vivo applications included SR95531 (Gabazine, 10 μM, Tocris), CNQX (10 μM, Tocris), and ketamine (50 μM).</p></sec><sec id="s4-8"><title>Tissue processing and immunohistochemistry</title><p>Mice were deeply anesthetized with isoflurane and transcardially perfused with 4% paraformaldehyde (PFA) in 0.1 M phosphate buffered saline (PBS). Brains were post-fixed for 1–5 days and washed in PBS, prior to sectioning at 50–100 µm on a vibratome (Leica Biosystems). Sections were pretreated in 0.2% Triton X-100 for an hour at RT, then blocked in 10% bovine serum albumin (BSA, Sigma-Aldrich, ST Louis, MO):PBS with 0.05 % Triton X-100 for 2 hr at RT, and incubated for 24–48 hr at 4°C with primary antibody solution in PBS with 0.2 % Triton X-100. On the following day, tissue was rinsed in PBS, reacted with secondary antibody for 2 hr at RT, rinsed again, then mounted onto Superfrost Plus slides (ThermoFisher Scientific, Waltham, MA). Sections were dried and coverslipped under ProLong Gold antifade reagent with DAPI (Molecular Probes, Life Technologies, Carlsbad, CA) or under glycerol:TBS (9:1) with Hoechst 33342 (2.5 µg/ml, ThermoFisher Scientific). Primary antibodies used in the study were rabbit anti-tyrosine hydroxylase (1:1000; AB152, Millipore, Burlington, MA), mouse anti-tyrosine hydroxylase (1:1000; AB129991, Abcam, Cambridge, UK), rabbit anti-RFP (1:500, 600-401-379, Rockland, Limerick, PA), and rabbit anti-c-Fos (1:5000; Synaptic Systems, Goettingen, Germany). Alexa Fluor 488-, Fluor 594-, or Fluor 647-conjugated secondary antibodies against rabbit or mouse(Life Technologies, Carlsbad, CA) were diluted 1:500. Whole sections were imaged with an Olympus VS120 slide scanning microscope (Olympus Scientific Solutions Americas, Waltham, MA). Confocal images were acquired with a Leica SP5 confocal microscope (Leica Microsystems). Depth-matched z-stacks of 2 µm-thick optical sections were analyzed in ImageJ (FIJI) (<xref ref-type="bibr" rid="bib109">Schindelin et al., 2012</xref>; <xref ref-type="bibr" rid="bib110">Schneider et al., 2012</xref>). For c-fos quantification, every four adjacent z stack slices were combined, for a total of 6 µm thickness. mCherry signal was used to localize cell bodies of hM3Dq-expressing neurons. Laser intensity and all imaging parameters were held constant across samples, and the same threshold was applied for subtracting background immunofluorescence. C-fos<sup>+</sup> neurons were identified by an experimenter blind to the conditions.</p></sec><sec id="s4-9"><title>Quantitative fluorescence in situ hybridization</title><p>Quantitative fluorescence in situ hybridization (FISH) was conducted following previously published procedures (<xref ref-type="bibr" rid="bib130">Xiao et al., 2018</xref>; <xref ref-type="bibr" rid="bib129">Xiao et al., 2017</xref>). Mice were deeply anesthetized by inhalation of isoflurane and decapitated. Brains were quickly removed and frozen in tissue-freezing medium on a mixture of dry ice and ethanol for 5–15 min prior to storage at 80°C. Brains were subsequently cut on a cryostat (Leica CM1850, Leica Biosystems) into 20-µm-thick sections, adhered to Superfrost Plus slides, and frozen at 80°C. Samples were fixed with 4% PFA in 0.1 M PBS at 4°C for 15 min, processed according to the manufacturer’s instructions in the RNAscope Fluorescent Multiplex Assay manual for fresh frozen tissue (Advanced Cell Diagnostics, Newark, CA), and coverslipped with ProLong Gold antifade reagent with DAPI (Molecular Probes). <italic>Drd1a</italic> receptor channel 2 (<italic>Drd1a</italic>) or <italic>Slc6a3</italic> (<italic>Dat</italic>) probes were added to slides in combination, and Amp4-b fluorescent amplification reagent was used for all experiments. Sections were subsequently imaged on a Leica SP5 confocal microscope in four channels with a ×40 objective lens at a zoom of 1.4 and resolution of 512 × 512 pixels with 1.0 µm between adjacent z sections.</p><p>FISH images were analyzed using FIJI (<xref ref-type="bibr" rid="bib109">Schindelin et al., 2012</xref>). Briefly, every four adjacent z stack slices were combined, for a total of 3 µm thickness, in order to minimize missed colocalization, while decreasing false positive colocalization driven by signal from cells at a different depth in a similar x-y position. All channels were thresholded. Cellular ROIs were defined using the retrobead<sup>+</sup> channel information to localize cell bodies. FISH molecule puncta were counted within established cell boundaries. Whether a cell was considered positive for a given marker was determined by setting a transcript-dependent threshold of the number of puncta (e.g. over five puncta/soma for <italic>Drd1a</italic><sup>+</sup>). These stringent parameters for co-localization and the challenges of quantifying low abundance receptor transcripts likely lead to underestimation of receptor-positive populations.</p></sec><sec id="s4-10"><title>Quantification of behavior</title><p>For evaluating locomotor behavior, Toxtrac (<xref ref-type="bibr" rid="bib102">Rodriguez et al., 2018</xref>) was used to track the animal’s position, defined by its body center position, and quantify the distance travelled in each session. To detect motion onset/offset, movement was defined by the body center moving &gt;30 mm/s for at least 0.5 s. The associated Ca<sup>2+</sup> transients were then aligned to transitions between motion start and stop times and averaged across all animals. Video was recorded and the mouse was tracked with Toxtrac.</p><p>Three state transition models were constructed for a given condition and behavioral response, by counting the occurrence of each of the three possible 2-response sequences in all animals and then dividing by the total number of the given response. For example, an escape can be followed by another escape, a failure, or a premature trial. The probability of a failure following an escape was calculated by counting the number of failures that followed escapes and dividing it by the total number of escape trials. The graphs for the transition models were constructed using GraphViz (<xref ref-type="bibr" rid="bib41">Gansner and North, 2000</xref>). The similarity between transition models was calculated as one minus the Frobenius norm (the Euclidean norm of a matrix) of the difference between models (<inline-formula><mml:math id="inf2"><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>n</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>m</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>m</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mi> </mml:mi><mml:msub><mml:mrow><mml:mi>m</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:math></inline-formula>). To depict individual learning trajectories, starting at zero, trajectory value incremented by one for each escape trial, decremented by one for each failure trial, and kept constant for spontaneous transitions in the shuttle box.</p><p>For the analysis of distributions of % failure to escape, the density histograms of percentage of failures were generated with a bin width = 4. Density histograms were fitted with the Gaussian distribution using fitdistrplus R package using a maximum likelihood estimation.</p></sec><sec id="s4-11"><title>Quantification of fiber photometry data</title><p>The heatmap of Ca<sup>2+</sup> transients was constructed by plotting single trial transients with signal amplitude depicted by color. The latency to peak was defined as the time from shock onset to the maximum Ca<sup>2+</sup> transient value within 8 s of shock onset. The negative and positive area under the curve (AUC) was calculated based on the direction of the peaks. Peaks were omitted from analyses if they were less than 5% of the distance from minimum to maximum dF/F or less than three times the standard deviation of the baseline period. The baseline was chosen by using the mean dF/F of the 5 s segment before the shock onset. For behavioral response-specific Ca<sup>2+</sup> transients, the transients for each behavioral response were averaged within a single subject, and then these data were averaged across all animals. The distance between escape and failure traces for each animal was computed as the Euclidean norm of the difference between the average of all their Ca<sup>2+</sup> transients on escape trials and the average of all their Ca<sup>2+</sup> transients on failure trials (<inline-formula><mml:math id="inf3"><mml:msub><mml:mrow><mml:mo>|</mml:mo><mml:mo>|</mml:mo><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mo>(</mml:mo><mml:mi>e</mml:mi><mml:mi>s</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>p</mml:mi><mml:mi>e</mml:mi><mml:mi> </mml:mi><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>s</mml:mi><mml:mo>)</mml:mo><mml:mo>-</mml:mo><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mo>(</mml:mo><mml:mi>f</mml:mi><mml:mi>a</mml:mi><mml:mi>i</mml:mi><mml:mi>l</mml:mi><mml:mi>u</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi> </mml:mi><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>s</mml:mi><mml:mo>)</mml:mo><mml:mo>|</mml:mo><mml:mo>|</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>).</p></sec><sec id="s4-12"><title>Quantification of two-photon Ca<sup>2+</sup> sensor imaging</title><p>ROIs of dopaminergic neuron somata were defined manually. Raw fluorescence intensity for all frames during 5-min recording sessions was extracted using FIJI (<xref ref-type="bibr" rid="bib109">Schindelin et al., 2012</xref>). For each neuron, the power spectral density of its baseline adjusted fluorescence was computed using Welch’s method (<xref ref-type="bibr" rid="bib125">Welch, 1967</xref>) with a Hann window and 50% overlap.</p></sec><sec id="s4-13"><title>Statistical analyses</title><p>Required sample sizes were estimated based on previous publications and past experience. The number of replicates was reported, and several internal replications are present in the study. No data were excluded after analyses. Animals were randomly assigned to treatment groups. Group statistical analyses were done using GraphPad Prism 7 and 8 software (GraphPad, LaJolla, CA). For N sizes, the number of trials or cells recorded, as well as the number of animals are provided. All data are expressed as mean ± SEM, or individual plots. Probabilities are expressed as aggregate probabilities within individuals. For two-group comparisons, statistical significance was determined by two-tailed Student’s t-tests. For multiple group comparisons, one-way or two-way analysis of variance (ANOVA) tests were used for normally distributed data, followed by post hoc analyses. For non-normally distributed data, non-parametric tests for the appropriate group numbers were used. Pearson regression was used to detect the correlation between two groups of data. p &lt; 0.05 was considered statistically significant. All computer code generated in the current study is available at <ext-link ext-link-type="uri" xlink:href="https://github.com/KozorovitskiyLaboratory/Wu_et_al_2021">https://github.com/KozorovitskiyLaboratory/Wu_et_al_2021</ext-link> (<xref ref-type="bibr" rid="bib128">Wu et al., 2021b</xref>; copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:895836814e93b490c5c6ae88419968fca143f465;origin=https://github.com/KozorovitskiyLaboratory/Wu_et_al_2021;visit=swh:1:snp:d766e23130cc0c25ad523fd07c81a9e0e1507fe0;anchor=swh:1:rev:459ff15a97a2af4e955d20531235b399b4be5b22">swh:1:rev:459ff15a97a2af4e955d20531235b399b4be5b22</ext-link>).</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Software, Validation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Investigation, Methodology, Resources, Software, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Data curation, funding-acquisition, Investigation, Methodology, project-administration, Resources, Software, supervision, Validation, Visualization, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animals were handled according to protocols approved by the Northwestern University Animal Care and Use Committee (IS00000707).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-64041-transrepform1-v2.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and supporting files. Source data files are provided for each figure.</p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors are grateful to Lindsey Butler for mouse colony management, Northwestern Biological Imaging Facility and Dr. Tiffany Schmidt for confocal microscope access. This work was supported by NINDS R01NS107539, NIMH R01MH117111, Rita Allen Foundation Scholar Award, Searle Scholar Award, Beckman Young Investigator Award, William and Bernice E Bumpus Young Innovator Award, NARSAD Young Investigator, and P&amp;S Fund Grant (all YK). MW was supported as an affiliate fellow of the NIH T32 AG20506, SM is a fellow of the National Science Foundation Graduate Research Fellowship DGE-1842165, and VD is a predoctoral fellow of the American Heart Association (19PRE34380056).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abler</surname><given-names>B</given-names></name><name><surname>Erk</surname><given-names>S</given-names></name><name><surname>Herwig</surname><given-names>U</given-names></name><name><surname>Walter</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Anticipation of aversive stimuli activates extended amygdala in unipolar depression</article-title><source>Journal of Psychiatric Research</source><volume>41</volume><fpage>511</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1016/J.JPSYCHIRES.2006.07.020</pub-id><pub-id pub-id-type="pmid">17010993</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abramson</surname><given-names>LY</given-names></name><name><surname>Seligman</surname><given-names>ME</given-names></name><name><surname>Teasdale</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="1978">1978</year><article-title>Learned helplessness in humans: Critique and reformulation</article-title><source>Journal of Abnormal Psychology</source><volume>87</volume><fpage>49</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1037/0021-843X.87.1.49</pub-id><pub-id pub-id-type="pmid">649856</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>F</given-names></name><name><surname>Gerhard</surname><given-names>DM</given-names></name><name><surname>Sweasy</surname><given-names>K</given-names></name><name><surname>Pothula</surname><given-names>S</given-names></name><name><surname>Pittenger</surname><given-names>C</given-names></name><name><surname>Duman</surname><given-names>RS</given-names></name><name><surname>Kwan</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Ketamine disinhibits dendrites and enhances calcium signals in prefrontal dendritic spines</article-title><source>Nature Communications</source><volume>11</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1038/s41467-019-13809-8</pub-id><pub-id pub-id-type="pmid">31911591</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antunes</surname><given-names>GF</given-names></name><name><surname>Gouveia</surname><given-names>FV</given-names></name><name><surname>Rezende</surname><given-names>FS</given-names></name><name><surname>Seno MD de</surname><given-names>J</given-names></name><name><surname>de Carvalho</surname><given-names>MC</given-names></name><name><surname>de Oliveira</surname><given-names>CC</given-names></name><name><surname>dos Santos</surname><given-names>LCT</given-names></name><name><surname>de Castro</surname><given-names>MC</given-names></name><name><surname>Kuroki</surname><given-names>MA</given-names></name><name><surname>Teixeira</surname><given-names>MJ</given-names></name><name><surname>Otoch</surname><given-names>JP</given-names></name><name><surname>Brandao</surname><given-names>ML</given-names></name><name><surname>Fonoff</surname><given-names>ET</given-names></name><name><surname>Martinez</surname><given-names>RCR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Dopamine modulates individual differences in avoidance behavior: A pharmacological, immunohistochemical, neurochemical and volumetric investigation</article-title><source>Neurobiology of Stress</source><volume>12</volume><elocation-id>100219</elocation-id><pub-id pub-id-type="doi">10.1016/j.ynstr.2020.100219</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armbruster</surname><given-names>BN</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Pausch</surname><given-names>MH</given-names></name><name><surname>Herlitze</surname><given-names>S</given-names></name><name><surname>Roth</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Evolving the lock to fit the key to create a family of g protein-coupled receptors potently activated by an inert ligand</article-title><source>PNAS</source><volume>104</volume><fpage>5163</fpage><lpage>5168</lpage><pub-id pub-id-type="doi">10.1073/pnas.0700293104</pub-id><pub-id pub-id-type="pmid">17360345</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bäckman</surname><given-names>CM</given-names></name><name><surname>Malik</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>YJ</given-names></name><name><surname>Shan</surname><given-names>L</given-names></name><name><surname>Grinberg</surname><given-names>A</given-names></name><name><surname>Hoffer</surname><given-names>BJ</given-names></name><name><surname>Westphal</surname><given-names>H</given-names></name><name><surname>Tomac</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Characterization of a mouse strain expressing Cre recombinase from the 3′ untranslated region of the dopamine transporter locus</article-title><source>Genesis</source><volume>44</volume><fpage>383</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1002/dvg.20228</pub-id><pub-id pub-id-type="pmid">16865686</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagot</surname><given-names>RC</given-names></name><name><surname>Parise</surname><given-names>EM</given-names></name><name><surname>Peña</surname><given-names>CJ</given-names></name><name><surname>Zhang</surname><given-names>HX</given-names></name><name><surname>Maze</surname><given-names>I</given-names></name><name><surname>Chaudhury</surname><given-names>D</given-names></name><name><surname>Persaud</surname><given-names>B</given-names></name><name><surname>Cachope</surname><given-names>R</given-names></name><name><surname>Bolaños-Guzmán</surname><given-names>CA</given-names></name><name><surname>Cheer</surname><given-names>J</given-names></name><name><surname>Deisseroth</surname><given-names>K</given-names></name><name><surname>Han</surname><given-names>MH</given-names></name><name><surname>Nestler</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Ventral hippocampal afferents to the nucleus accumbens regulate susceptibility to depression</article-title><source>Nature Communications</source><volume>6</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/ncomms8062</pub-id><pub-id pub-id-type="pmid">25952660</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagot</surname><given-names>RC</given-names></name><name><surname>Cates</surname><given-names>HM</given-names></name><name><surname>Purushothaman</surname><given-names>I</given-names></name><name><surname>Vialou</surname><given-names>V</given-names></name><name><surname>Heller</surname><given-names>EA</given-names></name><name><surname>Yieh</surname><given-names>L</given-names></name><name><surname>LaBonté</surname><given-names>B</given-names></name><name><surname>Peña</surname><given-names>CJ</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Wittenberg</surname><given-names>GM</given-names></name><name><surname>Nestler</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Ketamine and Imipramine Reverse Transcriptional Signatures of Susceptibility and Induce Resilience-Specific Gene Expression Profiles</article-title><source>Biological Psychiatry</source><volume>81</volume><fpage>285</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2016.06.012</pub-id><pub-id pub-id-type="pmid">27569543</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banala</surname><given-names>S</given-names></name><name><surname>Arvin</surname><given-names>MC</given-names></name><name><surname>Bannon</surname><given-names>NM</given-names></name><name><surname>Jin</surname><given-names>XT</given-names></name><name><surname>Macklin</surname><given-names>JJ</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Marshall</surname><given-names>JJ</given-names></name><name><surname>Gee</surname><given-names>KR</given-names></name><name><surname>Wokosin</surname><given-names>DL</given-names></name><name><surname>Kim</surname><given-names>VJ</given-names></name><name><surname>McIntosh</surname><given-names>JM</given-names></name><name><surname>Contractor</surname><given-names>A</given-names></name><name><surname>Lester</surname><given-names>HA</given-names></name><name><surname>Kozorovitskiy</surname><given-names>Y</given-names></name><name><surname>Drenan</surname><given-names>RM</given-names></name><name><surname>Lavis</surname><given-names>LD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Photoactivatable drugs for nicotinic optopharmacology</article-title><source>Nature Methods</source><volume>15</volume><fpage>347</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4637</pub-id><pub-id pub-id-type="pmid">29578537</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bariselli</surname><given-names>S</given-names></name><name><surname>Tzanoulinou</surname><given-names>S</given-names></name><name><surname>Glangetas</surname><given-names>C</given-names></name><name><surname>Prévost-Solié</surname><given-names>C</given-names></name><name><surname>Pucci</surname><given-names>L</given-names></name><name><surname>Viguié</surname><given-names>J</given-names></name><name><surname>Bezzi</surname><given-names>P</given-names></name><name><surname>O’Connor</surname><given-names>EC</given-names></name><name><surname>Georges</surname><given-names>F</given-names></name><name><surname>Lüscher</surname><given-names>C</given-names></name><name><surname>Bellone</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>SHANK3 controls maturation of social reward circuits in the VTA</article-title><source>Nature Neuroscience</source><volume>19</volume><fpage>926</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1038/nn.4319</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beier</surname><given-names>KT</given-names></name><name><surname>Steinberg</surname><given-names>EE</given-names></name><name><surname>DeLoach</surname><given-names>KE</given-names></name><name><surname>Xie</surname><given-names>S</given-names></name><name><surname>Miyamichi</surname><given-names>K</given-names></name><name><surname>Schwarz</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>XJ</given-names></name><name><surname>Kremer</surname><given-names>EJ</given-names></name><name><surname>Malenka</surname><given-names>RC</given-names></name><name><surname>Luo</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Circuit Architecture of VTA Dopamine Neurons Revealed by Systematic Input-Output Mapping</article-title><source>Cell</source><volume>162</volume><fpage>622</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1016/J.CELL.2015.07.015</pub-id><pub-id pub-id-type="pmid">26232228</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belujon</surname><given-names>P</given-names></name><name><surname>Grace</surname><given-names>AA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Restoring mood balance in depression: Ketamine reverses deficit in dopamine-dependent synaptic plasticity</article-title><source>Biological Psychiatry</source><volume>76</volume><fpage>927</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2014.04.014</pub-id><pub-id pub-id-type="pmid">24931705</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belujon</surname><given-names>P</given-names></name><name><surname>Grace</surname><given-names>AA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Dopamine System Dysregulation in Major Depressive Disorders</article-title><source>The International Journal of Neuropsychopharmacology</source><volume>20</volume><fpage>1036</fpage><lpage>1046</lpage><pub-id pub-id-type="doi">10.1093/ijnp/pyx056</pub-id><pub-id pub-id-type="pmid">29106542</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berman</surname><given-names>RM</given-names></name><name><surname>Cappiello</surname><given-names>A</given-names></name><name><surname>Anand</surname><given-names>A</given-names></name><name><surname>Oren</surname><given-names>DA</given-names></name><name><surname>Heninger</surname><given-names>GR</given-names></name><name><surname>Charney</surname><given-names>DS</given-names></name><name><surname>Krystal</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Antidepressant effects of ketamine in depressed patients</article-title><source>Biological Psychiatry</source><volume>47</volume><fpage>351</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1016/S0006-3223(99)00230-9</pub-id><pub-id pub-id-type="pmid">10686270</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berridge</surname><given-names>KC</given-names></name><name><surname>Kringelbach</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Pleasure Systems in the Brain</article-title><source>Neuron</source><volume>86</volume><fpage>646</fpage><lpage>664</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2015.02.018</pub-id><pub-id pub-id-type="pmid">25950633</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beurel</surname><given-names>E</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Jope</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice</article-title><source>Molecular Psychiatry</source><volume>16</volume><fpage>1068</fpage><lpage>1070</lpage><pub-id pub-id-type="doi">10.1038/mp.2011.47</pub-id><pub-id pub-id-type="pmid">21502951</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beyer</surname><given-names>DKE</given-names></name><name><surname>Freund</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Animal models for bipolar disorder: From bedside to the cage</article-title><source>International Journal of Bipolar Disorders</source><volume>5</volume><elocation-id>35</elocation-id><pub-id pub-id-type="doi">10.1186/s40345-017-0104-6</pub-id><pub-id pub-id-type="pmid">29027157</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biederman</surname><given-names>J</given-names></name><name><surname>Mick</surname><given-names>E</given-names></name><name><surname>Faraone</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Depression in attention deficit hyperactivity disorder (ADHD) children: “True” depression or demoralization?</article-title><source>Journal of Affective Disorders</source><volume>47</volume><fpage>113</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1016/S0165-0327(97)00127-4</pub-id><pub-id pub-id-type="pmid">9476751</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bylsma</surname><given-names>LM</given-names></name><name><surname>Morris</surname><given-names>BH</given-names></name><name><surname>Rottenberg</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>A meta-analysis of emotional reactivity in major depressive disorder</article-title><source>Clinical Psychology Review</source><volume>28</volume><fpage>676</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1016/j.cpr.2007.10.001</pub-id><pub-id pub-id-type="pmid">18006196</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carr</surname><given-names>DB</given-names></name><name><surname>Sesack</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Projections from the rat prefrontal cortex to the ventral tegmental area: Target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons</article-title><source>The Journal of Neuroscience</source><volume>20</volume><fpage>3864</fpage><lpage>3873</lpage><pub-id pub-id-type="doi">10.1523/jneurosci.20-10-03864.2000</pub-id><pub-id pub-id-type="pmid">10804226</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatterjee</surname><given-names>M</given-names></name><name><surname>Verma</surname><given-names>R</given-names></name><name><surname>Ganguly</surname><given-names>S</given-names></name><name><surname>Palit</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Neurochemical and molecular characterization of ketamine-induced experimental psychosis model in mice</article-title><source>Neuropharmacology</source><volume>63</volume><fpage>1161</fpage><lpage>1171</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2012.05.041</pub-id><pub-id pub-id-type="pmid">22683513</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhury</surname><given-names>D</given-names></name><name><surname>Walsh</surname><given-names>JJ</given-names></name><name><surname>Friedman</surname><given-names>AK</given-names></name><name><surname>Juarez</surname><given-names>B</given-names></name><name><surname>Ku</surname><given-names>SM</given-names></name><name><surname>Koo</surname><given-names>JW</given-names></name><name><surname>Ferguson</surname><given-names>D</given-names></name><name><surname>Tsai</surname><given-names>HC</given-names></name><name><surname>Pomeranz</surname><given-names>L</given-names></name><name><surname>Christoffel</surname><given-names>DJ</given-names></name><name><surname>Nectow</surname><given-names>AR</given-names></name><name><surname>Ekstrand</surname><given-names>M</given-names></name><name><surname>Domingos</surname><given-names>A</given-names></name><name><surname>Mazei-Robison</surname><given-names>MS</given-names></name><name><surname>Mouzon</surname><given-names>E</given-names></name><name><surname>Lobo</surname><given-names>MK</given-names></name><name><surname>Neve</surname><given-names>RL</given-names></name><name><surname>Friedman</surname><given-names>JM</given-names></name><name><surname>Russo</surname><given-names>SJ</given-names></name><name><surname>Deisseroth</surname><given-names>K</given-names></name><name><surname>Nestler</surname><given-names>EJ</given-names></name><name><surname>Han</surname><given-names>MH</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons</article-title><source>Nature</source><volume>493</volume><fpage>532</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1038/nature11713</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>TW</given-names></name><name><surname>Wardill</surname><given-names>TJ</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Pulver</surname><given-names>SR</given-names></name><name><surname>Renninger</surname><given-names>SL</given-names></name><name><surname>Baohan</surname><given-names>A</given-names></name><name><surname>Schreiter</surname><given-names>ER</given-names></name><name><surname>Kerr</surname><given-names>RA</given-names></name><name><surname>Orger</surname><given-names>MB</given-names></name><name><surname>Jayaraman</surname><given-names>V</given-names></name><name><surname>Looger</surname><given-names>LL</given-names></name><name><surname>Svoboda</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Ultrasensitive fluorescent proteins for imaging neuronal activity</article-title><source>Nature</source><volume>499</volume><fpage>295</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1038/nature12354</pub-id><pub-id pub-id-type="pmid">23868258</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chourbaji</surname><given-names>S</given-names></name><name><surname>Zacher</surname><given-names>C</given-names></name><name><surname>Sanchis-Segura</surname><given-names>C</given-names></name><name><surname>Dormann</surname><given-names>C</given-names></name><name><surname>Vollmayr</surname><given-names>B</given-names></name><name><surname>Gass</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Learned helplessness: Validity and reliability of depressive-like states in mice</article-title><source>Brain Research Protocols</source><volume>16</volume><fpage>70</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.brainresprot.2005.09.002</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corcos</surname><given-names>M</given-names></name><name><surname>Guilbaud</surname><given-names>O</given-names></name><name><surname>Speranza</surname><given-names>M</given-names></name><name><surname>Paterniti</surname><given-names>S</given-names></name><name><surname>Loas</surname><given-names>G</given-names></name><name><surname>Stephan</surname><given-names>P</given-names></name><name><surname>Jeammet</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Alexithymia and depression in eating disorders</article-title><source>Psychiatry Research</source><volume>93</volume><fpage>263</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1016/S0165-1781(00)00109-8</pub-id><pub-id pub-id-type="pmid">10760385</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Covington</surname><given-names>HE</given-names></name><name><surname>Lobo</surname><given-names>MK</given-names></name><name><surname>Maze</surname><given-names>I</given-names></name><name><surname>Vialou</surname><given-names>V</given-names></name><name><surname>Hyman</surname><given-names>JM</given-names></name><name><surname>Zaman</surname><given-names>S</given-names></name><name><surname>LaPlant</surname><given-names>Q</given-names></name><name><surname>Mouzon</surname><given-names>E</given-names></name><name><surname>Ghose</surname><given-names>S</given-names></name><name><surname>Tamminga</surname><given-names>CA</given-names></name><name><surname>Neve</surname><given-names>RL</given-names></name><name><surname>Deisseroth</surname><given-names>K</given-names></name><name><surname>Nestler</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex</article-title><source>The Journal of Neuroscience</source><volume>30</volume><fpage>16082</fpage><lpage>16090</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1731-10.2010</pub-id><pub-id pub-id-type="pmid">21123555</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Silva</surname><given-names>JA</given-names></name><name><surname>Tecuapetla</surname><given-names>F</given-names></name><name><surname>Paixão</surname><given-names>V</given-names></name><name><surname>Costa</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Dopamine neuron activity before action initiation gates and invigorates future movements</article-title><source>Nature</source><volume>554</volume><fpage>244</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1038/nature25457</pub-id><pub-id pub-id-type="pmid">29420469</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daly</surname><given-names>EJ</given-names></name><name><surname>Singh</surname><given-names>JB</given-names></name><name><surname>Fedgchin</surname><given-names>M</given-names></name><name><surname>Cooper</surname><given-names>K</given-names></name><name><surname>Lim</surname><given-names>P</given-names></name><name><surname>Shelton</surname><given-names>RC</given-names></name><name><surname>Thase</surname><given-names>ME</given-names></name><name><surname>Winokur</surname><given-names>A</given-names></name><name><surname>Van Nueten</surname><given-names>L</given-names></name><name><surname>Manji</surname><given-names>H</given-names></name><name><surname>Drevets</surname><given-names>WC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial</article-title><source>JAMA Psychiatry</source><volume>75</volume><fpage>139</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2017.3739</pub-id><pub-id pub-id-type="pmid">29282469</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darvas</surname><given-names>M</given-names></name><name><surname>Fadok</surname><given-names>JP</given-names></name><name><surname>Palmiter</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Requirement of dopamine signaling in the amygdala and striatum for learning and maintenance of a conditioned avoidance response</article-title><source>Learning &amp; Memory</source><volume>18</volume><fpage>136</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1101/lm.2041211</pub-id><pub-id pub-id-type="pmid">21325435</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Jong</surname><given-names>JW</given-names></name><name><surname>Afjei</surname><given-names>SA</given-names></name><name><surname>Dorocic</surname><given-names>P</given-names></name><name><surname>Peck</surname><given-names>JR</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Kim</surname><given-names>CK</given-names></name><name><surname>Tian</surname><given-names>L</given-names></name><name><surname>Deisseroth</surname><given-names>K</given-names></name><name><surname>Lammel</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A Neural Circuit Mechanism for Encoding Aversive Stimuli in the Mesolimbic Dopamine System</article-title><source>Neuron</source><volume>101</volume><fpage>133</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/J.NEURON.2018.11.005</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duman</surname><given-names>RS</given-names></name><name><surname>Aghajanian</surname><given-names>GK</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Synaptic dysfunction in depression: potential therapeutic targets</article-title><source>Science</source><volume>338</volume><fpage>68</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1126/science.1222939</pub-id><pub-id pub-id-type="pmid">23042884</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duman</surname><given-names>RS</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>RJ</given-names></name><name><surname>Duric</surname><given-names>V</given-names></name><name><surname>Aghajanian</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Signaling pathways underlying the rapid antidepressant actions of ketamine</article-title><source>Neuropharmacology</source><volume>62</volume><fpage>35</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/J.NEUROPHARM.2011.08.044</pub-id><pub-id pub-id-type="pmid">21907221</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duman</surname><given-names>RS</given-names></name><name><surname>Aghajanian</surname><given-names>GK</given-names></name><name><surname>Sanacora</surname><given-names>G</given-names></name><name><surname>Krystal</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants</article-title><source>Nature Medicine</source><volume>22</volume><fpage>238</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1038/nm.4050</pub-id><pub-id pub-id-type="pmid">26937618</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duman</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Ketamine and rapid-acting antidepressants: A new era in the battle against depression and suicide</article-title><source>F1000Research</source><volume>7</volume><elocation-id>659</elocation-id><pub-id pub-id-type="doi">10.12688/f1000research.14344.1</pub-id><pub-id pub-id-type="pmid">29899972</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eley</surname><given-names>TC</given-names></name><name><surname>Sugden</surname><given-names>K</given-names></name><name><surname>Corsico</surname><given-names>A</given-names></name><name><surname>Gregory</surname><given-names>AM</given-names></name><name><surname>Sham</surname><given-names>P</given-names></name><name><surname>McGuffin</surname><given-names>P</given-names></name><name><surname>Plomin</surname><given-names>R</given-names></name><name><surname>Craig</surname><given-names>IW</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Gene–environment interaction analysis of serotonin system markers with adolescent depression</article-title><source>Molecular Psychiatry</source><volume>9</volume><fpage>908</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.1038/sj.mp.4001546</pub-id><pub-id pub-id-type="pmid">15241435</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engelhard</surname><given-names>B</given-names></name><name><surname>Finkelstein</surname><given-names>J</given-names></name><name><surname>Cox</surname><given-names>J</given-names></name><name><surname>Fleming</surname><given-names>W</given-names></name><name><surname>Jang</surname><given-names>HJ</given-names></name><name><surname>Ornelas</surname><given-names>S</given-names></name><name><surname>Koay</surname><given-names>SA</given-names></name><name><surname>Thiberge</surname><given-names>SY</given-names></name><name><surname>Daw</surname><given-names>ND</given-names></name><name><surname>Tank</surname><given-names>DW</given-names></name><name><surname>Witten</surname><given-names>IB</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Specialized coding of sensory, motor and cognitive variables in VTA dopamine neurons</article-title><source>Nature</source><volume>570</volume><fpage>509</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1261-9</pub-id><pub-id pub-id-type="pmid">31142844</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felten</surname><given-names>A</given-names></name><name><surname>Montag</surname><given-names>C</given-names></name><name><surname>Markett</surname><given-names>S</given-names></name><name><surname>Walter</surname><given-names>NT</given-names></name><name><surname>Reuter</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Genetically determined dopamine availability predicts disposition for depression</article-title><source>Brain and Behavior</source><volume>1</volume><fpage>109</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1002/brb3.20</pub-id><pub-id pub-id-type="pmid">22399090</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>AK</given-names></name><name><surname>Walsh</surname><given-names>JJ</given-names></name><name><surname>Juarez</surname><given-names>B</given-names></name><name><surname>Ku</surname><given-names>SM</given-names></name><name><surname>Chaudhury</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Dietz</surname><given-names>DM</given-names></name><name><surname>Pan</surname><given-names>N</given-names></name><name><surname>Vialou</surname><given-names>VF</given-names></name><name><surname>Neve</surname><given-names>RL</given-names></name><name><surname>Yue</surname><given-names>Z</given-names></name><name><surname>Han</surname><given-names>MH</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Enhancing Depression Mechanisms in Midbrain Dopamine Neurons Achieves Homeostatic Resilience</article-title><source>Science</source><volume>344</volume><fpage>313</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1126/science.1249240</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frisch</surname><given-names>A</given-names></name><name><surname>Postilnick</surname><given-names>D</given-names></name><name><surname>Rockah</surname><given-names>R</given-names></name><name><surname>Michaelovsky</surname><given-names>E</given-names></name><name><surname>Postilnick</surname><given-names>S</given-names></name><name><surname>Birman</surname><given-names>E</given-names></name><name><surname>Laor</surname><given-names>N</given-names></name><name><surname>Rauchverger</surname><given-names>B</given-names></name><name><surname>Kreinin</surname><given-names>A</given-names></name><name><surname>Poyurovsky</surname><given-names>M</given-names></name><name><surname>Schneidman</surname><given-names>M</given-names></name><name><surname>Modai</surname><given-names>I</given-names></name><name><surname>Weizman</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Association of unipolar major depressive disorder with genes of the serotonergic and dopaminergic pathways</article-title><source>Molecular Psychiatry</source><volume>4</volume><fpage>389</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1038/sj.mp.4000536</pub-id><pub-id pub-id-type="pmid">10483058</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuchikami</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Wohleb</surname><given-names>ES</given-names></name><name><surname>Land</surname><given-names>BB</given-names></name><name><surname>DiLeone</surname><given-names>RJ</given-names></name><name><surname>Aghajanian</surname><given-names>GK</given-names></name><name><surname>Duman</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Optogenetic stimulation of infralimbic PFC reproduces ketamine’s rapid and sustained antidepressant actions</article-title><source>PNAS</source><volume>112</volume><fpage>8106</fpage><lpage>8111</lpage><pub-id pub-id-type="doi">10.1073/pnas.1414728112</pub-id><pub-id pub-id-type="pmid">26056286</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gansner</surname><given-names>ER</given-names></name><name><surname>North</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Open graph visualization system and its applications to software engineering</article-title><source>Software</source><volume>30</volume><fpage>1203</fpage><lpage>1233</lpage><pub-id pub-id-type="doi">10.1002/1097-024X(200009)30:113.0.CO;2-N</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gariano</surname><given-names>RF</given-names></name><name><surname>Groves</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Burst firing induced in midbrain dopamine neurons by stimulation of the medial prefrontal and anterior cingulate cortices</article-title><source>Brain Research</source><volume>462</volume><fpage>194</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/0006-8993(88)90606-3</pub-id><pub-id pub-id-type="pmid">3179734</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geisler</surname><given-names>S</given-names></name><name><surname>Derst</surname><given-names>C</given-names></name><name><surname>Veh</surname><given-names>RW</given-names></name><name><surname>Zahm</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Glutamatergic afferents of the ventral tegmental area in the rat</article-title><source>The Journal of Neuroscience</source><volume>27</volume><fpage>5730</fpage><lpage>5743</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0012-07.2007</pub-id><pub-id pub-id-type="pmid">17522317</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonçalves</surname><given-names>L</given-names></name><name><surname>Sego</surname><given-names>C</given-names></name><name><surname>Metzger</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Differential projections from the lateral habenula to the rostromedial tegmental nucleus and ventral tegmental area in the rat</article-title><source>The Journal of Comparative Neurology</source><volume>520</volume><fpage>1278</fpage><lpage>1300</lpage><pub-id pub-id-type="doi">10.1002/cne.22787</pub-id><pub-id pub-id-type="pmid">22020635</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>S</given-names></name><name><surname>Doughty</surname><given-names>M</given-names></name><name><surname>Harbaugh</surname><given-names>CR</given-names></name><name><surname>Cummins</surname><given-names>A</given-names></name><name><surname>Hatten</surname><given-names>ME</given-names></name><name><surname>Heintz</surname><given-names>N</given-names></name><name><surname>Gerfen</surname><given-names>CR</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Targeting Cre recombinase to specific neuron populations with bacterial artificial chromosome constructs</article-title><source>The Journal of Neuroscience</source><volume>27</volume><fpage>9817</fpage><lpage>9823</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2707-07.2007</pub-id><pub-id pub-id-type="pmid">17855595</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grace</surname><given-names>AA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression</article-title><source>Nature Reviews. Neuroscience</source><volume>17</volume><fpage>524</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1038/nrn.2016.57</pub-id><pub-id pub-id-type="pmid">27256556</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haeffel</surname><given-names>GJ</given-names></name><name><surname>Getchell</surname><given-names>M</given-names></name><name><surname>Koposov</surname><given-names>RA</given-names></name><name><surname>Yrigollen</surname><given-names>CM</given-names></name><name><surname>Deyoung</surname><given-names>CG</given-names></name><name><surname>Klinteberg</surname><given-names>BA</given-names></name><name><surname>Oreland</surname><given-names>L</given-names></name><name><surname>Ruchkin</surname><given-names>VV</given-names></name><name><surname>Grigorenko</surname><given-names>EL</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Association between polymorphisms in the dopamine transporter gene and depression: Evidence for a gene-environment interaction in a sample of juvenile detainees</article-title><source>Psychological Science</source><volume>19</volume><fpage>62</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1111/j.1467-9280.2008.02047.x</pub-id><pub-id pub-id-type="pmid">18181793</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hare</surname><given-names>BD</given-names></name><name><surname>Shinohara</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>RJ</given-names></name><name><surname>Pothula</surname><given-names>S</given-names></name><name><surname>DiLeone</surname><given-names>RJ</given-names></name><name><surname>Duman</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Optogenetic stimulation of medial prefrontal cortex drd1 neurons produces rapid and long-lasting antidepressant effects</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>223</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-08168-9</pub-id><pub-id pub-id-type="pmid">30644390</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hare</surname><given-names>BD</given-names></name><name><surname>Pothula</surname><given-names>S</given-names></name><name><surname>DiLeone</surname><given-names>RJ</given-names></name><name><surname>Duman</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Ketamine increases VMPFC activity: Effects of (r)- and (s)-stereoisomers and (2r,6r)-hydroxynorketamine metabolite</article-title><source>Neuropharmacology</source><volume>166</volume><elocation-id>107947</elocation-id><pub-id pub-id-type="doi">10.1016/j.neuropharm.2020.107947</pub-id><pub-id pub-id-type="pmid">31926944</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harmer</surname><given-names>CJ</given-names></name><name><surname>Duman</surname><given-names>RS</given-names></name><name><surname>Cowen</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>How do antidepressants work? New perspectives for refining future treatment approaches</article-title><source>The Lancet Psychiatry</source><volume>4</volume><fpage>409</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1016/S2215-0366(17)30015-9</pub-id><pub-id pub-id-type="pmid">28153641</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>CX</given-names></name><name><surname>Arroyo</surname><given-names>ED</given-names></name><name><surname>Cantu</surname><given-names>DA</given-names></name><name><surname>Goel</surname><given-names>A</given-names></name><name><surname>Portera-Cailliau</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A versatile method for viral transfection of calcium indicators in the neonatal mouse brain</article-title><source>Frontiers in Neural Circuits</source><volume>12</volume><elocation-id>56</elocation-id><pub-id pub-id-type="doi">10.3389/fncir.2018.00056</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heldt</surname><given-names>SA</given-names></name><name><surname>Stanek</surname><given-names>L</given-names></name><name><surname>Chhatwal</surname><given-names>JP</given-names></name><name><surname>Ressler</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Hippocampus-specific deletion of BDNF in adult mice impairs spatial memory and extinction of aversive memories</article-title><source>Molecular Psychiatry</source><volume>12</volume><fpage>656</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1038/sj.mp.4001957</pub-id><pub-id pub-id-type="pmid">17264839</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollon</surname><given-names>NG</given-names></name><name><surname>Burgeno</surname><given-names>LM</given-names></name><name><surname>Phillips</surname><given-names>PEM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Stress effects on the neural substrates of motivated behavior</article-title><source>Nature Neuroscience</source><volume>18</volume><fpage>1405</fpage><lpage>1412</lpage><pub-id pub-id-type="doi">10.1038/nn.4114</pub-id><pub-id pub-id-type="pmid">26404715</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homayoun</surname><given-names>H</given-names></name><name><surname>Moghaddam</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons</article-title><source>The Journal of Neuroscience</source><volume>27</volume><fpage>11496</fpage><lpage>11500</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2213-07.2007</pub-id><pub-id pub-id-type="pmid">17959792</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honey</surname><given-names>GD</given-names></name><name><surname>Corlett</surname><given-names>PR</given-names></name><name><surname>Absalom</surname><given-names>AR</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Pomarol-Clotet</surname><given-names>E</given-names></name><name><surname>Murray</surname><given-names>GK</given-names></name><name><surname>McKenna</surname><given-names>PJ</given-names></name><name><surname>Bullmore</surname><given-names>ET</given-names></name><name><surname>Menon</surname><given-names>DK</given-names></name><name><surname>Fletcher</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Individual differences in psychotic effects of ketamine are predicted by brain function measured under placebo</article-title><source>The Journal of Neuroscience</source><volume>28</volume><fpage>6295</fpage><lpage>6303</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0910-08.2008</pub-id><pub-id pub-id-type="pmid">18562599</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>XH</given-names></name><name><surname>Hyun</surname><given-names>M</given-names></name><name><surname>Taranda</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>KW</given-names></name><name><surname>Todd</surname><given-names>E</given-names></name><name><surname>Feng</surname><given-names>D</given-names></name><name><surname>Atwater</surname><given-names>E</given-names></name><name><surname>Croney</surname><given-names>D</given-names></name><name><surname>Zeidel</surname><given-names>ML</given-names></name><name><surname>Osten</surname><given-names>P</given-names></name><name><surname>Sabatini</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Central Control Circuit for Context-Dependent Micturition</article-title><source>Cell</source><volume>167</volume><fpage>73</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.08.073</pub-id><pub-id pub-id-type="pmid">27662084</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howe</surname><given-names>MW</given-names></name><name><surname>Dombeck</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Rapid signalling in distinct dopaminergic axons during locomotion and reward</article-title><source>Nature</source><volume>535</volume><fpage>505</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1038/nature18942</pub-id><pub-id pub-id-type="pmid">27398617</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jönsson</surname><given-names>EG</given-names></name><name><surname>Nöthen</surname><given-names>MM</given-names></name><name><surname>Grünhage</surname><given-names>F</given-names></name><name><surname>Farde</surname><given-names>L</given-names></name><name><surname>Nakashima</surname><given-names>Y</given-names></name><name><surname>Propping</surname><given-names>P</given-names></name><name><surname>Sedvall</surname><given-names>GC</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers</article-title><source>Molecular Psychiatry</source><volume>4</volume><fpage>290</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1038/sj.mp.4000532</pub-id><pub-id pub-id-type="pmid">10395223</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kokkinou</surname><given-names>M</given-names></name><name><surname>Ashok</surname><given-names>AH</given-names></name><name><surname>Howes</surname><given-names>OD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The effects of ketamine on dopaminergic function: Meta-Analysis and review of the implications for neuropsychiatric disorders</article-title><source>Molecular Psychiatry</source><volume>23</volume><fpage>59</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1038/mp.2017.190</pub-id><pub-id pub-id-type="pmid">28972576</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kozorovitskiy</surname><given-names>Y</given-names></name><name><surname>Saunders</surname><given-names>A</given-names></name><name><surname>Johnson</surname><given-names>CA</given-names></name><name><surname>Lowell</surname><given-names>BB</given-names></name><name><surname>Sabatini</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Recurrent network activity drives striatal synaptogenesis</article-title><source>Nature</source><volume>485</volume><fpage>646</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1038/nature11052</pub-id><pub-id pub-id-type="pmid">22660328</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kozorovitskiy</surname><given-names>Y</given-names></name><name><surname>Peixoto</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Saunders</surname><given-names>A</given-names></name><name><surname>Sabatini</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Neuromodulation of excitatory synaptogenesis in striatal development</article-title><source>eLife</source><volume>4</volume><elocation-id>e10111</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.10111</pub-id><pub-id pub-id-type="pmid">26551563</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krashes</surname><given-names>MJ</given-names></name><name><surname>Koda</surname><given-names>S</given-names></name><name><surname>Ye</surname><given-names>C</given-names></name><name><surname>Rogan</surname><given-names>SC</given-names></name><name><surname>Adams</surname><given-names>AC</given-names></name><name><surname>Cusher</surname><given-names>DS</given-names></name><name><surname>Maratos-Flier</surname><given-names>E</given-names></name><name><surname>Roth</surname><given-names>BL</given-names></name><name><surname>Lowell</surname><given-names>BB</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Rapid, reversible activation of AgRP neurons drives feeding behavior in mice</article-title><source>The Journal of Clinical Investigation</source><volume>121</volume><fpage>1424</fpage><lpage>1428</lpage><pub-id pub-id-type="doi">10.1172/JCI46229</pub-id><pub-id pub-id-type="pmid">21364278</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishnan</surname><given-names>V</given-names></name><name><surname>Nestler</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Animal models of depression: molecular perspectives</article-title><source>Current Topics in Behavioral Neurosciences</source><volume>7</volume><fpage>121</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1007/7854_2010_108</pub-id><pub-id pub-id-type="pmid">21225412</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Black</surname><given-names>SJ</given-names></name><name><surname>Hultman</surname><given-names>R</given-names></name><name><surname>Szabo</surname><given-names>ST</given-names></name><name><surname>Demaio</surname><given-names>KD</given-names></name><name><surname>Du</surname><given-names>J</given-names></name><name><surname>Katz</surname><given-names>BM</given-names></name><name><surname>Feng</surname><given-names>G</given-names></name><name><surname>Covington</surname><given-names>HE</given-names></name><name><surname>Dzirasa</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Cortical control of affective networks</article-title><source>The Journal of Neuroscience</source><volume>33</volume><fpage>1116</fpage><lpage>1129</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0092-12.2013</pub-id><pub-id pub-id-type="pmid">23325249</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lammel</surname><given-names>S</given-names></name><name><surname>Ion</surname><given-names>DI</given-names></name><name><surname>Roeper</surname><given-names>J</given-names></name><name><surname>Malenka</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Projection-Specific Modulation of Dopamine Neuron Synapses by Aversive and Rewarding Stimuli</article-title><source>Neuron</source><volume>70</volume><fpage>855</fpage><lpage>862</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2011.03.025</pub-id><pub-id pub-id-type="pmid">21658580</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lammel</surname><given-names>S</given-names></name><name><surname>Lim</surname><given-names>BK</given-names></name><name><surname>Ran</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>KW</given-names></name><name><surname>Betley</surname><given-names>MJ</given-names></name><name><surname>Tye</surname><given-names>KM</given-names></name><name><surname>Deisseroth</surname><given-names>K</given-names></name><name><surname>Malenka</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Input-specific control of reward and aversion in the ventral tegmental area</article-title><source>Nature</source><volume>491</volume><fpage>212</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1038/nature11527</pub-id><pub-id pub-id-type="pmid">23064228</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lammel</surname><given-names>S</given-names></name><name><surname>Lim</surname><given-names>BK</given-names></name><name><surname>Malenka</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Reward and aversion in a heterogeneous midbrain dopamine system</article-title><source>Neuropharmacology</source><volume>76 Pt B</volume><fpage>351</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2013.03.019</pub-id><pub-id pub-id-type="pmid">23578393</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Lodder</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Patriarchi</surname><given-names>T</given-names></name><name><surname>Tian</surname><given-names>L</given-names></name><name><surname>Sabatini</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cell-type-specific asynchronous modulation of PKA by dopamine in learning</article-title><source>Nature</source><volume>590</volume><elocation-id>451</elocation-id><pub-id pub-id-type="doi">10.1038/s41586-020-03050-5</pub-id><pub-id pub-id-type="pmid">33361810</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lerner</surname><given-names>TN</given-names></name><name><surname>Shilyansky</surname><given-names>C</given-names></name><name><surname>Davidson</surname><given-names>TJ</given-names></name><name><surname>Evans</surname><given-names>KE</given-names></name><name><surname>Beier</surname><given-names>KT</given-names></name><name><surname>Zalocusky</surname><given-names>KA</given-names></name><name><surname>Crow</surname><given-names>AK</given-names></name><name><surname>Malenka</surname><given-names>RC</given-names></name><name><surname>Luo</surname><given-names>L</given-names></name><name><surname>Tomer</surname><given-names>R</given-names></name><name><surname>Deisseroth</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Intact-Brain Analyses Reveal Distinct Information Carried by SNc Dopamine Subcircuits</article-title><source>Cell</source><volume>162</volume><fpage>635</fpage><lpage>647</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.07.014</pub-id><pub-id pub-id-type="pmid">26232229</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>RJ</given-names></name><name><surname>Banasr</surname><given-names>M</given-names></name><name><surname>Dwyer</surname><given-names>JM</given-names></name><name><surname>Iwata</surname><given-names>M</given-names></name><name><surname>X-Y</surname><given-names>L</given-names></name><name><surname>Aghajanian</surname><given-names>G</given-names></name><name><surname>Duman</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Mtor-dependent synapse formation underlies the rapid antidepressant effects of nmda antagonists</article-title><source>Science</source><volume>329</volume><fpage>959</fpage><lpage>964</lpage><pub-id pub-id-type="doi">10.1126/science.1190287</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Piriz</surname><given-names>J</given-names></name><name><surname>Mirrione</surname><given-names>M</given-names></name><name><surname>Chung</surname><given-names>C</given-names></name><name><surname>Proulx</surname><given-names>CD</given-names></name><name><surname>Schulz</surname><given-names>D</given-names></name><name><surname>Henn</surname><given-names>F</given-names></name><name><surname>Malinow</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Synaptic potentiation onto habenula neurons in the learned helplessness model of depression</article-title><source>Nature</source><volume>470</volume><fpage>535</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1038/nature09742</pub-id><pub-id pub-id-type="pmid">21350486</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>RJ</given-names></name><name><surname>Fuchikami</surname><given-names>M</given-names></name><name><surname>Dwyer</surname><given-names>JM</given-names></name><name><surname>Lepack</surname><given-names>AE</given-names></name><name><surname>Duman</surname><given-names>RS</given-names></name><name><surname>Aghajanian</surname><given-names>GK</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine</article-title><source>Neuropsychopharmacology</source><volume>38</volume><fpage>2268</fpage><lpage>2277</lpage><pub-id pub-id-type="doi">10.1038/npp.2013.128</pub-id><pub-id pub-id-type="pmid">23680942</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lodge</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The medial prefrontal and orbitofrontal cortices differentially regulate dopamine system function</article-title><source>Neuropsychopharmacology</source><volume>36</volume><fpage>1227</fpage><lpage>1236</lpage><pub-id pub-id-type="doi">10.1038/npp.2011.7</pub-id><pub-id pub-id-type="pmid">21307842</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorrain</surname><given-names>D</given-names></name><name><surname>Baccei</surname><given-names>C</given-names></name><name><surname>Bristow</surname><given-names>L</given-names></name><name><surname>Anderson</surname><given-names>J</given-names></name><name><surname>Varney</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Effects of ketamine and n-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268</article-title><source>Neuroscience</source><volume>117</volume><fpage>697</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1016/S0306-4522(02)00652-8</pub-id><pub-id pub-id-type="pmid">12617973</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacDonald</surname><given-names>SWS</given-names></name><name><surname>Karlsson</surname><given-names>S</given-names></name><name><surname>Rieckmann</surname><given-names>A</given-names></name><name><surname>Nyberg</surname><given-names>L</given-names></name><name><surname>Backman</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Aging-Related Increases in Behavioral Variability: Relations to Losses of Dopamine D1 Receptors</article-title><source>The Journal of Neuroscience</source><volume>32</volume><fpage>8186</fpage><lpage>8191</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5474-11.2012</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maeng</surname><given-names>S</given-names></name><name><surname>Zarate</surname><given-names>CA</given-names></name><name><surname>Du</surname><given-names>J</given-names></name><name><surname>Schloesser</surname><given-names>RJ</given-names></name><name><surname>McCammon</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Manji</surname><given-names>HK</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors</article-title><source>Biological Psychiatry</source><volume>63</volume><fpage>349</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2007.05.028</pub-id><pub-id pub-id-type="pmid">17643398</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maier</surname><given-names>SF</given-names></name><name><surname>Seligman</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="1976">1976</year><article-title>Learned helplessness: Theory and evidence</article-title><source>Journal of Experimental Psychology. General</source><volume>105</volume><fpage>3</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1037/0096-3445.105.1.3</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maier</surname><given-names>SF</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>Learned helplessness and animal models of depression</article-title><source>Prog Neuro-Psychopharmacology Biol Psychiatry</source><volume>8</volume><fpage>435</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1016/S0278-5846(84)80032-9</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maier</surname><given-names>SF</given-names></name><name><surname>Seligman</surname><given-names>MEP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Learned helplessness at fifty: Insights from neuroscience</article-title><source>Psychological Review</source><volume>123</volume><fpage>1</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1037/rev0000033</pub-id><pub-id pub-id-type="pmid">27337390</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masellis</surname><given-names>M</given-names></name><name><surname>Rector</surname><given-names>NA</given-names></name><name><surname>Richter</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Quality of life in OCD: Differential impact of obsessions, compulsions, and depression comorbidity</article-title><source>Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie</source><volume>48</volume><fpage>72</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1177/070674370304800202</pub-id><pub-id pub-id-type="pmid">12655903</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayeux</surname><given-names>R</given-names></name><name><surname>Stern</surname><given-names>Y</given-names></name><name><surname>Rosen</surname><given-names>J</given-names></name><name><surname>Leventhal</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1981">1981</year><article-title>Depression, intellectual impairment, and Parkinson disease</article-title><source>Neurology</source><volume>31</volume><elocation-id>645</elocation-id><pub-id pub-id-type="doi">10.1212/WNL.31.6.645</pub-id><pub-id pub-id-type="pmid">7195481</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCullough</surname><given-names>LD</given-names></name><name><surname>Sokolowski</surname><given-names>JD</given-names></name><name><surname>Salamone</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>A neurochemical and behavioral investigation of the involvement of nucleus accumbens dopamine in instrumental avoidance</article-title><source>Neuroscience</source><volume>52</volume><fpage>919</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.1016/0306-4522(93)90538-Q</pub-id><pub-id pub-id-type="pmid">8450978</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moda-Sava</surname><given-names>RN</given-names></name><name><surname>Murdock</surname><given-names>MH</given-names></name><name><surname>Parekh</surname><given-names>PK</given-names></name><name><surname>Fetcho</surname><given-names>RN</given-names></name><name><surname>Huang</surname><given-names>BS</given-names></name><name><surname>Huynh</surname><given-names>TN</given-names></name><name><surname>Witztum</surname><given-names>J</given-names></name><name><surname>Shaver</surname><given-names>DC</given-names></name><name><surname>Rosenthal</surname><given-names>DL</given-names></name><name><surname>Alway</surname><given-names>EJ</given-names></name><name><surname>Lopez</surname><given-names>K</given-names></name><name><surname>Meng</surname><given-names>Y</given-names></name><name><surname>Nellissen</surname><given-names>L</given-names></name><name><surname>Grosenick</surname><given-names>L</given-names></name><name><surname>Milner</surname><given-names>TA</given-names></name><name><surname>Deisseroth</surname><given-names>K</given-names></name><name><surname>Bito</surname><given-names>H</given-names></name><name><surname>Kasai</surname><given-names>H</given-names></name><name><surname>Liston</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation</article-title><source>Science</source><volume>364</volume><elocation-id>eaat8078</elocation-id><pub-id pub-id-type="doi">10.1126/science.aat8078</pub-id><pub-id pub-id-type="pmid">30975859</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morales</surname><given-names>M</given-names></name><name><surname>Margolis</surname><given-names>EB</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Ventral tegmental area: Cellular heterogeneity, connectivity and behaviour</article-title><source>Nature Reviews. Neuroscience</source><volume>18</volume><fpage>73</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1038/nrn.2016.165</pub-id><pub-id pub-id-type="pmid">28053327</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nestler</surname><given-names>EJ</given-names></name><name><surname>Carlezon</surname><given-names>WA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The Mesolimbic Dopamine Reward Circuit in Depression</article-title><source>Biological Psychiatry</source><volume>59</volume><fpage>1151</fpage><lpage>1159</lpage><pub-id pub-id-type="doi">10.1016/J.BIOPSYCH.2005.09.018</pub-id><pub-id pub-id-type="pmid">16566899</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>LHL</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><name><surname>Chang</surname><given-names>RC</given-names></name><name><surname>Chan</surname><given-names>YS</given-names></name><name><surname>Lai</surname><given-names>CSW</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Ketamine and selective activation of parvalbumin interneurons inhibit stress-induced dendritic spine elimination</article-title><source>Translational Psychiatry</source><volume>8</volume><elocation-id>272</elocation-id><pub-id pub-id-type="doi">10.1038/s41398-018-0321-5</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nutt</surname><given-names>DJ</given-names></name><name><surname>Baldwin</surname><given-names>DS</given-names></name><name><surname>Clayton</surname><given-names>AH</given-names></name><name><surname>Elgie</surname><given-names>R</given-names></name><name><surname>Lecrubier</surname><given-names>Y</given-names></name><name><surname>Montejo</surname><given-names>AL</given-names></name><name><surname>Papakostas</surname><given-names>GI</given-names></name><name><surname>Souery</surname><given-names>D</given-names></name><name><surname>Trivedi</surname><given-names>MH</given-names></name><name><surname>Tylee</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Consensus statement and research needs: The role of dopamine and norepinephrine in depression and antidepressant treatment</article-title><source>The Journal of Clinical Psychiatry</source><volume>67</volume><fpage>46</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">16848678</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okubo</surname><given-names>Y</given-names></name><name><surname>Suhara</surname><given-names>T</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Inoue</surname><given-names>O</given-names></name><name><surname>Terasaki</surname><given-names>O</given-names></name><name><surname>Someya</surname><given-names>Y</given-names></name><name><surname>Sassa</surname><given-names>T</given-names></name><name><surname>Sudo</surname><given-names>Y</given-names></name><name><surname>Matsushima</surname><given-names>E</given-names></name><name><surname>Iyo</surname><given-names>M</given-names></name><name><surname>Tateno</surname><given-names>Y</given-names></name><name><surname>Toru</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET</article-title><source>Nature</source><volume>385</volume><fpage>634</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1038/385634a0</pub-id><pub-id pub-id-type="pmid">9024661</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oleson</surname><given-names>EB</given-names></name><name><surname>Gentry</surname><given-names>RN</given-names></name><name><surname>Chioma</surname><given-names>VC</given-names></name><name><surname>Cheer</surname><given-names>JF</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Subsecond dopamine release in the nucleus accumbens predicts conditioned punishment and its successful avoidance</article-title><source>The Journal of Neuroscience</source><volume>32</volume><fpage>14804</fpage><lpage>14808</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3087-12.2012</pub-id><pub-id pub-id-type="pmid">23077064</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oleson</surname><given-names>EB</given-names></name><name><surname>Cheer</surname><given-names>JF</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>On the role of subsecond dopamine release in conditioned avoidance</article-title><source>Frontiers in Neuroscience</source><volume>7</volume><elocation-id>96</elocation-id><pub-id pub-id-type="doi">10.3389/fnins.2013.00096</pub-id><pub-id pub-id-type="pmid">23759871</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Donnell</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Adolescent maturation of cortical dopamine</article-title><source>Neurotoxicity Research</source><volume>18</volume><fpage>306</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1007/s12640-010-9157-3</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patriarchi</surname><given-names>T</given-names></name><name><surname>Cho</surname><given-names>JR</given-names></name><name><surname>Merten</surname><given-names>K</given-names></name><name><surname>Howe</surname><given-names>MW</given-names></name><name><surname>Marley</surname><given-names>A</given-names></name><name><surname>Xiong</surname><given-names>WH</given-names></name><name><surname>Folk</surname><given-names>RW</given-names></name><name><surname>Broussard</surname><given-names>GJ</given-names></name><name><surname>Liang</surname><given-names>R</given-names></name><name><surname>Jang</surname><given-names>MJ</given-names></name><name><surname>Zhong</surname><given-names>H</given-names></name><name><surname>Dombeck</surname><given-names>D</given-names></name><name><surname>von Zastrow</surname><given-names>M</given-names></name><name><surname>Nimmerjahn</surname><given-names>A</given-names></name><name><surname>Gradinaru</surname><given-names>V</given-names></name><name><surname>Williams</surname><given-names>JT</given-names></name><name><surname>Tian</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Ultrafast neuronal imaging of dopamine dynamics with designed genetically encoded sensors</article-title><source>Science</source><volume>360</volume><elocation-id>eaat4422</elocation-id><pub-id pub-id-type="doi">10.1126/science.aat4422</pub-id><pub-id pub-id-type="pmid">29853555</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearson-Fuhrhop</surname><given-names>KM</given-names></name><name><surname>Dunn</surname><given-names>EC</given-names></name><name><surname>Mortero</surname><given-names>S</given-names></name><name><surname>Devan</surname><given-names>WJ</given-names></name><name><surname>Falcone</surname><given-names>GJ</given-names></name><name><surname>Lee</surname><given-names>P</given-names></name><name><surname>Holmes</surname><given-names>AJ</given-names></name><name><surname>Hollinshead</surname><given-names>MO</given-names></name><name><surname>Roffman</surname><given-names>JL</given-names></name><name><surname>Smoller</surname><given-names>JW</given-names></name><name><surname>Rosand</surname><given-names>J</given-names></name><name><surname>Cramer</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Dopamine genetic risk score predicts depressive symptoms in healthy adults and adults with depression</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e93772</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0093772</pub-id><pub-id pub-id-type="pmid">24834916</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peixoto</surname><given-names>RT</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Croney</surname><given-names>DM</given-names></name><name><surname>Kozorovitskiy</surname><given-names>Y</given-names></name><name><surname>Sabatini</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Early hyperactivity and precocious maturation of corticostriatal circuits in Shank3B−/− mice</article-title><source>Nature Neuroscience</source><volume>19</volume><fpage>716</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1038/nn.4260</pub-id><pub-id pub-id-type="pmid">26928064</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peltoniemi</surname><given-names>MA</given-names></name><name><surname>Hagelberg</surname><given-names>NM</given-names></name><name><surname>Olkkola</surname><given-names>KT</given-names></name><name><surname>Saari</surname><given-names>TI</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy</article-title><source>Clinical Pharmacokinetics</source><volume>55</volume><fpage>1059</fpage><lpage>1077</lpage><pub-id pub-id-type="doi">10.1007/s40262-016-0383-6</pub-id><pub-id pub-id-type="pmid">27028535</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peña</surname><given-names>CJ</given-names></name><name><surname>Kronman</surname><given-names>HG</given-names></name><name><surname>Walker</surname><given-names>DM</given-names></name><name><surname>Cates</surname><given-names>HM</given-names></name><name><surname>Bagot</surname><given-names>RC</given-names></name><name><surname>Purushothaman</surname><given-names>I</given-names></name><name><surname>Issler</surname><given-names>O</given-names></name><name><surname>Eddie Loh</surname><given-names>YH</given-names></name><name><surname>Leong</surname><given-names>T</given-names></name><name><surname>Kiraly</surname><given-names>DD</given-names></name><name><surname>Goodman</surname><given-names>E</given-names></name><name><surname>Neve</surname><given-names>RL</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Nestler</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Early life stress confers lifelong stress susceptibility in mice via ventral tegmental area OTX2</article-title><source>Science</source><volume>356</volume><fpage>1185</fpage><lpage>1188</lpage><pub-id pub-id-type="doi">10.1126/science.aan4491</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peña</surname><given-names>CJ</given-names></name><name><surname>Smith</surname><given-names>M</given-names></name><name><surname>Ramakrishnan</surname><given-names>A</given-names></name><name><surname>Cates</surname><given-names>HM</given-names></name><name><surname>Bagot</surname><given-names>RC</given-names></name><name><surname>Kronman</surname><given-names>HG</given-names></name><name><surname>Patel</surname><given-names>B</given-names></name><name><surname>Chang</surname><given-names>AB</given-names></name><name><surname>Purushothaman</surname><given-names>I</given-names></name><name><surname>Dudley</surname><given-names>J</given-names></name><name><surname>Morishita</surname><given-names>H</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Nestler</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Early life stress alters transcriptomic patterning across reward circuitry in male and female mice</article-title><source>Nature Communications</source><volume>10</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1038/s41467-019-13085-6</pub-id><pub-id pub-id-type="pmid">31704941</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Picard</surname><given-names>N</given-names></name><name><surname>Takesian</surname><given-names>AE</given-names></name><name><surname>Fagiolini</surname><given-names>M</given-names></name><name><surname>Hensch</surname><given-names>TK</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>NMDA 2A receptors in parvalbumin cells mediate sex-specific rapid ketamine response on cortical activity</article-title><source>Molecular Psychiatry</source><volume>24</volume><fpage>828</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1038/s41380-018-0341-9</pub-id><pub-id pub-id-type="pmid">30696941</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pignatelli</surname><given-names>M</given-names></name><name><surname>Tejeda</surname><given-names>HA</given-names></name><name><surname>Barker</surname><given-names>DJ</given-names></name><name><surname>Bontempi</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Lopez</surname><given-names>A</given-names></name><name><surname>Palma Ribeiro</surname><given-names>S</given-names></name><name><surname>Lucantonio</surname><given-names>F</given-names></name><name><surname>Parise</surname><given-names>EM</given-names></name><name><surname>Torres-Berrio</surname><given-names>A</given-names></name><name><surname>Alvarez-Bagnarol</surname><given-names>Y</given-names></name><name><surname>Marino</surname><given-names>RAM</given-names></name><name><surname>Cai</surname><given-names>ZL</given-names></name><name><surname>Xue</surname><given-names>M</given-names></name><name><surname>Morales</surname><given-names>M</given-names></name><name><surname>Tamminga</surname><given-names>CA</given-names></name><name><surname>Nestler</surname><given-names>EJ</given-names></name><name><surname>Bonci</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cooperative synaptic and intrinsic plasticity in a disynaptic limbic circuit drive stress-induced anhedonia and passive coping in mice</article-title><source>Molecular Psychiatry</source><volume>1</volume><elocation-id>20</elocation-id><pub-id pub-id-type="doi">10.1038/s41380-020-0686-8</pub-id><pub-id pub-id-type="pmid">32161361</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pologruto</surname><given-names>TA</given-names></name><name><surname>Sabatini</surname><given-names>BL</given-names></name><name><surname>Svoboda</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Scanimage: Flexible software for operating laser scanning microscopes</article-title><source>Biomedical Engineering Online</source><volume>2</volume><elocation-id>13</elocation-id><pub-id pub-id-type="doi">10.1186/1475-925X-2-13</pub-id><pub-id pub-id-type="pmid">12801419</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Proulx</surname><given-names>CD</given-names></name><name><surname>Hikosaka</surname><given-names>O</given-names></name><name><surname>Malinow</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Reward processing by the lateral habenula in normal and depressive behaviors</article-title><source>Nature Neuroscience</source><volume>17</volume><fpage>1146</fpage><lpage>1152</lpage><pub-id pub-id-type="doi">10.1038/nn.3779</pub-id><pub-id pub-id-type="pmid">25157511</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Klaminder</surname><given-names>J</given-names></name><name><surname>Brodin</surname><given-names>T</given-names></name><name><surname>Andersson</surname><given-names>PL</given-names></name><name><surname>Andersson</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>ToxTrac: A fast and robust software for tracking organisms</article-title><source>Methods in Ecology and Evolution</source><volume>9</volume><fpage>460</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1111/2041-210X.12874</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>DREADDs for Neuroscientists</article-title><source>Neuron</source><volume>89</volume><fpage>683</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2016.01.040</pub-id><pub-id pub-id-type="pmid">26889809</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rottenberg</surname><given-names>J</given-names></name><name><surname>Gross</surname><given-names>JJ</given-names></name><name><surname>Gotlib</surname><given-names>IH</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Emotion context insensitivity in major depressive disorder</article-title><source>Journal of Abnormal Psychology</source><volume>114</volume><fpage>627</fpage><lpage>639</lpage><pub-id pub-id-type="doi">10.1037/0021-843X.114.4.627</pub-id><pub-id pub-id-type="pmid">16351385</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rottenberg</surname><given-names>J</given-names></name><name><surname>Hindash</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Emerging evidence for emotion context insensitivity in depression</article-title><source>Current Opinion in Psychology</source><volume>4</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.copsyc.2014.12.025</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rottenberg</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Emotions in Depression: What Do We Really Know</article-title><source>Annual Review of Clinical Psychology</source><volume>13</volume><fpage>241</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1146/annurev-clinpsy-032816-045252</pub-id><pub-id pub-id-type="pmid">28375721</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>SJ</given-names></name><name><surname>Nestler</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The brain reward circuitry in mood disorders</article-title><source>Nature Reviews. Neuroscience</source><volume>14</volume><fpage>609</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1038/nrn3381</pub-id><pub-id pub-id-type="pmid">23942470</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarkar</surname><given-names>A</given-names></name><name><surname>Kabbaj</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Sex Differences in Effects of Ketamine on Behavior, Spine Density, and Synaptic Proteins in Socially Isolated Rats</article-title><source>Biological Psychiatry</source><volume>80</volume><fpage>448</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2015.12.025</pub-id><pub-id pub-id-type="pmid">26957131</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindelin</surname><given-names>J</given-names></name><name><surname>Arganda-Carreras</surname><given-names>I</given-names></name><name><surname>Frise</surname><given-names>E</given-names></name><name><surname>Kaynig</surname><given-names>V</given-names></name><name><surname>Longair</surname><given-names>M</given-names></name><name><surname>Pietzsch</surname><given-names>T</given-names></name><name><surname>Preibisch</surname><given-names>S</given-names></name><name><surname>Rueden</surname><given-names>C</given-names></name><name><surname>Saalfeld</surname><given-names>S</given-names></name><name><surname>Schmid</surname><given-names>B</given-names></name><name><surname>Tinevez</surname><given-names>JY</given-names></name><name><surname>White</surname><given-names>DJ</given-names></name><name><surname>Hartenstein</surname><given-names>V</given-names></name><name><surname>Eliceiri</surname><given-names>K</given-names></name><name><surname>Tomancak</surname><given-names>P</given-names></name><name><surname>Cardona</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fiji: an open-source platform for biological-image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id><pub-id pub-id-type="pmid">22743772</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>CA</given-names></name><name><surname>Rasband</surname><given-names>WS</given-names></name><name><surname>Eliceiri</surname><given-names>KW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>NIH Image to ImageJ: 25 years of image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>671</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2089</pub-id><pub-id pub-id-type="pmid">22930834</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schultz</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Dopamine reward prediction-error signalling: a two-component response</article-title><source>Nature Reviews. Neuroscience</source><volume>17</volume><fpage>183</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1038/nrn.2015.26</pub-id><pub-id pub-id-type="pmid">26865020</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seligman</surname><given-names>ME</given-names></name><name><surname>Maier</surname><given-names>SF</given-names></name></person-group><year iso-8601-date="1967">1967</year><article-title>Failure to escape traumatic shock</article-title><source>Journal of Experimental Psychology</source><volume>74</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1037/h0024514</pub-id><pub-id pub-id-type="pmid">6032570</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirayama</surname><given-names>Y</given-names></name><name><surname>Hashimoto</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Effects of a single bilateral infusion of R-ketamine in the rat brain regions of a learned helplessness model of depression</article-title><source>European Archives of Psychiatry and Clinical Neuroscience</source><volume>267</volume><fpage>177</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1007/s00406-016-0718-1</pub-id><pub-id pub-id-type="pmid">27480092</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siris</surname><given-names>SG</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Depression in schizophrenia: Perspective in the era of “atypical” antipsychotic agents</article-title><source>The American Journal of Psychiatry</source><volume>157</volume><fpage>1379</fpage><lpage>1389</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.157.9.1379</pub-id><pub-id pub-id-type="pmid">10964850</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stelly</surname><given-names>CE</given-names></name><name><surname>Haug</surname><given-names>GC</given-names></name><name><surname>Fonzi</surname><given-names>KM</given-names></name><name><surname>Garcia</surname><given-names>MA</given-names></name><name><surname>Tritley</surname><given-names>SC</given-names></name><name><surname>Magnon</surname><given-names>AP</given-names></name><name><surname>Ramos</surname><given-names>MAP</given-names></name><name><surname>Wanat</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Pattern of dopamine signaling during aversive events predicts active avoidance learning</article-title><source>PNAS</source><volume>116</volume><fpage>13641</fpage><lpage>13650</lpage><pub-id pub-id-type="doi">10.1073/pnas.1904249116</pub-id><pub-id pub-id-type="pmid">31209016</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>KR</given-names></name><name><surname>Yvon</surname><given-names>C</given-names></name><name><surname>Turiault</surname><given-names>M</given-names></name><name><surname>Mirzabekov</surname><given-names>JJ</given-names></name><name><surname>Doehner</surname><given-names>J</given-names></name><name><surname>Labouèbe</surname><given-names>G</given-names></name><name><surname>Deisseroth</surname><given-names>K</given-names></name><name><surname>Tye</surname><given-names>KM</given-names></name><name><surname>Lüscher</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>GABA Neurons of the VTA Drive Conditioned Place Aversion</article-title><source>Neuron</source><volume>73</volume><fpage>1173</fpage><lpage>1183</lpage><pub-id pub-id-type="doi">10.1016/J.NEURON.2012.02.015</pub-id><pub-id pub-id-type="pmid">22445344</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>ZY</given-names></name><name><surname>Overton</surname><given-names>PG</given-names></name><name><surname>Clark</surname><given-names>D</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Stimulation of the prefrontal cortex in the rat induces patterns of activity in midbrain dopaminergic neurons which resemble natural burst events</article-title><source>Synapse</source><volume>22</volume><fpage>195</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1098-2396(199603)22:33.0.CO;2-7</pub-id><pub-id pub-id-type="pmid">9132987</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>HC</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Adamantidis</surname><given-names>A</given-names></name><name><surname>Stuber</surname><given-names>GD</given-names></name><name><surname>Bonci</surname><given-names>A</given-names></name><name><surname>de Lecea</surname><given-names>L</given-names></name><name><surname>Deisseroth</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Phasic Firing in Dopaminergic Neurons Is Sufficient for Behavioral Conditioning</article-title><source>Science</source><volume>324</volume><fpage>1080</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.1126/science.1168878</pub-id><pub-id pub-id-type="pmid">19389999</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tye</surname><given-names>KM</given-names></name><name><surname>Mirzabekov</surname><given-names>JJ</given-names></name><name><surname>Warden</surname><given-names>MR</given-names></name><name><surname>Ferenczi</surname><given-names>EA</given-names></name><name><surname>Tsai</surname><given-names>HC</given-names></name><name><surname>Finkelstein</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Adhikari</surname><given-names>A</given-names></name><name><surname>Thompson</surname><given-names>KR</given-names></name><name><surname>Andalman</surname><given-names>AS</given-names></name><name><surname>Gunaydin</surname><given-names>LA</given-names></name><name><surname>Witten</surname><given-names>IB</given-names></name><name><surname>Deisseroth</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Dopamine neurons modulate neural encoding and expression of depression-related behaviour</article-title><source>Nature</source><volume>493</volume><fpage>537</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1038/nature11740</pub-id><pub-id pub-id-type="pmid">23235822</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volkow</surname><given-names>ND</given-names></name><name><surname>Fowler</surname><given-names>JS</given-names></name><name><surname>Gatley</surname><given-names>SJ</given-names></name><name><surname>Logan</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>GJ</given-names></name><name><surname>Ding</surname><given-names>YS</given-names></name><name><surname>Dewey</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>PET Evaluation of the Dopamine System of the Human Brain</article-title><source>Journal of Nuclear Medicine</source><volume>37</volume><fpage>1242</fpage><lpage>1256</lpage><pub-id pub-id-type="pmid">8965206</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wahlstrom</surname><given-names>D</given-names></name><name><surname>Collins</surname><given-names>P</given-names></name><name><surname>White</surname><given-names>T</given-names></name><name><surname>Luciana</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Developmental changes in dopamine neurotransmission in adolescence: Behavioral implications and issues in assessment</article-title><source>Brain and Cognition</source><volume>72</volume><fpage>146</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1016/j.bandc.2009.10.013</pub-id><pub-id pub-id-type="pmid">19944514</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>ER</given-names></name><name><surname>McGee</surname><given-names>RE</given-names></name><name><surname>Druss</surname><given-names>BG</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mortality in mental disorders and global disease burden implications a systematic review and meta-analysis</article-title><source>JAMA Psychiatry</source><volume>72</volume><fpage>334</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2014.2502</pub-id><pub-id pub-id-type="pmid">25671328</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Timberlake</surname><given-names>MA</given-names></name><name><surname>Prall</surname><given-names>K</given-names></name><name><surname>Dwivedi</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The recent progress in animal models of depression</article-title><source>Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry</source><volume>77</volume><fpage>99</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2017.04.008</pub-id><pub-id pub-id-type="pmid">28396255</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watabe-Uchida</surname><given-names>M</given-names></name><name><surname>Eshel</surname><given-names>N</given-names></name><name><surname>Uchida</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Neural Circuitry of Reward Prediction Error</article-title><source>Annual Review of Neuroscience</source><volume>40</volume><fpage>373</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1146/annurev-neuro-072116-031109</pub-id><pub-id pub-id-type="pmid">28441114</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welch</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="1967">1967</year><article-title>The Use of Fast Fourier Transform for the Estimation of Power Spectra: A Method Based on Time Averaging Over Short, Modified Periodograms</article-title><source>IEEE Trans Audio Electroacoust</source><volume>15</volume><fpage>70</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1109/TAU.1967.1161901</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wenzel</surname><given-names>JM</given-names></name><name><surname>Oleson</surname><given-names>EB</given-names></name><name><surname>Gove</surname><given-names>WN</given-names></name><name><surname>Cole</surname><given-names>AB</given-names></name><name><surname>Gyawali</surname><given-names>U</given-names></name><name><surname>Dantrassy</surname><given-names>HM</given-names></name><name><surname>Bluett</surname><given-names>RJ</given-names></name><name><surname>Dryanovski</surname><given-names>DI</given-names></name><name><surname>Stuber</surname><given-names>GD</given-names></name><name><surname>Deisseroth</surname><given-names>K</given-names></name><name><surname>Mathur</surname><given-names>BN</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Lupica</surname><given-names>CR</given-names></name><name><surname>Cheer</surname><given-names>JF</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Phasic Dopamine Signals in the Nucleus Accumbens that Cause Active Avoidance Require Endocannabinoid Mobilization in the Midbrain</article-title><source>Current Biology</source><volume>28</volume><fpage>1392</fpage><lpage>1404</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2018.03.037</pub-id><pub-id pub-id-type="pmid">29681476</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Minkowicz</surname><given-names>S</given-names></name><name><surname>Dumrongprechachan</surname><given-names>V</given-names></name><name><surname>Hamilton</surname><given-names>P</given-names></name><name><surname>Kozorovitskiy</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>Ketamine rapidly enhances glutamate-evoked dendritic spinogenesis in medial prefrontal cortex through dopaminergic mechanisms</article-title><source>Biological Psychiatry</source><volume>89</volume><elocation-id>22</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopsych.2020.12.022</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Minkowicz</surname><given-names>S</given-names></name><name><surname>Dumrongprechachan</surname><given-names>V</given-names></name><name><surname>Hamilton</surname><given-names>P</given-names></name><name><surname>Xiao</surname><given-names>L</given-names></name><name><surname>Kozorovitskiy</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021b</year><data-title>Code accompanying: Attenuated dopamine signaling after aversive learning is restored by ketamine to rescue escape actions</data-title><publisher-name>Software Heritage</publisher-name><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:895836814e93b490c5c6ae88419968fca143f465;origin=https://github.com/KozorovitskiyLaboratory/Wu_et_al_2021;visit=swh:1:snp:d766e23130cc0c25ad523fd07c81a9e0e1507fe0;anchor=swh:1:rev:459ff15a97a2af4e955d20531235b399b4be5b22">https://archive.softwareheritage.org/swh:1:dir:895836814e93b490c5c6ae88419968fca143f465;origin=https://github.com/KozorovitskiyLaboratory/Wu_et_al_2021;visit=swh:1:snp:d766e23130cc0c25ad523fd07c81a9e0e1507fe0;anchor=swh:1:rev:459ff15a97a2af4e955d20531235b399b4be5b22</ext-link></element-citation></ref><ref id="bib129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>L</given-names></name><name><surname>Priest</surname><given-names>MF</given-names></name><name><surname>Nasenbeny</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>T</given-names></name><name><surname>Kozorovitskiy</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Biased Oxytocinergic Modulation of Midbrain Dopamine Systems</article-title><source>Neuron</source><volume>95</volume><fpage>368</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2017.06.003</pub-id><pub-id pub-id-type="pmid">28669546</pub-id></element-citation></ref><ref id="bib130"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>L</given-names></name><name><surname>Priest</surname><given-names>MF</given-names></name><name><surname>Kozorovitskiy</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Oxytocin functions as a spatiotemporal filter for excitatory synaptic inputs to VTA dopamine neurons</article-title><source>eLife</source><volume>7</volume><elocation-id>e33892</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.33892</pub-id><pub-id pub-id-type="pmid">29676731</pub-id></element-citation></ref><ref id="bib131"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Sang</surname><given-names>K</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Ni</surname><given-names>Z</given-names></name><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018a</year><article-title>Ketamine blocks bursting in the lateral habenula to rapidly relieve depression</article-title><source>Nature</source><volume>554</volume><fpage>317</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1038/nature25509</pub-id><pub-id pub-id-type="pmid">29446381</pub-id></element-citation></ref><ref id="bib132"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>de Jong</surname><given-names>JW</given-names></name><name><surname>Tak</surname><given-names>YE</given-names></name><name><surname>Peck</surname><given-names>J</given-names></name><name><surname>Bateup</surname><given-names>HS</given-names></name><name><surname>Lammel</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018b</year><article-title>Nucleus accumbens subnuclei regulate motivated behavior via direct inhibition and disinhibition of VTA dopamine subpopulations</article-title><source>Neuron</source><volume>97</volume><fpage>434</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2017.12.022</pub-id><pub-id pub-id-type="pmid">29307710</pub-id></element-citation></ref><ref id="bib133"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>You</surname><given-names>ZB</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Zitzman</surname><given-names>D</given-names></name><name><surname>Azari</surname><given-names>S</given-names></name><name><surname>Wise</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>A role for conditioned ventral tegmental glutamate release in cocaine seeking</article-title><source>The Journal of Neuroscience</source><volume>27</volume><fpage>10546</fpage><lpage>10555</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2967-07.2007</pub-id><pub-id pub-id-type="pmid">17898226</pub-id></element-citation></ref><ref id="bib134"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanos</surname><given-names>P</given-names></name><name><surname>Moaddel</surname><given-names>R</given-names></name><name><surname>Morris</surname><given-names>PJ</given-names></name><name><surname>Georgiou</surname><given-names>P</given-names></name><name><surname>Fischell</surname><given-names>J</given-names></name><name><surname>Elmer</surname><given-names>GI</given-names></name><name><surname>Alkondon</surname><given-names>M</given-names></name><name><surname>Yuan</surname><given-names>P</given-names></name><name><surname>Pribut</surname><given-names>HJ</given-names></name><name><surname>Singh</surname><given-names>NS</given-names></name><name><surname>Dossou</surname><given-names>KSS</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>XP</given-names></name><name><surname>Mayo</surname><given-names>CL</given-names></name><name><surname>Wainer</surname><given-names>IW</given-names></name><name><surname>Albuquerque</surname><given-names>EX</given-names></name><name><surname>Thompson</surname><given-names>SM</given-names></name><name><surname>Thomas</surname><given-names>CJ</given-names></name><name><surname>Zarate</surname><given-names>CA</given-names></name><name><surname>Gould</surname><given-names>TD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>NMDAR inhibition-independent antidepressant actions of ketamine metabolites</article-title><source>Nature</source><volume>533</volume><fpage>481</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1038/nature17998</pub-id><pub-id pub-id-type="pmid">27144355</pub-id></element-citation></ref><ref id="bib135"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanos</surname><given-names>P</given-names></name><name><surname>Gould</surname><given-names>TD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mechanisms of ketamine action as an antidepressant</article-title><source>Molecular Psychiatry</source><volume>23</volume><fpage>801</fpage><lpage>811</lpage><pub-id pub-id-type="doi">10.1038/mp.2017.255</pub-id><pub-id pub-id-type="pmid">29532791</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.64041.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Penzo</surname><given-names>Mario</given-names></name><role>Reviewing Editor</role><aff><institution>National Institute of Mental Health</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Mameli</surname><given-names>Manuel</given-names></name><role>Reviewer</role><aff><institution>The University of Lausanne</institution><country>Switzerland</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>The authors employed fiber photometry-based in vivo calcium imaging, pharmacological manipulations, and the learned helplessness behavioral model in mice to show that aversive states and helpless behavior are associated with attenuated dopaminergic transmission, specifically from dopaminergic neurons of the ventral tegmental area. Importantly, the authors demonstrate that ketamine can restore both the dopaminergic and behavioral deficits associated with learned helplessness. This is a timely observation, considering the broad interest in understanding how ketamine - which was recently approved by the FDA as a treatment of depression - yields its known behavioral effects.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Attenuated dopamine signaling after aversive learning is restored by ketamine to rescue escape actions&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Kate Wassum as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Manuel Mameli (Reviewer #3).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is &quot;in revision at <italic>eLife</italic>&quot;. Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)</p><p>Summary:</p><p>The authors employed fiber photometry-based in vivo calcium imaging, pharmacological manipulations, and the learned helplessness behavioral model in mice to show that aversive states and helpless behavior are associated with attenuated dopaminergic transmission, specifically from dopaminergic neurons of the ventral tegmental area. Importantly, the authors demonstrate that ketamine can restore both the dopaminergic and behavioral deficits associated with learned helplessness. This is a timely observation, considering the broad interest in understanding how ketamine – which was recently approved by the FDA as a treatment of depression – yields its known behavioral effects.</p><p>Essential revisions:</p><p>The reviewers were collectively enthusiastic about the study, highlighting that the work is elegant and that key findings are robust. However, they agree that before a final decision can be made on the manuscript, a series of important issues must be addressed. As you will see, while for many of the points raised by the Reviewers additional discussion or highlighting of caveats will suffice, in some case additional experimental work is required. Each of the Reviewers' points is described in detail below.</p><p>1. The authors claim that ketamine rescues deficits in escape behavior induced by LH via VTA DA neuron activation mediated by a recurrent VTA – mPFC D1 neuron circuit. The data supporting a role for VTA DA neurons in ketamine's effect on escape behavior are convincing, however, the recurrent circuit component of the study is lacking a causal link. The authors fail to reject the recurrent circuit hypothesis based on (1) the lack of an effect of ketamine on VTA DA neuron GCaMP responses in brain slices, (2) the presence of Drd1a mRNA in the majority of VTA-projecting PFC neurons, (3) an increase in spontaneous GCaMP6 fluorescence in mPFC D1 neurons acutely and 24 hr after ketamine, (4) rescue of VTA DA dynamics during inescapable shocks by intra-mPFC ketamine, and (5) a rescue of escape responses after chemogenetic activation of global mPFC D1 neurons. All above observations, with the exception of the retrograde tracing/in-situ hybridization experiment, are agnostic to the projection target of VTA or mPFC neurons. Therefore, they do not differentiate between the recurrent hypothesis proposed by the authors and alternative hypotheses, such as activation of DA neurons that project to the nucleus accumbens or amygdala and control avoidance behavior (Darvas et al. 2020 Learning and Memory; Wenzel et al. 2018 Current Biology; Stelly et al. 2020 PNAS; among many others) or activation of PFC D1 neurons that project to the BLA shown to mediate antidepressant effects and be involved in ketamine's antidepressant effects (Hare et al. 2019 Nat Comm). The authors should discuss the assumptions/caveats associated with their present findings or provide additional experiments aimed at supporting this conclusion.</p><p>2. Related to the previous point. The mPFC projection is among the sources of glutamate to VTA DA neurons, yet not the only one; importantly not the only one sensitive to ketamine. The authors state the importance of mPFC but cannot rule out whether or not ketamine is also acting elsewhere. The authors should present additional experimental evidence demonstrating selectivity for the mPFC.</p><p>3. Did the authors conduct fiber photometry recordings from mice treated with saline for the wLH? The authors did include this control group in the behavioral studies in figure 1 but the lack of this in photometry experiments should be addressed as animals must adapt behavior in light of changing contingencies during behavioral training. In the wLH procedures the animal goes from a setting where escape behavior is reinforced (baseline days 1 and 2) to a setting where there is extinction of the escape response (wLH after day 2), and subsequent reinstatement of the avoidance behavior with reinforcement of escape behavior (days 3-6). Saline controls will be necessary to determine how much of the ketamine rescue effect is contributed by on-going reinforcement behavior after the wLH induction.</p><p>4. Were the mice that were used for the photometry recordings performed during inescapable footshocks testing (strong LH) in figure 1 also exposed to baseline escapable shocks? Similar to the previous comment, the history of reinforcement of escape behavior is predicted to shape responses during inescapable shocks. The authors should clarify this in the manuscript.</p><p>5. For the intra-mPFC ketamine rescue in figure 4 were the same mice plotted in figure 4g also used to generate data in figure 4h? Were responses during the baseline escapable shocks recorded? The authors should also provide recordings obtained from their control mice.</p><p>6. For the wLH experiments in figure 2, the mice in the wLH group are already showing increased failures, despite the text stating the wLH induction occurred at the end of day 2. This would suggest that mice in this group were already developing higher levels of failed avoidance from the escapable footshock testing relative to controls undergoing the same procedures. This should be clarified/addressed. Were the behavioral data in figure 2B from both controls and wLH mice separate that underwent photometry recordings? Were any recordings performed in control animals?</p><p>7. The authors conclude that ketamine has no effect on VTA DA neurons based on slice GCaMP imaging. However, NMDA receptors, a major target of ketamine, are unlikely to regulate tonic firing under these conditions but may be important for regulating plasticity of inputs and bursting in-vivo or in slices when afferent inputs might be engaged (Wang et al. 2011; Zweiffel et al. 2008; Jastrzebska et al. 2016; Mansvelder and McGehee 2000 Neuron; Yuan et al. 2013 Neuron). The authors should use other methods besides calcium imaging in slice to examine the effect of ketamine ex vivo. Electrophysiological studies will be more sensitive and reveal additional local effects, and should be conducted to control for effects directly…and sensitivity of calcium imaging dynamics.</p><p>8. The authors should also record and plot the failure rate in trials alongside the DRD1 neuronal activity following LH induction? They may already have this data, and it would be useful to see how that fits with their model.</p><p>9. A group of mice whereby they authors use a chemogenetic approach or optogenetic method to inhibit/silence the Drd1 neurons in the mPFC during ketamine exposure in the LH induced mice, to see if this manipulation blocks the rescue of the escape behavior.</p><p>10. Recent data suggest that the action of Ketamine in restoring depressive-like symptoms, likely including escapable actions, relies on targeting a variety of brain structures like the mPFC (Liston Laboratory) or the astrocytes function in the lateral habenula (Hu Laboratory). The authors should discuss this mechanistic debate around ketamine's action.</p><p>11. The field largely discusses how low doses of ketamine can be efficient in restoring behavioral adaptations. Do the authors have a dose response for their behavioral and functional data? If so, it would be good to include this information in the manuscript, as it may boost the clinical importance of such study.</p><p>12. Dopamine neurons subpopulations underlie discrete behaviors. Do the authors think their dopamine responses are homogeneous throughout the VTA, or in light of the circuits they are embedded? This should be either tested experimentally or at least discussed.</p><p>13. The authors performed an analysis to obtain a relationship between an animal's ketamine responsiveness and VTA DA activity. Several laboratories reported that the effectiveness of the LH protocol only accounts for a fraction of animals. In other words a fraction of animals is resilient. How is DA activity in these animals? Does VTA DA activity represents a &quot;biomarker&quot; for susceptibility versus resilience? The authors could use existing behavioral data to address this point.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.64041.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p></disp-quote><disp-quote content-type="editor-comment"><p>The reviewers were collectively enthusiastic about the study, highlighting that the work is elegant and that key findings are robust. However, they agree that before a final decision can be made on the manuscript, a series of important issues must be addressed. As you will see, while for many of the points raised by the Reviewers additional discussion or highlighting of caveats will suffice, in some case additional experimental work is required. Each of the Reviewers' points is described in detail below.</p></disp-quote><disp-quote content-type="editor-comment"><p>1. The authors claim that ketamine rescues deficits in escape behavior induced by LH via VTA DA neuron activation mediated by a recurrent VTA – mPFC D1 neuron circuit. The data supporting a role for VTA DA neurons in ketamine's effect on escape behavior are convincing, however, the recurrent circuit component of the study is lacking a causal link.</p></disp-quote><p>We agree with the Reviewer’s that while the significance of the actions of VTA DA neurons is well supported by this manuscript, we have not provided sufficient evidence directly supporting the importance of recurrent connectivity. We have removed claims regarding causal involvement of the VTA-mPFC recurrent circuit in the regulation of escape actions, reviewing a number of key other circuits that are likely involved. Instead, we propose potential future directions of study related to this hypothetical framework in the Discussion section. Lines: 378-387, 398-432.</p><disp-quote content-type="editor-comment"><p>The authors fail to reject the recurrent circuit hypothesis based on 1) the lack of an effect of ketamine on VTA DA neuron GCaMP responses in brain slices, 2) the presence of Drd1a mRNA in the majority of VTA-projecting PFC neurons, 3) an increase in spontaneous GCaMP6 fluorescence in mPFC D1 neurons acutely and 24 hr after ketamine, 4) rescue of VTA DA dynamics during inescapable shocks by intra-mPFC ketamine, and 5) a rescue of escape responses after chemogenetic activation of global mPFC D1 neurons. All above observations, with the exception of the retrograde tracing/in-situ hybridization experiment, are agnostic to the projection target of VTA or mPFC neurons. Therefore, they do not differentiate between the recurrent hypothesis proposed by the authors and alternative hypotheses, such as activation of DA neurons that project to the nucleus accumbens or amygdala and control avoidance behavior (Darvas et al. 2020 Learning and Memory; Wenzel et al. 2018 Current Biology; Stelly et al. 2020 PNAS; among many others) or activation of PFC D1 neurons that project to the BLA shown to mediate antidepressant effects and be involved in ketamine's antidepressant effects (Hare et al. 2019 Nat Comm). The authors should discuss the assumptions/caveats associated with their present findings or provide additional experiments aimed at supporting this conclusion.</p></disp-quote><p>We agree with the Reviewers that DA signaling in many brain regions other than mPFC is involved in the regulation of escape actions and avoidance behaviors. For example, the release and postsynaptic function of DA in the NAc and amygdala have been extensively studied in conditioned avoidance learning (Antunes et al., 2020; Darvas et al., 2011; McCullough et al., 1993; Oleson et al., 2012; Oleson and Cheer, 2013; Stelly et al., 2019; Wenzel et al., 2018). In our study, we found that VTA DA activity is not necessarily critical for innate escape actions, since chemogenetic suppression of VTA DA activity does not increase failures to escape from shock stimuli in the absence of prior learning. Importantly, after LH, responses of VTA DA neurons to both inescapable and escapable shocks are significantly changed. Since DA release has been shown to be highly correlated with somatic DA neuronal activity (de Jong et al., 2019; Lee et al., 2020; Patriarchi et al., 2018), we predict that downstream DA release in the NAc and amygdala are also modulated after learned helplessness, and after ketamine treatment. Given the importance of NAc and amygdala DA signaling in avoidance learning and maintenance (Antunes et al., 2020; Darvas et al., 2011; Stelly et al., 2019), behavioral outcomes to escapable shock may depend on DA release across multiple regions. We have expanded relevant components in the Discussion section. Lines: 378-387.</p><p>DA signaling in the mPFC regulates the processing of aversive stimuli, food intake, and other behaviors (Land et al., 2014; Shinohara et al., 2018; Vander Weele et al., 2018; Wass et al., 2018; Winter et al., 2009). A recent publication from Hare et al. showed that activation of mPFC D1 neurons projections in the BLA produced antidepressant-like effects (Hare et al., 2019). Importantly, BLA receives DA inputs from the VTA and is involved in avoidance learning. Therefore, after ketamine treatment, BLA may serve as a convergence site that synthesizes inputs from VTA and mPFC to facilitate the rescue of escape actions.</p><p>Thus, we do not suggest that the mPFC and VTA are the only brain regions that control escape behaviors. However, we think the enhanced activity within these two brain regions is one of the important mechanisms underlying behavioral effects of ketamine. Our data show that:</p><p>1. Local mPFC ketamine infusion rescues VTA DA activity and behavior (Figure 5b, d)</p><p><italic>2.</italic> In vivo ketamine treatment rapidly enhances D1 neuronal activity in mPFC (Figure 6—figure supplement 1c, d)</p><p>3. Chemogenetic activation of mPFC D1 neurons rescues escape behaviors (Figure 6g)</p><p>Moreover, in recently published work from our lab, we show that DA signaling through Drd1 activation is necessary for ketamine’s action on restoring glutamate-dependent dendritic spinogenesis (Wu et al., 2021), which has been shown to maintain the lasting behavioral effects of ketamine after corticosterone treatment (Moda-Sava et al., 2019). Chemogenetic activation of Gα<sub>s</sub>-coupled signaling cascades downstream of Drd1 activation in mPFC also rescues escape after LH as well (Wu et al., 2021). Based on the sum of these data, we hypothesize that the initial enhancement of activity induced by ketamine in mPFC may be amplified within this brain circuit, which may potentially extend ketamine’s behavioral effects from hours to days. This hypothesis, along with important caveats and alternative interpretations, is presented in the Discussion section. Lines: 398-432.</p><disp-quote content-type="editor-comment"><p>2. Related to the previous point. The mPFC projection is among the sources of glutamate to VTA DA neurons, yet not the only one; importantly not the only one sensitive to ketamine. The authors state the importance of mPFC but cannot rule out whether or not ketamine is also acting elsewhere. The authors should present additional experimental evidence demonstrating selectivity for the mPFC.</p></disp-quote><p>In addition to our prior experiments that directly infuse ketamine into mPFC, we have now added new experiments where we infused ketamine locally into another three brain regions (PAG, PPTg, and VTA) followed by behavioral testing. We selected PAG and PPTg for two reasons: (1) these brain regions contain a large number of glutamatergic neurons that regulate the activity of DA neurons in the VTA (Morales and Margolis, 2017); (2) behavioral effects of local ketamine infusion into these regions have not been previously demonstrated, to our knowledge, although antidepressant effects of local PAG infusion of (2R,6R)-HNK have been reported (Chou et al., 2018). We also carried out local infusions of ketamine into the VTA itself, to evaluate the possibility of direct in vivo effects there (in addition to our prior and new data showing a lack of effects of ketamine on VTA DA neuron synaptic inputs and activity in the acute slice preparation, Figure 4). Our results show that local infusion of ketamine (12.5 µg in 500 nl ACSF) into any selected region other than mPFC does not rescue escape behavior after LH, supporting the idea that not all glutamatergic inputs into the VTA are modulated by ketamine to rescue escape actions (Figure 5b). Lines: 259-269.</p><p>We agree with the Reviewers that the mPFC is not the only region sensitive to ketamine. It is very likely that ketamine exerts antidepressant effects through synergistic effects across many brain regions, including direct effects and indirect consequences of changes in cortical neural activity. For example, prior studies have demonstrated that local infusion of ketamine into DG/CA3 of hippocampus increases escape behaviors after LH (Shirayama and Hashimoto, 2017) and local infusions of ketamine into lateral habenula improves depressive-like behaviors (Y. Yang et al., 2018). Nevertheless, our data suggest that the disinhibition and activation of mPFC neurons, as shown in this study (for Drd1 neurons) and other studies (for broader populations, e.g., (Hare et al., 2020)), may serve as an important mechanism by which ketamine recovers the activity of VTA DA neurons. Lines: 423-432.</p><disp-quote content-type="editor-comment"><p>3. Did the authors conduct fiber photometry recordings from mice treated with saline for the wLH? The authors did include this control group in the behavioral studies in figure 1 but the lack of this in photometry experiments should be addressed as animals must adapt behavior in light of changing contingencies during behavioral training. In the wLH procedures the animal goes from a setting where escape behavior is reinforced (baseline days 1 and 2) to a setting where there is extinction of the escape response (wLH after day 2), and subsequent reinstatement of the avoidance behavior with reinforcement of escape behavior (days 3-6). Saline controls will be necessary to determine how much of the ketamine rescue effect is contributed by on-going reinforcement behavior after the wLH induction.</p></disp-quote><p>In new experiments, we carried out saline injections on Day 5 after wLH and recorded the activity of VTA DA neurons during escapable shocks. Saline injections do not reduce failures to escape on Days 5-6 relative to Days 3-4. A single dose of ketamine treatment suffices to reduce failures compared to saline-treated animals (Figure 2b). Also, saline treatment does not change the activity of DA neurons during either escape or failure trials (Figure 2—figure supplement 4a, b). Together, our data suggest that reduced failures and restored DA dynamics on Day 5-6 after ketamine treatment is unlikely to be driven by ongoing reinforcement behavior after wLH induction. Lines: 188-190.</p><p>4. Were the mice that were used for the photometry recordings performed during inescapable footshocks testing (strong LH) in figure 1 also exposed to baseline escapable shocks? Similar to the previous comment, the history of reinforcement of escape behavior is predicted to shape responses during inescapable shocks. The authors should clarify this in the manuscript.</p><p>We have clarified that the animals were exposed to escapable foot shocks prior to LH induction. Line: 107.</p><disp-quote content-type="editor-comment"><p>5. For the intra-mPFC ketamine rescue in figure 4 were the same mice plotted in figure 4g also used to generate data in figure 4h? Were responses during the baseline escapable shocks recorded? The authors should also provide recordings obtained from their control mice.</p></disp-quote><p>The responses during baseline escapable shocks were not recorded in the initial experiments. We carried out new photometry recording in a separate group of mice receiving local ACSF infusions in mPFC. Our results show that local ACSF infusion in mPFC does not significantly change the responses of VTA DA to inescapable shocks after LH, providing an important control experiment (Figure 5—figure supplement 1b, c). Lines: 273-274.</p><disp-quote content-type="editor-comment"><p>6. For the wLH experiments in figure 2, the mice in the wLH group are already showing increased failures, despite the text stating the wLH induction occurred at the end of day 2. This would suggest that mice in this group were already developing higher levels of failed avoidance from the escapable footshock testing relative to controls undergoing the same procedures. This should be clarified/addressed. Were the behavioral data in figure 2B from both controls and wLH mice separate that underwent photometry recordings? Were any recordings performed in control animals?</p></disp-quote><p>The Reviewers noted a small difference across days 1 and 2 in baseline performance of animals prior to LH induction; however, this difference did not reach statistical significance on a two-way ANOVA post hoc comparison:</p><p>We included new behavioral data in the control group for obtaining photometry recordings discussed in the paragraph below (Figure 2—figure supplement 3) and carried out two-way ANOVA analysis in panel 2b to compare escape behaviors across different days and between groups (control vs wLH). Both row factor (days) and column factor (groups) significantly contribute to the variation (p &lt; 0.0001). We performed multiple comparisons to specifically determine the difference across days. We did not observe a significant difference between Day 1 and Day 2 (Sidak’s test, Day 1 vs Day 2, p = 0.1862), among the two groups on Day 1 (Sidak’s test, wLH vs control, p = 0.9934), or on Day 2 (Sidak’s test, wLH vs control, p = 0.1147). We do see a non-significant trend towards increased failures in the wLH group at Day 2 relative to Day 1 (Sidak’s test, p = 0.1010) and we agree that some form of experience-dependent learning occurs when animals are repeatedly exposed to escapable shocks. However, the wLH induction with inescapable shocks is necessary to induce aversive learning as operationalized in this study, since escapable shocks alone in the control group do not change daily escape actions (Figure 2b). Lines: 160-161.</p><p>Further, we carried out photometry recording in a separate group of control mice that did not go through wLH induction but were only exposed to escapable shocks. We compared the activity patterns of VTA DA in escape and failure trials across days. Responses of VTA DA during escapes and during failures did not change across days (Figure 2—figure supplement 3a, b). These data support the argument that wLH induction with inescapable shocks is necessary to reshape VTA DA responses. Lines: 186-188.</p><disp-quote content-type="editor-comment"><p>7. The authors conclude that ketamine has no effect on VTA DA neurons based on slice GCaMP imaging. However, NMDA receptors, a major target of ketamine, are unlikely to regulate tonic firing under these conditions but may be important for regulating plasticity of inputs and bursting in-vivo or in slices when afferent inputs might be engaged (Wang et al. 2011; Zweiffel et al. 2008; Jastrzebska et al. 2016; Mansvelder and McGehee 2000 Neuron; Yuan et al. 2013 Neuron). The authors should use other methods besides calcium imaging in slice to examine the effect of ketamine ex vivo. Electrophysiological studies will be more sensitive and reveal additional local effects, and should be conducted to control for effects directly…and sensitivity of calcium imaging dynamics.</p></disp-quote><p>We have carried out new cell-attached electrophysiological recordings and whole-cell voltage clamp recordings to further investigate the potential direct local effects of ketamine on genetically targeted VTA DA neurons (Figure 4g-o). Consistent with our prior GCaMP imaging results, ex vivo application of ketamine did not change the spontaneous firing rate of VTA DA cells that we recorded in cell-attached mode (Figure 4g-i). Furthermore, our results from whole-cell voltage clamp recordings show that ex vivo application of ketamine does not significantly change the amplitudes or inter-event intervals of spontaneous excitatory or inhibitory postsynaptic currents, EPSCs and IPSCs, recorded in separate experiments (Figure 4j-o). In addition, in vivo local injection of ketamine directly into the VTA does not rescue escape actions after LH (Figure 5b). Although glutamatergic receptors on VTA DA neurons are of course critical for many aspects of their function (Engblom et al., 2008; Sun et al., 2005; Wang et al., 2011; Zweifel et al., 2008), our data suggest the in vivo effects of ketamine on DA activity and behavior are not likely to be caused by local ketamine action in the VTA. Lines: 251-257.</p><disp-quote content-type="editor-comment"><p>8. The authors should also record and plot the failure rate in trials alongside the DRD1 neuronal activity following LH induction? They may already have this data, and it would be useful to see how that fits with their model.</p></disp-quote><p>We did not carry out behavioral manipulations in this experiment. The goal of the experiment was to simply evaluate baseline ketamine effects on the Drd1 neuronal activity in mPFC. The increased activity we observed in Drd1 neurons is consistent with a prior study that demonstrated a rapid enhancement of neuronal activity in mPFC pyramidal neurons following ketamine treatment, where mPFC neurons were broadly targeted via a CamKII promoter for GCaMP expression (Hare et al., 2020).</p><disp-quote content-type="editor-comment"><p>9. A group of mice whereby they authors use a chemogenetic approach or optogenetic method to inhibit/silence the Drd1 neurons in the mPFC during ketamine exposure in the LH induced mice, to see if this manipulation blocks the rescue of the escape behavior.</p></disp-quote><p>We carried out new experiments using chemogenetic approaches to inhibit mPFC Drd1 neurons following ketamine treatment after LH. Our results showed that inhibition of mPFC Drd1<sup>+</sup> neuronal excitability blocked the behavioral effects of ketamine (Figure 6—figure supplement 2a, b), consistent with a recently published study (Hare et al., 2019). Altogether, these data confirm that the activation of mPFC Drd1 neurons is important for the behavioral effects of ketamine. Lines: 306-308.</p><disp-quote content-type="editor-comment"><p>10. Recent data suggest that the action of Ketamine in restoring depressive-like symptoms, likely including escapable actions, relies on targeting a variety of brain structures like the mPFC (Liston Laboratory) or the astrocytes function in the lateral habenula (Hu Laboratory). The authors should discuss this mechanistic debate around ketamine's action.</p></disp-quote><p>Given the lack of ketamine’s local, direct effects on VTA DA neuronal activity, the modulation of VTA DA activity by ketamine <italic>in vivo</italic> must depend on changes in the activity of projections from other brain regions. Numerous studies demonstrate that mPFC is broadly involved in the rapid and lasting behavioral effects of ketamine (Homayoun and Moghaddam, 2007; Kinoshita et al., 2018; Li et al., 2010; Lindefors et al., 1997; Liu et al., 2013; Lorrain et al., 2003; Moda-Sava et al., 2019; Phoumthipphavong et al., 2016; Wu et al., 2021). Another such potential mechanism could involve actions in the lateral habenula, which sends glutamatergic inputs to GABAergic neurons that suppress VTA DA activity (Gonçalves et al., 2012). We have expanded the Discussion section to ground the new findings in the literature on the functions of mPFC and lateral habenula in ketamine’s effects. Lines: 363-377, 426-432.</p><disp-quote content-type="editor-comment"><p>11. The field largely discusses how low doses of ketamine can be efficient in restoring behavioral adaptations. Do the authors have a dose response for their behavioral and functional data? If so, it would be good to include this information in the manuscript, as it may boost the clinical importance of such study.</p></disp-quote><p>Dose responses to ketamine have been carefully mapped out in human patients and animal models (Berman et al., 2000; Daly et al., 2018; Glue et al., 2011; Kurdi et al., 2014; Laskowski et al., 2011; Sassano-Higgins et al., 2016; Zarate et al., 2006). We do not have a dose response in our behavioral and functional data, because this detailed knowledge is available in the field (<xref ref-type="fig" rid="sa2fig1">Author response image 1A</xref>). The chosen sub-anesthetic dose of ketamine should approximately match the human clinically relevant dosing (<xref ref-type="fig" rid="sa2fig1">Author response image 1B</xref>, Nair and Jacob, 2016) and matches the dosing used in other animal studies (Ali et al., 2020; Belujon and Grace, 2014; Li et al., 2010; Miller et al., 2014; Moda-Sava et al., 2019).</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><caption><p>(<bold>a</bold>) Ketamine dosage in clinical practice. Figure adapted from Glue et al., 2011. (<bold>b</bold>). Dose conversion calculation between rodents and humans. Table adapted from Nair and Jacob, 2016.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64041-sa2-fig1-v2.tif"/></fig><p>12. Dopamine neurons subpopulations underlie discrete behaviors. Do the authors think their dopamine responses are homogeneous throughout the VTA, or in light of the circuits they are embedded? This should be either tested experimentally or at least discussed.</p><p>VTA DA neurons are highly heterogenous based on their input/output anatomy and transcriptional profiles (Beier et al., 2015; Do et al., 2016; Morales and Margolis, 2017). Prior studies have demonstrated that VTA DA neurons respond to foot shocks differently, based on the brain regions they project to de Jong et al., 2019. In this study, we do not distinguish responses of DA neurons based on their projections or transcriptional profiles. We consider this a strength. The observed effects are sufficiently powerful to be seen on the background of projection target diversity. We have expanded the Discussion section to consider important points related to VTA DA neuron heterogeneity. Lines: 388-396.</p><disp-quote content-type="editor-comment"><p>13. The authors performed an analysis to obtain a relationship between an animal's ketamine responsiveness and VTA DA activity. Several laboratories reported that the effectiveness of the LH protocol only accounts for a fraction of animals. In other words a fraction of animals is resilient. How is DA activity in these animals? Does VTA DA activity represents a &quot;biomarker&quot; for susceptibility versus resilience? The authors could use existing behavioral data to address this point.</p></disp-quote><p>In this study, the distribution of behavioral outcomes after LH does not appear to be bimodal (Figure 6—figure supplement 3a, b), so we elected to not force a binary classification but display the full distributions of data. Lines: 341-344.</p><p>We observed biologically significant variability in VTA DA response which correlated with future behavioral outcomes. When VTA DA neuron activity substantially distinguishes failures to escape from successful escapes, individuals show less failures after LH. Based on this observation, it is expected that task specific VTA DA activity may represent the degree of susceptibility to stressful events as a potential biomarker. In the context of human populations, PET studies have been used to measure aspects of DA system function (Jönsson et al., 1999; Volkow et al., 1996). Importantly, human genetic variability, which can drive clinically relevant differences in DA signaling (Jönsson et al., 1999), could provide additional biomarkers to predict ketamine efficacy. <italic>Lines: 338-354.</italic></p><p>References:</p><p>Ali F, Gerhard DM, Sweasy K, Pothula S, Pittenger C, Duman RS, Kwan AC. 2020. Ketamine disinhibits dendrites and enhances calcium signals in prefrontal dendritic spines. Nat Commun 11:1–15. doi:10.1038/s41467-019-13809-8</p><p>Antunes GF, Gouveia FV, Rezende FS, Seno MD de J, de Carvalho MC, de Oliveira CC, dos Santos LCT, de Castro MC, Kuroki MA, Teixeira MJ, Otoch JP, Brandao ML, Fonoff ET, Martinez RCR. 2020. Dopamine modulates individual differences in avoidance behavior: A pharmacological, immunohistochemical, neurochemical and volumetric investigation. Neurobiol Stress 12:100219. doi:10.1016/j.ynstr.2020.100219</p><p>Bagot RC, Cates HM, Purushothaman I, Vialou V, Heller EA, Yieh L, LaBonté B, Peña CJ, Shen L, Wittenberg GM, Nestler EJ. 2017. Ketamine and Imipramine Reverse Transcriptional Signatures of Susceptibility and Induce Resilience-Specific Gene Expression Profiles. Biol Psychiatry 81:285–295. doi:10.1016/j.biopsych.2016.06.012</p><p>Bagot RC, Parise EM, Peña CJ, Zhang HX, Maze I, Chaudhury D, Persaud B, Cachope R, Bolaños-Guzmán CA, Cheer J, Deisseroth K, Han MH, Nestler EJ. 2015. Ventral hippocampal afferents to the nucleus accumbens regulate susceptibility to depression. Nat Commun 6:1–9. doi:10.1038/ncomms8062</p><p>Beier KT, Steinberg EE, DeLoach KE, Xie S, Miyamichi K, Schwarz L, Gao XJ, Kremer EJ, Malenka RC, Luo L. 2015. Circuit Architecture of VTA Dopamine Neurons Revealed by Systematic Input-Output Mapping. Cell 162:622–634. doi:10.1016/J.CELL.2015.07.015</p><p>Belujon P, Grace AA. 2014. Restoring mood balance in depression: Ketamine reverses deficit in dopamine-dependent synaptic plasticity. Biol Psychiatry 76:927–936. doi:10.1016/j.biopsych.2014.04.014</p><p>Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. 2000. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351–354. doi:10.1016/S0006-3223(99)00230-9</p><p>Chou D, Peng HY, Lin T Bin, Lai CY, Hsieh MC, Wen YC, Lee AS, Wang HH, Yang PS, Chen G Den, Ho YC. 2018. (2R,6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray. Neuropharmacology 139:1–12. doi:10.1016/j.neuropharm.2018.06.033</p><p>Covington HE, Lobo MK, Maze I, Vialou V, Hyman JM, Zaman S, LaPlant Q, Mouzon E, Ghose S, Tamminga CA, Neve RL, Deisseroth K, Nestler EJ. 2010. Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex. J Neurosci 30:16082–16090. doi:10.1523/JNEUROSCI.1731-10.2010</p><p>Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, Thase ME, Winokur A, Van Nueten L, Manji H, Drevets WC. 2018. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial. JAMA Psychiatry 75:139–148. doi:10.1001/jamapsychiatry.2017.3739</p><p>Darvas M, Fadok JP, Palmiter RD. 2011. Requirement of dopamine signaling in the amygdala and striatum for learning and maintenance of a conditioned avoidance response. Learn Mem 18:136–143. doi:10.1101/lm.2041211</p><p>de Jong JW, Afjei SA, Pollak Dorocic I, Peck JR, Liu C, Kim CK, Tian L, Deisseroth K, Lammel S. 2019. A Neural Circuit Mechanism for Encoding Aversive Stimuli in the Mesolimbic Dopamine System. Neuron 101:133-151.e7. doi:10.1016/J.NEURON.2018.11.005</p><p>Do JP, Xu M, Lee S-H, Chang W-C, Zhang S, Chung S, Yung TJ, Fan JL, Miyamichi K, Luo L, Dan Y. 2016. Cell type-specific long-range connections of basal forebrain circuit. <italic>eLife</italic> 5:1–17. doi:10.7554/<italic>eLife</italic>.13214</p><p>Duman RS, Li N, Liu R-J, Duric V, Aghajanian G. 2012. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 62:35–41. doi:10.1016/J.NEUROPHARM.2011.08.044</p><p>Engblom D, Bilbao A, Sanchis-Segura C, Dahan L, Perreau-Lenz S, Balland B, Parkitna JR, Luján R, Halbout B, Mameli M, Parlato R, Sprengel R, Lüscher C, Schütz G, Spanagel R. 2008. Glutamate Receptors on Dopamine Neurons Control the Persistence of Cocaine Seeking. Neuron 59:497–508. doi:10.1016/j.neuron.2008.07.010</p><p>Felten A, Montag C, Markett S, Walter NT, Reuter M. 2011. Genetically determined dopamine availability predicts disposition for depression. Brain Behav 1:109–118. doi:10.1002/brb3.20</p><p>Friedman AK, Walsh JJ, Juarez B, Ku SM, Chaudhury D, Wang J, Li X, Dietz DM, Pan N, Vialou VF, Neve RL, Yue Z, Han M-H. 2014. Enhancing Depression Mechanisms in Midbrain Dopamine Neurons Achieves Homeostatic Resilience. Science 344:313–319. doi:10.1126/science.1249240</p><p>Frisch A, Postilnick D, Rockah R, Michaelovsky E, Postilnick S, Birman E, Laor N, Rauchverger B, Kreinin A, Poyurovsky M, Schneidman M, Modai I, Weizman R. 1999. Association of unipolar major depressive disorder with genes of the serotonergic and dopaminergic pathways. Mol Psychiatry 4:389–392. doi:10.1038/sj.mp.4000536</p><p>Fuchikami M, Thomas A, Liu R, Wohleb ES, Land BB, DiLeone RJ, Aghajanian GK, Duman RS. 2015. Optogenetic stimulation of infralimbic PFC reproduces ketamine’s rapid and sustained antidepressant actions. Proc Natl Acad Sci 112:8106–8111. doi:10.1073/pnas.1414728112</p><p>Glue P, Gulati A, Le Nedelec M, Duffull S. 2011. Dose- and exposure-response to ketamine in depression. Biol Psychiatry. doi:10.1016/j.biopsych.2010.11.031</p><p>Gonçalves L, Sego C, Metzger M. 2012. Differential projections from the lateral habenula to the rostromedial tegmental nucleus and ventral tegmental area in the rat. J Comp Neurol 520:1278–1300. doi:10.1002/cne.22787</p><p>Haeffel GJ, Getchell M, Koposov RA, Yrigollen CM, Deyoung CG, Klinteberg BA, Oreland L, Ruchkin V V, Grigorenko EL. 2008. Association between polymorphisms in the dopamine transporter gene and depression: evidence for a gene-environment interaction in a sample of juvenile detainees. Psychol Sci 19:62–9. doi:10.1111/j.1467-9280.2008.02047.x</p><p>Hare BD, Pothula S, DiLeone RJ, Duman RS. 2020. Ketamine increases vmPFC activity: Effects of (R)- and (S)-stereoisomers and (2R,6R)-hydroxynorketamine metabolite. Neuropharmacology 166:107947. doi:10.1016/j.neuropharm.2020.107947</p><p>Homayoun H, Moghaddam B. 2007. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 27:11496–500. doi:10.1523/JNEUROSCI.2213-07.2007</p><p>Jendryka M, Palchaudhuri M, Ursu D, van der Veen B, Liss B, Kätzel D, Nissen W, Pekcec A. 2019. Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice. Sci Rep 9. doi:10.1038/s41598-019-41088-2</p><p>Jönsson EG, Nöthen MM, Grünhage F, Farde L, Nakashima Y, Propping P, Sedvall GC. 1999. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 4:290–296. doi:10.1038/sj.mp.4000532</p><p>Kinoshita H, Nishitani N, Nagai Y, Andoh C, Asaoka N, Kawai H, Shibui N, Nagayasu K, Shirakawa H, Nakagawa T, Kaneko S. 2018. Ketamine-Induced Prefrontal Serotonin Release Is Mediated by Cholinergic Neurons in the Pedunculopontine Tegmental Nucleus. Int J Neuropsychopharmacol 21:305–310. doi:10.1093/ijnp/pyy007</p><p>Kumar S, Black SJ, Hultman R, Szabo ST, Demaio KD, Du J, Katz BM, Feng G, Covington HE, Dzirasa K. 2013. Cortical control of affective networks. J Neurosci 33:1116–1129. doi:10.1523/JNEUROSCI.0092-12.2013</p><p>Kurdi MS, Theerth KA, Deva RS. 2014. Ketamine: Current applications in anesthesia, pain, and critical care. Anesth essays Res 8:283–90. doi:10.4103/0259-1162.143110</p><p>Lammel S, Lim BK, Ran C, Huang KW, Betley MJ, Tye KM, Deisseroth K, Malenka RC. 2012. Input-specific control of reward and aversion in the ventral tegmental area. Nature 491:212–217. doi:10.1038/nature11527</p><p>Land BB, Narayanan NS, Liu RJ, Gianessi CA, Brayton CE, M Grimaldi D, Sarhan M, Guarnieri DJ, Deisseroth K, Aghajanian GK, Dileone RJ. 2014. Medial prefrontal D1 dopamine neurons control food intake. Nat Neurosci 17:248–253. doi:10.1038/nn.3625</p><p>Laskowski K, Stirling A, McKay WP, Lim HJ. 2011. A systematic review of intravenous ketamine for postoperative analgesia. Can J Anesth. doi:10.1007/s12630-011-9560-0</p><p>Lee SJ, Lodder B, Chen Y, Patriarchi T, Tian L, Sabatini BL. 2020. Cell-type-specific asynchronous modulation of PKA by dopamine in learning. Nature 590:451. doi:10.1038/s41586-020-03050-5</p><p>Li B, Piriz J, Mirrione M, Chung C, Proulx CD, Schulz D, Henn F, Malinow R. 2011. Synaptic potentiation onto habenula neurons in the learned helplessness model of depression. Nature 470:535–539. doi:10.1038/nature09742</p><p>Li N, Lee B, Liu R-J, Banasr M, Dwyer JM, Iwata M, Li X-Y, Aghajanian G, Duman RS. 2010. mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists. Science 329:959–964. doi:10.1126/science.1190287</p><p>Lindefors N, Barati S, O’Connor WT. 1997. Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontal cortex. Brain Res 759:205–212. doi:10.1016/S0006-8993(97)00255-2</p><p>Liu RJ, Fuchikami M, Dwyer JM, Lepack AE, Duman RS, Aghajanian GK. 2013. GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. Neuropsychopharmacology 38:2268–2277. doi:10.1038/npp.2013.128</p><p>Lorrain D., Baccei C., Bristow L., Anderson J., Varney M. 2003. Effects of ketamine and n-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 117:697–706. doi:10.1016/S0306-4522(02)00652-8</p><p>Manvich DF, Webster KA, Foster SL, Farrell MS, Ritchie JC, Porter JH, Weinshenker D. 2018. The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice. Sci Rep 8:3840. doi:10.1038/s41598-018-22116-z</p><p>McCullough LD, Sokolowski JD, Salamone JD. 1993. A neurochemical and behavioral investigation of the involvement of nucleus accumbens dopamine in instrumental avoidance. Neuroscience 52:919–925. doi:10.1016/0306-4522(93)90538-Q</p><p>Miller OH, Yang L, Wang C-C, Hargroder EA, Zhang Y, Delpire E, Hall BJ. 2014. GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine. <italic>eLife</italic> 3:e03581. doi:10.7554/<italic>eLife</italic>.03581</p><p>Moda-Sava RN, Murdock MH, Parekh PK, Fetcho RN, Huang BS, Huynh TN, Witztum J, Shaver DC, Rosenthal DL, Alway EJ, Lopez K, Meng Y, Nellissen L, Grosenick L, Milner TA, Deisseroth K, Bito H, Kasai H, Liston C. 2019. Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. Science 364:eaat8078. doi:10.1126/science.aat8078</p><p>Morales M, Margolis EB. 2017. Ventral tegmental area: Cellular heterogeneity, connectivity and behaviour. Nat Rev Neurosci 18:73–85. doi:10.1038/nrn.2016.165</p><p>Nair A, Jacob S. 2016. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm 7:27. doi:10.4103/0976-0105.177703</p><p>Oleson EB, Cheer JF. 2013. On the role of subsecond dopamine release in conditioned avoidance. Front Neurosci 7:96. doi:10.3389/fnins.2013.00096</p><p>Oleson EB, Gentry RN, Chioma VC, Cheer JF. 2012. Subsecond dopamine release in the nucleus accumbens predicts conditioned punishment and its successful avoidance. J Neurosci 32:14804–14808. doi:10.1523/JNEUROSCI.3087-12.2012</p><p>Patriarchi T, Cho JR, Merten K, Howe MW, Marley A, Xiong W-H, Folk RW, Broussard GJ, Liang R, Jang MJ, Zhong H, Dombeck D, von Zastrow M, Nimmerjahn A, Gradinaru V, Williams JT, Tian L. 2018. Ultrafast neuronal imaging of dopamine dynamics with designed genetically encoded sensors. Science 360:eaat4422. doi:10.1126/science.aat4422</p><p>Pearson-Fuhrhop KM, Dunn EC, Mortero S, Devan WJ, Falcone GJ, Lee P, Holmes AJ, Hollinshead MO, Roffman JL, Smoller JW, Rosand J, Cramer SC. 2014. Dopamine Genetic Risk Score Predicts Depressive Symptoms in Healthy Adults and Adults with Depression. PLoS One 9:e93772. doi:10.1371/journal.pone.0093772</p><p>Peña CJ, Kronman HG, Walker DM, Cates HM, Bagot RC, Purushothaman I, Issler O, Eddie Loh YH, Leong T, Kiraly DD, Goodman E, Neve RL, Shen L, Nestler EJ. 2017. Early life stress confers lifelong stress susceptibility in mice via ventral tegmental area OTX2. Science (80- ) 356:1185–1188. doi:10.1126/science.aan4491</p><p>Peña CJ, Smith M, Ramakrishnan A, Cates HM, Bagot RC, Kronman HG, Patel B, Chang AB, Purushothaman I, Dudley J, Morishita H, Shen L, Nestler EJ. 2019. Early life stress alters transcriptomic patterning across reward circuitry in male and female mice. Nat Commun 10:1–13. doi:10.1038/s41467-019-13085-6</p><p>Phoumthipphavong V, Barthas F, Hassett S, Kwan AC. 2016. Longitudinal effects of ketamine on dendritic architecture in vivo in the mouse medial frontal cortex. eNeuro 3:91–95. doi:10.1523/ENEURO.0133-15.2016</p><p>Picard N, Takesian AE, Fagiolini M, Hensch TK. 2019. NMDA 2A receptors in parvalbumin cells mediate sex-specific rapid ketamine response on cortical activity. Mol Psychiatry 24:828–838. doi:10.1038/s41380-018-0341-9</p><p>Pignatelli M, Tejeda HA, Barker DJ, Bontempi L, Wu J, Lopez A, Palma Ribeiro S, Lucantonio F, Parise EM, Torres-Berrio A, Alvarez-Bagnarol Y, Marino RAM, Cai ZL, Xue M, Morales M, Tamminga CA, Nestler EJ, Bonci A. 2020. Cooperative synaptic and intrinsic plasticity in a disynaptic limbic circuit drive stress-induced anhedonia and passive coping in mice. Mol Psychiatry 1–20. doi:10.1038/s41380-020-0686-8</p><p>Sarkar A, Kabbaj M. 2016. Sex Differences in Effects of Ketamine on Behavior, Spine Density, and Synaptic Proteins in Socially Isolated Rats. Biol Psychiatry 80:448–456. doi:10.1016/j.biopsych.2015.12.025</p><p>Sassano-Higgins S, Baron D, Juarez G, Esmaili N, Gold M. 2016. A REVIEW OF KETAMINE ABUSE AND DIVERSION. Depress Anxiety 33:718–727. doi:10.1002/da.22536</p><p>Shinohara R, Taniguchi M, Ehrlich AT, Yokogawa K, Deguchi Y, Cherasse Y, Lazarus M, Urade Y, Ogawa A, Kitaoka S, Sawa A, Narumiya S, Furuyashiki T. 2018. Dopamine D1 receptor subtype mediates acute stress-induced dendritic growth in excitatory neurons of the medial prefrontal cortex and contributes to suppression of stress susceptibility in mice. Mol Psychiatry 23:1717–1730. doi:10.1038/mp.2017.177</p><p>Shirayama Y, Hashimoto K. 2017. Effects of a single bilateral infusion of R-ketamine in the rat brain regions of a learned helplessness model of depression. Eur Arch Psychiatry Clin Neurosci 267:177–182. doi:10.1007/s00406-016-0718-1</p><p>Sun W, Akins CK, Mattingly AE, Rebec G V. 2005. Ionotropic glutamate receptors in the ventral tegmental area regulate cocaine-seeking behavior in rats. Neuropsychopharmacology 30:2073–2081. doi:10.1038/sj.npp.1300744</p><p>Vander Weele CM, Siciliano CA, Matthews GA, Namburi P, Izadmehr EM, Espinel IC, Nieh EH, Schut EHS, Padilla-Coreano N, Burgos-Robles A, Chang C-J, Kimchi EY, Beyeler A, Wichmann R, Wildes CP, Tye KM. 2018. Dopamine enhances signal-to-noise ratio in cortical-brainstem encoding of aversive stimuli. Nature 563:397–401. doi:10.1038/s41586-018-0682-1</p><p>Volkow ND, Fowler JS, Gatley SJ, Logan J, Wang G-J, Ding Y-S, Dewey S. 1996. PET Evaluation of the Dopamine System of the Human Brain. J Nucl Med 37.Wahlstrom D, Collins P, White T, Luciana M. 2010. Developmental changes in dopamine neurotransmission in adolescence: Behavioral implications and issues in assessment. Brain Cogn. doi:10.1016/j.bandc.2009.10.013</p><p>Wang LP, Li F, Wang Dong, Xie K, Wang Deheng, Shen X, Tsien JZ. 2011. NMDA receptors in dopaminergic neurons are crucial for habit learning. Neuron 72:1055–1066. doi:10.1016/j.neuron.2011.10.019</p><p>Wass C, Sauce B, Pizzo A, Matzel LD. 2018. Dopamine D1 receptor density in the mPFC responds to cognitive demands and receptor turnover contributes to general cognitive ability in mice. Sci Rep 8:4533. doi:10.1038/s41598-018-22668-0</p><p>Wenzel JM, Oleson EB, Gove WN, Cole AB, Gyawali U, Dantrassy HM, Bluett RJ, Dryanovski DI, Stuber GD, Deisseroth K, Mathur BN, Patel S, Lupica CR, Cheer JF. 2018. Phasic Dopamine Signals in the Nucleus Accumbens that Cause Active Avoidance Require Endocannabinoid Mobilization in the Midbrain. Curr Biol 28:1392-1404.e5. doi:10.1016/j.cub.2018.03.037</p><p>Winter S, Dieckmann M, Schwabe K. 2009. Dopamine in the prefrontal cortex regulates rats behavioral flexibility to changing reward value. Behav Brain Res 198:206–213. doi:10.1016/J.BBR.2008.10.040</p><p>Wu M, Minkowicz S, Dumrongprechachan V, Hamilton P, Kozorovitskiy Y. 2021. Ketamine rapidly enhances glutamate-evoked dendritic spinogenesis in medial prefrontal cortex through dopaminergic mechanisms. Biol Psychiatry 0. doi:10.1016/j.biopsych.2020.12.022</p><p>Yang H, de Jong JW, Tak YE, Peck J, Bateup HS, Lammel S. 2018. Nucleus Accumbens Subnuclei Regulate Motivated Behavior via Direct Inhibition and Disinhibition of VTA Dopamine Subpopulations. Neuron 97:434-449.e4. doi:10.1016/j.neuron.2017.12.022</p><p>Yang Y, Cui Y, Sang K, Dong Y, Ni Z, Ma S, Hu H. 2018. Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. Nature 554:317–322. doi:10.1038/nature25509</p><p>Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. 2006. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856–864. doi:10.1001/archpsyc.63.8.856</p><p>Zweifel LS, Argilli E, Bonci A, Palmiter RD. 2008. Role of NMDA Receptors in Dopamine Neurons for Plasticity and Addictive Behaviors. Neuron 59:486–496. doi:10.1016/j.neuron.2008.05.028</p></body></sub-article></article>